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Abstract  
The aim of the work presented in this thesis was to explore the use of FT-IR 
spectroscopy, as a complementary clinical tool for haematological laboratory analysis. 
 
FT-IR spectra were measured from air-dried and frozen cell lines derived from 
lymphoma, lymphoid, myeloid leukaemia and normal and chronic lymphocytic 
leukaemia blood samples. Multivariate statistical analysis was used to extract important 
spectral information with the greatest discriminative power. Principal component fed 
linear discriminant spectral models have been tested with leave one out cross validation 
procedures. A preliminary unfiltered classification model using 50 frozen and air-dried 
samples correctly classified 54% of 18556 spectra. The performance improved with the 
three cell line group datasets, with 71% of 19903 spectra correctly classified. 
Furthermore, the use of the frozen spectra improved the performance of the three cell 
line group classification model considerably. Findings showed that 73.3% of 9920 
spectra were correctly classified in the frozen datasets, whereas in the air-dried only 
41.5% of 9983 spectra are correctly classified. Optimisation of the spectral models by 
selection of principal components, application of Savitsky-Golay filters and selecting 
spectra using standard deviation and absorption filter tool was investigated. Using the 
first 25 significant PCs, a 0
th
 derivative Savitsky-Golay filter and the absorbance filter 
tool on the frozen five cell line spectral dataset were shown to be the optimal parameters 
for constructing a classification model. When tested with leave one batch out cross 
validation 90% of the spectra were correctly classified for the five cell line model. 
Blood component classification models tested with leave one batch out cross validation 
performed well. The whole blood model correctly classified 70% of 1736 spectra, 
measured on 22 samples. The plasma model correctly classified 80.6% of 331 spectra 
and the buffy coat model correctly classified 99.5% of 1438 spectra. This demonstrated 
that the buffy coat (containing white blood cells) holds the key biochemical information 
for discrimination between the pathology of the blood samples. Partial least squares 
analysis has been demonstrated as a method to support whole blood count tests for real 
time prediction of cellular constituents. These findings demonstrate the potential of FT-
IR spectroscopy as a clinical tool although more work is needed if it is to be applied in 
clinical practice.  
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This thesis presents the application of Fourier Transform Infrared (FT-IR) spectroscopy 
as a potential diagnostic tool in a clinical setting for the detection of leukaemia and 
lymphomas. Chapter 1 is structured to introduce haematological malignancies and 
provide a general overview of the clinical rationale, highlighting incidence and 
histological classifications of leukaemia and lymphomas. The stages involved in the 
development of leukaemia and lymphomas are also discussed. This is followed by a 
review of “gold standards” used by haematologists as well as the associated 
deficiencies. It also introduces the need for improved techniques in early detection of 
haematological malignancies. A number of competing optical diagnostic techniques are 
discussed prior to introducing FT-IR spectroscopy. Chapter 1 concludes with detailed 
aims and objectives of this research project and an outline of the work presented.  
 
1.1 Background 
 
The scope of this thesis applies vibrational spectroscopy, which has mainly served for 
analytical chemistry and physics, to an area of clinical relevance. Leukaemia and 
lymphoma are haematological malignancies that result from clonal expansion. At the 
time of diagnosis, the normal marrow cell population has usually been replaced by the 
leukaemia clone accompanied by haematogenous dissemination to a variety of 
extramedullary sites. Current immunological, cytopathological and molecular biology 
procedures identify variations in cellular morphology or granularity or use antibodies to 
detect abnormal leucocytes and cell-specific marker proteins. Although these methods 
are well established, they are invasive, requiring extensive sample preparation as well as 
highly trained personnel for interpretation. In addition, none of these diagnostic tools 
are able to yield biochemical information. 
 
The interest in the potential use of FT-IR spectroscopy, which is based on mid-infrared 
absorption, arises from the fact that this spectroscopic technique can provide details of 
the biochemical composition and molecular structures of cells and tissues. In principle, 
disease and other pathological alterations lead to biochemical and structural changes at a 
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molecular level thus modifying the infrared spectrum, which becomes a phenotypic 
marker of the disease. As these spectral changes are very specific and unique, they are 
also refered to as fingerprints. The added advantages of the method are that it is non-
destructive and does not require the use of extrinsic staining agents. Automated, 
repetitive analyses can therefore be carried out at a low cost with the added advantage 
of utilizing a small volume of the sample.  
 
This research project aims to provide a practical, effective spectroscopic method that 
will compete on all levels with the present gold standards in diagnosis, analysis, and 
imaging of haematological malignancies. This will identify key biomarkers and 
potentially provide information to clinicians that are otherwise not available.  
 
1.1.1 Incidence of leukemia and lymphoma  
 
Cancer is a major cause of morbidity in the UK with more than a quarter of a million 
people newly diagnosed with cancer every year (Cancerstats 2009). In the UK, acute 
and chronic leukaemia and lymphomas combined represent a total of 6.5% of all 
cancers in both men and women (Cancerstats 2009). Furthermore, one in twenty five 
people have a risk of developing blood cancer in their lifetime. In 2005, 7,279 (2%) 
both acute and chronic leukaemia incidence cases, 1,564 (0.5%) Hodgkin’s lymphoma 
(HL) and 10,310 (4%) Non-Hodgkin’s lymphoma (NHL) cases were registered 
(Cancerstats 2009). Chronic leukaemia is the most common leukaemia in adults, 
accounting for approximately 40% of all leukaemias. The overall incidence is about 
3/100,000 per year (Cancerstats 2009). Overall, one-year and five-year survival from 
acute and chronic leukaemia and lymphomas remains low, despite improvements in 
diagnosis and treatment (Figure 1-1). 
 
 
 
 
 3 
Figure 1-1: Survival rates for Leukaemia, Hodgkin’s Lymphoma and Non-
Hodgkins Lymphoma in men and women at one and five years during 1971-2001 
(Cancerstats 2009) 
 
The spectrum of haematological malignancies varies significantly between children and 
adults (Figure 1-2). In children (0-14 years), the majority of leukaemia are of the acute 
type (acute lymphocytic leukaemia (ALL)), whereas in adults (> 19 years), chronic 
leukaemia (chronic lymphoblastic leukaemia (CLL) and chronic myeloid leukaemia 
(CML)) are more common (Pui 1999; Downing 2002). Incidence of NHL is prominent 
in adults. Overall acute and chronic leukaemia and lymphoma are slightly more 
common in males than females, with a male to female incidence case ratio of 1.3:1 
(Levi 2000). The risk of developing leukaemia and lymphoma increases with age 
characterised by a bimodal age distribution. The highest incidence in children is in the 
0-4 age group. Rates then decline until the early 20’s, and increase slowly from the 
early 30’s to the early 50’s. Incidence rates rise sharply and peak in the over 85’s (Xie 
2003).  
 
This thesis concentrates on CLL, which is of particular concern in the Western world 
since it is the most common type of leukaemia. 35 out of every 100 people have a risk 
of developing CLL in their lifetime. 
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Figure 1-2: Frequency of the major subtypes of haematological malignancies in 
children and adults. Adapted from Downing 2002 
 
Risk factors for CLL, apart from old age are not clearly defined. CLL is uncommon in 
childhood, rare in adolescents and becomes progressively more common from the age 
of 35 years (Cancerstats). Some differences in CLL incidence exist between 
geographical regions and ethnic groups, suggesting genetic or environmental influence 
(Alexander 1995). The incidence amongst Caucasians and non-Caucasians is 
approximately equal but the disease is rare in Asians (Groves 1995 and Xie 2003). 
Familial links have been observed, but the nature of possible hereditary factors is yet to 
be elucidated (Redaelli 2004).  
 
1.1.2 Haematological Malignancies 
 
Haematological malignancies derive from the haematopoietic (bone marrow) or 
lymphoid tissues and hence are targets for malignant transformations and clonal 
proliferation of lymphocytes. The biology and pathology of bone marrow and lymphoid 
tissues are detailed in Appendix A.  
 
During normal haematopoiesis, blood cells arise from an immature haematopoietic stem 
cell (HSC) in the bone marrow. HSCs go through stages of development until they 
matures into a functioning cells. HSCs are programmed to differentiate into lymphoid or 
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myeloid progenitors. The lymphoid cells migrate to the thymus, lymph node and the 
spleen and mature into lymphocytes (T cells and B cells) and natural killer (NK) cells 
(Figure 1-3). The myeloid cell differentiates into several cell types: erythrocytes, 
basophils, megakaryocytes, neutrophils, monocytes, and esinophils (Kwong 1988). 
Following maturation these cells are released from the bone marrow into the blood 
stream. Haematopoiesis is controlled by cytokines, growth factors and interleukins as 
well as an array of genes that maintain the balance of cell growth, differentiation, and 
programmed cell death (apoptosis) in the bone marrow (Kwong 1988; Cantor 2001; 
Fisher 2002). 
 
 
 
Figure 1-3: Illustration of Haematopoiesis. Haematopoiesis occurs in the bone 
marrow which gives rise to HSCs. These develop into an assortment of committed 
stem cells, which then differentiate into mature cells. Erythrocytes distribute 
oxygen and carbon dioxide between lungs and tissues. Megakaryocytes (platelets) 
co-ordinate coagulation that prevents blood loss in damaged vessels. Basophils, 
neutrophils, monocytes, eosinophils and lymphocytes are collectively known as 
leucocytes. Neutrophils and monocytes are known as phagocytes as they defend the 
body by engulfing and ingesting bacteria and viruses. Lymphocytes (B-cells and T-
cells) react against invading bacteria or viruses by producing antibodies. 
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Haematological malignancies can arise at any stage during the process of differentiation 
and maturation within the different cellular lineages, leading to many different types of 
leukaemia and lymphoma (Bonnet 1997, Enver 1998 and Tenen 2003). Lymphoma and 
lymphocytic leukaemia develop from lymphocytes, whereas myeloid leukaemia stem 
from myeloid cells.  
 
In leukaemia, early haematopoietic progenitors fail to respond to external stimuli within 
the bone marrow microenvironment and differentiate into discrete types of blood cells 
(Figure 1-4) (Fialkow 1981). These leukaemia cells tend to lose their capacity to 
terminally differentiate, resulting in the progressive accumulation of immature, non-
functional cells with a relatively prolonged life span in the bone marrow and then spill 
into the peripheral blood. As leukaemia cells do not undergo apoptosis and fail to 
differentiate (Domen 2001) it makes them disorders of both haematopoietic cell 
differentiation and apoptosis (Tsiftsoglou 2003) (see Figure 1-4).  
 
 
 
Figure 1-4: Diagrammatic presentation of normal haematopoiesis and 
leukemiogenesis. Normally, long-term HSCs (LT-HSCs) that self-renew also 
produce short-term HSCs (ST-HSCs) that subsequently differentiate into late 
progenitors (committed haematopoietic progenitors) and mature blood cells. In 
leukemic state, ST-HSCs regenerate early progenitors that are transformed and 
unable to respond to differentiation stimuli. Source: Tsiftsoglou 2003 
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A failure in the apoptotic pathway creates a permissive environment for genetic 
instabilities and accumulations of genetic mutations involving oncogenes (myc, ras, and 
bcl-2) and tumour suppressor genes (p53) (Debatin 2003). The activation of a proto-
oncogene creates a pathological activity whereby the cell receives increased growth or 
proliferation signals (Figure 1-5). Inactivation or loss of a tumour suppressor gene 
results in loss of function and malignant cells do not undergo apoptosis (Debatin 2003). 
As a result, malignant cells tend to lose their capacity to terminally differentiate. This 
further cause deregulated expansion of malignant cells leading to tumour initiation and 
progression.  
 
 
 
 
Figure 1-5: Cell balance. Proliferation of normal cell depends on a balance 
between the action of proto-oncogenes and tumour suppressor genes. In a 
malignant cell this balance is disturbed leading to uncontrolled cell proliferation. 
Adapted from Hoffbrand 2006 
 
 
 
 
 
+ 
- 
Proto-
oncogene 
Tumour 
suppressor 
gene 
Normal Cell 
Regulated 
proliferation 
and apoptosis 
 Oncogen
e 
Tumour 
suppressor 
gene 
Malignant Cell 
Excess proliferation 
and failure of 
apoptosis X  
Chemicals, radiation,  
drugs, virus,  
translocation, 
deletions 
 8 
1.1.3 Histological Classification of leukaemia and lymphoma 
 
Leukaemia (“white blood” in Greek): “When the colour of blood is fading” was first 
described by a British pathologist, John Hughes Bennett in 1845 (Tefferi 2008). 
Leukaemias are a group of heterogeneous disorders. They are characterised by the 
proliferation and accumulation of malignant (blast) white cells in the bone marrow and 
circulating blood. The main classification is into four types (Hoffbrand 2006): acute and 
chronic leukaemia, which are further divided into lymphoid or myeloid lineages. Acute 
leukaemia (ALL and AML) is aggressive in nature. Malignant transformation is caused 
by rapid proliferation and accumulation of immature, non-functioning HSCs (blast 
cells). Chronic leukaemia (CLL and CML) involves prolonged progression of mature, 
well differentiated leukocytes (Figure 1-6). The lymphoid lineage is further subdivided 
into either into B or T cell origin whist the myeloid lineage involves cells derived from 
the myeloid stem cells (that is cells from neutrophils, eosinophils, monocytes, basophils 
and megakaryocytes).  
 
CLL are mostly derived from B-cells. T-cell CLL is rare. The scoring system is based 
on distinct morphology and presence of certain antigens (immunophenotyping) on the 
surface of malignant lymphocytes. 
 
Lymphomas are divided into two types: “Hodgkin’s lymphoma (HL)” (named after 
Dr.Thomas Hodgkin, who first recognised it in 1832) and non-Hodgkin’s lymphoma 
(NHL). Classification of lymphoma is based on immunohistochemical staining as well 
as conventional morphology. Genetic parameters are also included since they have 
diagnostic value important for clinical decisions. The World Health Organisation 
(WHO) Classification released in 2001 is used by clinicians and pathologists to classify 
lymphomas (Jaffe 2001). NHL includes more than 20 subtypes based on B cell or T cell 
origin according to the WHO Classification. HL is classified into five subtypes 
according to the Rye classification system, based upon presence of Reed Sternberg (RS) 
cell morphology (Isaacson 2000). 
 
 
 9 
 
 
Figure 1-6: Classification of leukaemia and lymphoma and characteristics of 
malignant cells 
 
1.1.4 Staging of CLL and lymphoma 
 
Clinical staging of CLL and lymphoma is used to determine the extent of spread of the 
disease from its starting point. In CLL, period of activity can prolong and go undetected 
from several months up to 10-20 years. In many patients, CLL is diagnosed by chance 
when a full blood count is done for another reason (Hoffbrand 2007). Prognosis of CLL 
is estimated through the use of clinical staging systems developed by Rai 1975 and 
Binet 1981. The Rai staging system (Stage 0-IV) is used primarily in the USA while the 
Binet staging system (Stage A-C) is commonly used in the Europe. These systems 
define early (Rai 0, Binet A), intermediate
 
(Rai I/II, Binet B) and advanced (Rai III/IV, 
Binet C) stages of the disease (Appendix B). 
 
Clinical staging/grading of lymphomas (HL and NHL) depends on the number of lymph 
nodes affected, location and distribution of the affected lymph nodes throughout the 
body. Lymphomas of different grades/stages proliferate at different rates and respond to 
treatment differently. According to the Ann Arbour Staging system (Appendix C), 
lymphomas are divided into three main grades (clinical stages): Low-grade lymphomas 
are also referred to as indolent lymphomas; Intermediate- grade lymphomas as faster 
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growing lymphomas and High-grade lymphomas are also known as highly aggressive 
lymphomas which tend to grow and spread quickly. 
 
1.1.5 Current diagnostic techniques and associated deficiencies 
 
In haematological malignancies, normal bone marrow haematopoiesis is often disrupted 
due to infiltration of clonal tumour cell growth. This is the main reason for the common 
laboratory findings of anaemia, granulocytopaenia and thrombocytopaenia. The blood 
leukocyte count is often elevated due to clonal expansion of malignant cells. These 
changes in blood cell composition are reflected in the clinical symptoms of fatigue, 
tendency to bleed and bruise easily as well as an increased susceptibility to infections. 
Other common symptoms are malaise, lymph node enlargement, fever, weight loss and 
night sweats.  
 
The malignancy further evolves by the accumulation of mutations within a clone 
resulting in genetic diversity. The nature of the clone determines the clinical outcome, 
which can often be time consuming. Confirmation results for the exact diagnosis can 
take about 5 days causing possible delays in prognosis and treatment. Delay in 
diagnosis increases the likelihood that the clone will have progressed to the point that 
additional mutations will have been acquired. Survival rates heavily depend on the 
disease stage and early diagnosis is a primary requirement for successful treatment. The 
role of clinicians in the management and the ideal strategy for early diagnosis of CLL 
and lymphoma is prompt attention to clinical manifestations, close follow-up for 
individuals with a known genetic abnormality and early identification of abnormal 
leucocytes. Currently in the UK, routine diagnostic procedures for CLL and lymphomas 
rely on presentation of clinical manifestations, morphology and cytochemistry. These 
are frequently combined with molecular methods, flow cytometric immunophenotyping 
and cytogenetic studies (Basso 2007). The results from these investigations serve as a 
mandatory prerequisite for individual treatment strategies and for the evaluation of 
treatment response.  
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1.1.5.1 Gold Standard for CLL diagnosis 
 
The “gold standard” diagnostic criterion for CLL is morphology. This involves the 
evaluation of stained (Haematoxylin and Eosin (H&E) stain) blood specimens or bone 
marrow aspiration films under a microscope. The morphological examination 
determines the distinctive architectural features of CLL cells. Morphological 
investigations form the initial diagnosis for CLL but are not sufficient to identify the 
various clinical subsets within the main category of CLL. The main difficulty associated 
with the morphology involves targeting malignant cells due to variations in the fraction 
of circulating CLL cells and the distribution of cell deoxyribose nucleic acid (DNA) 
content. Interpreting results in heterogeneous samples or those with few malignant cells 
can therefore prove to be difficult. The problem is further complicated by sampling 
large numbers of viable cells as well as requiring numerous staining reagents per patient 
sample. 
 
In most cases morphological assessment is combined with secondary 
immunophenotyping (flow cytometry) investigations to establish a precise classification 
(Richards 2003). Immunophotyping defines immunologic phenotype of malignant cells 
by using monoclonal antibodies (MAbs) reactive against lymphoid or myeloid 
associated antigens. Although being able to separate and evaluate single cells from 
mixed populations, this technique requires expensive equipment and reagents. In 
addition, there is no visualisation of cell architecture and interpretation of data in 
heterogeneous sample or those with few blasts is difficult.  
 
In a minority of difficult cases (5–10%) further molecular investigations may be 
required for an accurate diagnosis (Szczepanski 2003). This involves the use of 
polymerase chain reaction (PCR) and fluorescence in situ hybridisation (FISH) assays 
for detection of genetic rearrangement and chromosomal translocations (e.g. trisomy 
12). These methods target specific part of the DNA sequences but due to DNA 
contamination and degradation tend to be prone to false positive results. Despite all 
investigations, up to 5% of CLL cases defy lineage assessment (Szczepanski 2003).  
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1.1.5.2 Gold Standard for Lymphoma diagnosis 
 
The gold standard for detection of HL and NHL involves histological examination of 
excised lymph nodes. This technique involves examining an H&E stained lymph node 
tissue section (one cell thick (<10 microns)) under a conventional light microscope. 
Changes in tissue morphology and presence of Reed Sternberg (RS) cells can therefore 
be identified in order to determine histological classification and stages of disease. 
Often, the patient presents several enlarged lymph nodes during diagnosis. In such cases 
the largest lymph node is chosen for biopsy as smaller lymph nodes, although easily 
accessible, may show nonspecific histological changes that may obscure the correct 
diagnosis. This results in delayed diagnosis or even erroneous results. Furthermore, 
surgical biopsy is affected by random sampling (only a small part of the tissue is 
removed and examined) therefore the extent of the disease can not always be quantified. 
Although fine needle aspirate (FNA) biopsy techniques have reduced the number of 
patients undergoing surgical biopsies for early detection of lymphomas, there is a delay 
in obtaining immediate results. FNA biopsy yields a high rate of conclusive cytological 
diagnoses in the assessment of high grade NHL (79–90%), but has lower performance 
in the assessment of low grade NHL with an average accuracy rate of 75-80% (Hehn 
2004; Lioe 1999; Kocjan 1997; Young 1999 and Dong 2001). 
 
The analysis of sectioned lymph node tissue is prone to high levels of inconsistencies 
between histopathologists. In one study, amongst expert haematopathologists, 
interobserve agreement ranged between 21-65% (Benard 1985). In complex cases, 
immunological marker studies (flow cytometric immunophenotyping) may be used to 
classify lymphoma with either T or B cell lineage. Although highly specific, the process 
requires a comprehensive and costly panel of antibodies and there are sometimes 
problems associated with suboptimal antibody selection and inadequate or insufficient 
fresh material (Katz 1997; Mourad 2003 and Olsen 2007). Despite the best efforts of 
morphology and immunophenotyping, some lymphomas are impossible to diagnose 
(Hans 2003; Landgen 2004). Genetic rearrangement studies are helpful in uncommon 
cases where immunophenotypic studies are unable to assign lineage (T versus B). 
Standard imaging tests such as x-rays, computed tomography (CT) scans, magnetic 
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resonance imaging (MRI) and positron emission tomography (PET) scanning may also 
be performed for advanced investigations to determine the degree of malignant 
lymphocyte invasion in other areas of the body. These imaging techniques can be 
expensive and involve patients being exposed to ionizing radiation.  
 
1.1.6 Summary 
 
Overall, the diagnostic strategy for haematological malignancies is not based on a single 
diagnostic procedure, but relies upon a diverse range of measurements and observations 
to determine the presence and nature of malignancy. The extensive sample preparation 
procedures required by these diagnostic methods rely upon the experience and skills of 
both the haematologists and histopathologists to achieve an accurate diagnosis. The 
complexity is further enhanced by the existence of approximately various subtypes of 
CLL and lymphoma, each with its own genetic signature requiring a different prognosis 
and treatment. As a result, testing for CLL and lymphoma is complicated, expensive 
and occasionally inaccurate.  
 
Laboratory investigations rely on as many as 5-6 different technologies to provide 
diagnostic and prognostic information. Even so, a number of patients are misdiagnosed 
in regards regardless of the use of various diagnostic tests. Furthermore, a significant 
number of malignancies are either not detected or have advanced by the time they are 
diagnosed. Part of the problem stems from the steep cost of various technologies used to 
diagnose haematological malignancies. Furthermore, these methods comprise of large 
lab-to-lab variability with the resulting risk that the patient might not receive the right 
treatment or delayed in a situation where time is critical. The problem is compounded 
by significant inter-observer variability between histopathologists and haematologists.  
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1.2 Optical Diagnostic Techniques 
 
1.2.1 Clinical Need 
 
There is a clinical need for new technologies that can overcome inadequacies of current 
diagnostic methods and provide automated, accurate methods for detection of 
haematological malignancies at an early stage. The demand for a real-time technique is 
on the increase to fulfil clinical needs. The main reasons include: i) to determine 
prognosis and to aid in the selection of the best treatment for an individual; ii) to 
determine accurate pathological classification of leukaemia and lymphoma and iii) to 
advance knowledge on the biochemical changes underlying disease progression. A 
potential complementary detection test should be cost effective, easy to use with 
minimum sample processing. In, addition it needs to provide real-time detection and 
accurate classification of pathological changes enabling immediate diagnosis. In any 
diagnosis, clinicians look for deviations from the norm, especially changes in 
morphology and biochemical composition of the organs, tissues and fluids they affect; 
these differences are the basis of everyday clinical tests, tissue staining and medical 
imaging techniques.  
 
Current diagnostic techniques provide limited information on the biochemical changes 
that occur during disease progression at a cellular level. As all malignancies are caused 
by changes in the cellular biochemistry, detection of biochemical changes can provide 
quantitative information which can prove vital in the early diagnosis of CLL and 
lymphoma. Qualitative analyses of biochemical changes can also provide important 
information in measuring the extent of the disease process as well as accurate 
classification. An easier and accurate diagnosis of haematological malignancies at an 
early stage is important in the identification of high risk patients and monitoring the 
efficiency of treatment.  
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The detection of biochemical constituents via optical diagnostic techniques has been 
proposed to comply with these clinical needs for detection and classification of 
haematological malignancies. Optical diagnostic techniques have become increasingly 
important in recent years and shown great potential to date. They have been proposed to 
assist in providing reliable, real-time and non-invasive diagnostic tool to suit the 
demand of the medical community. These methods rely upon the measurement of the 
interaction of light with the biochemical constitutes to study abnormalities is cells and 
tissue. The data obtained can provide evaluation of changes in morphology and altered 
concentration of sub-cellular attributes. This information can aid in the early detection 
and classification of leukaemia and lymphoma, providing possible benefits to both 
clinicians and patients.  
 
The main techniques being explored for detection of biochemical changes are 
Fluorescence spectroscopy (FS), Elastic scattering spectroscopy (ESS), Vibrational 
spectroscopy including Raman spectroscopy and Fourier transform infrared (FT-IR) 
spectroscopy.  
 
1.2.2 Properties of electromagnetic radiation 
 
The spectrum of electromagnetic radiation is divided into different regions as shown on 
Figure 1-7. Electromagnetic radiation consists of an oscillating electrical fields and an 
oscillating magnetic fields perpendicular to each other. However in IR it is the electric 
field that is of importance. The infrared spectrum ranges from 1 μm to 1000 μm, and is 
surrounded by the visible and microwave regions (Figure 1-7). The IR region is further 
subdivided in the near infrared, the mid infrared and the far infrared regions.  
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Figure 1-7: Infrared region of the electromagnetic spectrum 
 
1.2.3 Interactions of light with matter 
 
Light can interact with matter in various manners including, scattering (elastic scattering 
and inelastic scattering), fluorescence and absorption.  
 
The major form of elastic light scattering is Rayleigh scattering. Inelastic scattering 
effects include Raman scattering. Light that is scattered due to vibrations in molecules 
or optical phonons is called Raman scattering. The Raman scattering is an inelastic 
scattering and depends upon the polarizability of the molecules.  
 
1.2.3.1 Elastic Scattering Spectroscopy (ESS)  
 
ESS uses the scattering of light that generates a wavelength dependant spectrum. It 
reflects structural and morphological change within subcellular components to 
differentiate between normal and abnormal tissue (Swinson 2006). 
 
An elastic scattering event redirects incident photon without a change in wavelength or 
energy (Song 2005). The principle relies on the fact that tissues with a higher density 
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have a higher refractive index and therefore have a greater ability to scatter light. Higher 
densities that occur at cellular and sub-cellular levels result in a higher refractive index 
and are therefore responsible for the majority of the elastic scattering. The structures 
that induce elastic scattering are the nucleus, chromatin concentration, and sub-cellular 
organelles. Thus, ESS has been shown to be sensitive to nuclear size, chromatin content, 
nuclear/cytoplasmic ratio and cellular crowding which are all criteria that the 
histopathologist looks for when establishing of malignancy within a tissue (Wallace 
2000).  
 
ESS has been involved in various clinical fields. Main interest is diagnosis of 
melanocytic lesions (Scarisbrick 2004) premalignant/malignant lesions in oral tissues 
(Sharwani 2006), breast cancer (Bigio 2000), Barrett’s oesophagus (Lovat 2006) and 
sentinel lymph node metastases (Chicken 2004). Classification of normal hyperplastic 
and dysplastic polyps and adenocarcinoma using principal component fed linear 
discriminant analysis (PCA-fed-LDA) and cross validation has also been reported 
recently with sensitivity and specificity ranging between 75-88% (Dhar 2006).  
 
1.2.3.2 Inelastic scattering (Raman Effect)  
 
The scattering of light by various media had long been studied by Rayleigh in 1871, 
Einstein in 1910. The theory of Raman Effect was discovered by Sir C. V. Raman 
(1928), together with K. S. Krishnan and independently by Grigory Landsberg and 
Leonid Mandelstam (Krishnan 1981). Raman won the Nobel Prize in Physics in 1930 
for this discovery.  
 
Raman scattering (Raman Effect) is the inelastic scattering of monochromatic light, in 
which the energy of the scattered photons either donate or receive energy to cause 
vibrations of molecular bonds (Song 2005). Molecules are excited to a virtual state on 
interaction with photons. Majority of these molecules de-excite back to the initial 
vibrational energy level, which results in release of photons of the same energy and 
wavelength (Rayleigh scattering). These are filtered out and the remaining light is 
dispersed onto a detector. A small proportion (approximately 1 in 10
7
) of the scattered 
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radiation is shifted to a different wavelength. This change in the wavelength is known as 
the Raman shift which is specific to the species of the molecule responsible for the 
scattering. When all the shifted wavelengths from photons scattered by the different 
molecules present in a sample are combined they form a Raman spectrum (wavelength 
shift vs. photon count). The spectrum provides a biochemical fingerprint, revealing 
characteristic peaks caused by the molecular vibrations.   
 
Raman shifted photons of light can be either of higher or lower energy, depending upon 
the vibrational state of the molecule. Stokes Raman scattering (molecule absorbs 
energy) occurs when the final energy level is higher than the initial level, while anti-
stokes Raman scattering (molecule loses energy) occurs when the final energy level is 
lower than the starting level (Figure 1-8). Energy differences between the incident and 
scattered light is proportional to the vibrational energy of the scattered molecules. This 
change in vibration produces a change in polorizability, which is the change of the 
dipole moment with distance. Stokes scattering is more common than anti-stokes 
scattering because at any given time an electron in the most common temperature range 
is most likely to be in its lowest energy state, in accordance with the Boltzmann 
distribution. Thus the Stokes spectrum is more intense than the anti-Stokes spectrum 
and therefore is commonly used in spectroscopy.  
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Figure 1-8: Energy-level diagrams of Rayleigh scattering, Strokes Raman 
scattering, and anti-stokes Raman scattering 
 
Raman scattering is a relatively weak process (Song 2005). The number of photons 
scattered is quite small, especially when probing cell samples or body fluids. However, 
there are several processes which can be used to enhance the sensitivity and improve the 
spatial resolution of a Raman measurement as well as acquire specific information. 
These include: 
 
a) Surface Enhanced Raman Spectroscopy (SERS), which uses silver or gold colloid 
substrate to enhance the intensity of Raman signal of biomolecules measured (by up to 
10
11
) within body fluid such as lactic acid (Hui 2005) and glucose (Haynes 2005). The 
feasibilty of SERS has also been investigated in live cells (Kneipp 2002) and detection 
of cancer gene (Vo-Dinh 2002). 
 
b) Optical Tweezers Raman Spectroscopy (OTRS), which examines individual particles 
and biochemical processes in single cells trapped by optical tweezers. This technique 
has been applied for single-cell analysis of eukaryotic cells (Snook 2009), leukaemia 
cells (Chan 2008) and live prostate and bladder cancer cell lines (Harvey 2008). 
Mid IR            Stokes Raman           Rayleigh          Anti-Stokes Raman          Fluorescence 
Electronic 
States 
Virtual 
States 
Vibrational States 
Ground State 
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As mentioned previously, the peaks within the Raman spectrum are characteristic of 
different molecular vibrations. Individual peaks are directly proportional to the 
concentration of varying biochemical constituents present in tissue and cells. Therefore 
the spectrum can be utilised to obtain quantitative information making Raman 
spectroscopy potentially a powerful tool for biomedical application. Although the 
Raman Effect was first observed in 1928, it was not until the early 1990s that Raman 
spectroscopy was applied in the successful analysis of cancerous and precancerous 
tissues (Mahadevan-Jensen 1996). Applications of Raman spectroscopy have been used 
to study various cancers and pre-cancers including cervix (Jess 2007; Lyng 2007 and 
Kanter 2009), oesophagus (Kendall 2003; Shetty 2006 and Song 2006), prostate (Crow 
2003 and Crow 2005), bladder (Crow 2005 and Grimbergen 2009), breast (Haka 2006 
and Rehman 2007), larynx (Stone 2000 and Lau 2005) and oral tissue (Malini 2006). 
 
Raman spectroscopy has also advanced in several single cells studies including living 
cells (Notingher 2005), embryonic stem cells (Notingher 2004) and single red blood 
cells (Wood 2002). Other studies evaluate spectral features of cells and sub-cellular 
components of freeze dried and living cells in media (Krafft 2003). In a study by 
Krishna 2005, the efficiency of Raman spectroscopy was evaluated to identify a cell 
type in randomly distributed mixed cell populations of human promyelocytic leukaemia 
(HL60), human breast cancer (MCF7) and human uterine sarcoma (Mes-sa) cell lines. 
Raman spectroscopy has also been applied to discriminate normal and transformed 
human haematopoietic cells (Chan 2006), identify leukaemia cells (Chan 2008); 
differentiate between normal and gastrointestinal cancer cells (Yan 2005) and prostatic 
adenocarcinoma cells (Crow 2005). Identification of sub-cellular organelles such as 
nucleus, cytoplasm, endoplasmic reticulum, vesicles and cellular membrane have also 
been investigated in single human lung fibroblast cells by Raman microspectrocopic 
mapping (Kraft 2005). Furthermore, the Raman microspectrocopic approach has been 
applied to study the nuclei and cytoplasmic regions of single human granulocytes 
(Puppels 1991). 
 
The analysis of body fluids is a recent advancement in application of Raman 
spectroscopy. Whole blood analysis, although proven to be difficult due to contributions 
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from fluorophores and haemaglobin, quantification of biochemical constiutents has 
been possible. Berger 1999 have reported quantification of glucose, cholestrol, 
triglycerides, urea, albulmin and total protiens in whole blood. Qualtification of 
haemaglobin and haematocrit have also been determined (Enejder 2002 and Wood 
2002). To overcome some of the complexity asssociated with whole blood 
measurements, serum or plasma samples have been used for the quantification of 
biochemical constiutents such as glucose (Dou 1996), total proteins, cholestrol, high- 
and low- density lipoproteins, triglycerides, glucose, urea and uric acid (Rohleder 
2004). Serum samples from breast cancer patients have also been examined by Raman 
spectroscopy to highlight changes in the biochemical composition (Pichardo-Molino 
2007). The prediction of concentrations of all these biochemical constituents in the 
various body fluid analyses were determined by partial least square (PLS) analysis.  
 
1.2.3.3 Fluorescence Spectroscopy (FS) 
FS is a type of electromagnetic spectroscopy used for analyzing fluorescent spectra. It 
uses incident beam of UV light to excite electrons in molecules, which emit light of a 
lower energy and varying colours. This light is called fluorescence and is detected 
qualitaively by sensitive spectrometers (Swinson 2006). All tissues fluoresce due to the 
presence of fluorescent chromophores (fluorophores) e.g. NADH, collagen, elastin and 
flavins (FAD, FMN). FS can detect these substances and provide characteristic spectra 
that reflect biochemical and architectural changes occurring within the tissue. The 
resultant spectra not only detect the light that is fluoresced but also are sensitive to the 
structures that absorb light (Swinson 2006). Alfano 1984 first described the use of 
autofluoresence spectroscopy in vivo to differentiate between normal and malignant 
tissues. Since then fluorescence spectroscopy has been applied to investigate cervical 
cancer (Chang 2005). 
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1.2.3.4 Infrared (IR) Absorption Spectroscopy 
 
IR spectroscopy is a powerful tool for determining structure of biochemical compounds 
within biological tissues and fluids. In addition, IR analysis may be used for 
quantification of biochemical components. 
 
Infrared spectroscopy utilizes the mid-IR region of the light to obtain an IR spectrum. It 
involves absorption measurements of different IR frequencies by a sample positioned in 
the path of an IR beam. The absorption of IR light results in changes in the vibrational 
modes of molecules that are IR active. For a vibrational transition to be IR active there 
must be a dipole moment of the molecule during vibration. If the vibration affects the 
polorisability of the molecule then the vibrational mode will be Raman active. Thus, 
mid-IR absorption spectroscopy is complimentary to Raman since each is sensitive to 
different functional groups due to selection rules. Most biological molecules are IR 
active allowing proteins, nucleic acids and lipids to be examined. Changes in a spectrum 
are the result of subsequent structural changes in the configuration of these IR active 
biological molecules in single cells or tissues. These are key factors that differentiate 
abnormal from normal.  
 
IR spectroscopy has experienced vast improvements with the introduction of 
interferometry and availability of new detection elements (charge-coupled device 
(CCD)) technology. With the development of rapid digital data acquisition and 
processing, the speed of FT-IR spectrometers has increased considerably. These 
implementations contribute to high reproducibility and low sampling noise. By 
combining the FT-IR spectrometer with a light microscope which includes a stepping 
motor an efficient IR imaging tool has become available. This provides structural detail 
of the sample along with information on the biochemical composition of the sample. 
Furthermore, the introduction of synchrotron IR source permits smaller regions to be 
measured without affecting the signal to noise ratio compared to conventional IR 
source. The development of a robust attenuated total reflection (ATR) probe also makes 
mid-IR spectroscopy a potential tool for monitoring biochemical processes at cellular 
level. In addition, new sampling techniques have been introduced, enabling 
measurements of samples in solvents, as well as the measurements of cell suspensions 
 23 
and dried films. The incorporation of advanced computational and multivariate 
statistical methods has enabled the immense utilisation of FT-IR spectroscopy for 
research purposes in diagnosis, follow-up and prediction of various cancers.  
 
Infrared spectroscopy can be used for mapping studies, providing imaging of tissue 
sections as well as of single cells (Diem 2000). As IR spectroscopy is the main 
technique utilised within this study further details of principles and theory of infrared 
spectroscopy as well as the instrumentation of IR spectroscopy is outlined in Chapter 2. 
Applications of FT-IR spectroscopy are reviewed in Chapter 3.  
 
1.2.4 Summary 
 
Future prospects of these optical spectroscopic techniques range from application in 
real-time diagnostics to an important complementary tool to improve detection and 
classification of haematological malignancies. Optical spectroscopic techniques 
mentioned above each have advantages and disadvantages: 
 ESS only a point measurement technique. There is no potential for imaging 
analysis. It only provides information on morphology.  
 
 Fluorescence spectroscopy is sensitive and can detect low quantities of the 
compound in a sample but requires expensive and sophisticated equipment. 
 
 Raman can provide detailed biochemical information but Raman signal is weak, 
which leads to low sensitivity, making it difficult to measure low concentrations 
of biochemical substances. Vast majority of molecules are not Raman-active, 
producing weak interactions. However, recent technological advances have 
overcome such a limiting factor. Sample thickness is another limitation. 
Measurements from a thin dried film can prove to be difficult due to large 
contributions from CaF2, cosmic rays, fluorescence and artefacts. Water is only a 
weak Raman scatter and adding little interference.  
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 Mid-IR spectroscopy is established for probing biochemical changes. The signal 
is greater than Raman scatter with a higher signal to noise ratio of spectra. 
Imaging methods are also more rapid than Raman mapping techniques. IR 
spectroscopy is limited by water absorption; however this is overcome by 
eliminating water and air-drying cell samples into thin layer films. As a result, 
acquiring IR spectra of thin monolayer cell preparations is feasible with less 
difficulty than Raman spectra in view of the higher sensitivity of IR 
spectroscopy. 
 
Compared to other techniques discussed in this section, IR spectroscopy is the technique 
of choice as it holds several attractions for consideration in the haematology laboratory 
with advantages such as: 
1) No chemical reagents or specific molecular probes are required for sample 
preparation- the IR spectral patterns of the species of interest can provide the basis for 
detection and quantitation.  
 
2) The IR light is not damaging to the sample, thus subsequent analyses are readily 
feasible.  
 
3) Only small amounts of the sample (of the order of microliters of fluids, or small 
number of cells (10
3
)) are required, leaving ample material for other clinical tests. 
 
4) Less time consuming, as the measuring process of the spectrum for one sample is 
completed within approximately few minutes, with little training required for the 
operator. 
 
5) It is a computer-operated system where the analysis of a large number of samples is 
feasible by the continuously automated process.  
 
6) Uses all IR energy simultaneously and therefore achieve a low noise level. 
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7) An internal laser calibrates the interference information, providing high wavenumber 
accuracy and reproducibility. 
1.3 Aims and Objectives  
 
The rapid developments in the field of infrared spectroscopy in the past decade have 
demonstrated a potential for disease diagnosis. Several studies have highlighted the 
advantages of using infrared spectroscopy in the mid-infrared region for diagnostic 
purposes at a clinical level. Most of the studies to date have focused their research on 
differentiation of normal and diseased tissues in various organs using biopsy material 
from solid tissues at specific sites. Very little work has been done on the identification 
and classification of liquid-phase haematological malignancies, which are on the 
increase. The ability to diagnose the early onset of haematological malignancies rapidly 
has multiple benefits. These include the early prognosis and intervention of therapeutic 
strategies leading to an increase chance of survival. In addition, the identification of 
some biomarkers of disease could also be used to monitor the progression of therapy.  
 
The aim of this project was to carry out a detailed study of the application of Fourier 
transform infrared (FT-IR) spectroscopy as a potential diagnostic tool for clinical use 
for the detection of leukaemia and lymphomas. The study shows the application of FT-
IR spectroscopy as a method to characterise biochemical differences that detect and 
distinguish leukaemia and lymphoma types based the use of diverse liquid-based 
clinical/biological samples. This is based on the FT-IR spectroscopic measurements and 
statistical analysis of leukaemia and lymphoma derived cell lines as well as normal and 
leukaemia blood samples. The study aims to address the following objectives: 
 
1. Cell lines 
 Interpret and assess differences in spectral profile of lymphoid, myeloid 
and lymphoma derived cell lines.  
 Classify cell lines combining objective measurements and multivariate 
statistical techniques to assess feasibility and validation of the 
spectroscopic method 
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 Assess the effect of storage of cell lines at room temperature (air-dried) 
and -80ºC (frozen). 
2. Normal and Chronic Lymphoid Leukaemia (CLL) blood specimens 
 Interpret and assess differences in spectral profile of normal whole blood 
and its components (buffy coat and plasma). 
 Interpret and assess differences in spectral profile of leukaemia (CLL) 
whole blood and its components (buffy coat and plasma). 
 Interpret and compare infrared spectra of normal and leukaemia blood 
(biochemical differences). 
 Classify normal and leukaemia blood using multivariate statistical 
techniques to assess feasibility and validation of the spectroscopic 
method. 
 Compare concentration levels of various cellular components within 
normal and leukaemia blood (lipids, proteins and nucleic acids etc) using 
chemometric techniques. 
 Quantitative analysis of cellular analytes within FT-IR spectra of normal 
and CLL samples through partial least square (PLS) analysis.  
 
The overall aim of this research was to study the application of highly informative 
technique, FT-IR spectroscopy to detect spectral parameters to distinguish between 
leukaemia and lymphomas using a variety of specimens, all of which are liquid based.  
The differences in the spectral profile between the various specimens may serve as 
biomarkers for the identification and detection of different pathological subgroups of 
leukaemia and lymphoma. The identification of leukaemia and lymphomas at various 
clinical stages/grades could indicate changes in the degree of maturation of malignant 
cells as well as in their biochemical composition. This may give insight into the 
biochemical changes and their impact on the blood and tissues, which is of great 
importance in understanding the pathological processes associated with leukaemia and 
lymphoma progression. Clinicians may arrive at a diagnosis and classification of 
specific subtypes of leukaemia and lymphomas at a much earlier stage and help to 
decide available potential treatments. 
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1.4 Thesis Structure  
 
Chapter 2 provides an overview of the theory and principles of FT-IR spectroscopy as 
well as instrumentation. Chapter 3 reviews the literature highlighting applications of 
FT-IR spectroscopy in biomedicine. This will include detailed discussion of 
spectroscopic studies of various diseases in human tissues, single cells and bio-fluids. 
Chapter 4 gives a review of all the subsequent chemometric techniques used in this 
study. This is followed by an outline of the Materials and Methods used for the 
processing, measurement and classification of cell line and blood samples in Chapter 5. 
This chapter also covers system optimisation and data analysis. The Results are 
presented in Chapter 6 with discussion as the data was analysed. The Results chapter is 
divided into 3 sections, presenting and discussing results from a) cell line analysis, b) 
classification model optimisation and c) blood sample analysis. The Conclusions drawn 
from the work follow in Chapter 7 with suggestions for Future Work in Chapter 8. 
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2.1 FT-IR Instrumentation 
 
In IR spectroscopy, the attenuation of the intensity of a radiation beam of polychromatic 
infrared light upon passing through a sample is measured. This attenuation is caused by 
the interaction of the light with the vibrational transitions of the sample molecules. This 
principle is described in further detail in Section 2.2. There are three basic spectrometer 
components in an FT-IR system that makes this course of action possible. These 
include: IR radiation source, Michelson interferometer, and detector (mercury cadmium 
telluride (MCT detector)). A simplified layout of a typical FT-IR spectrometer is 
illustrated in Figure 2-1. 
 
 
 
 
Figure 2-1: Simplified layout of a typical FT-IR spectrometer 
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2.1.1 Interferometer 
 
The Michelson interferometer consists of three active components: a moving mirror, a 
fixed mirror oriented perpendicularly and a beam splitter (Figure 2-2). The 
interferometer splits the IR radiation into two beams by means of a semi transparent 
mirror (beam splitter) at right angles. The beam splitter is thinly coated with germanium 
sandwiched between two pieces of Potassium bromide (KBr), which split the IR beam. 
At the beam splitter, half the IR beam is transmitted to the fixed mirror and the other 
half is reflected to the moving mirror. These beams recombine at the beamsplitter, but 
the difference in path lengths creates constructive and destructive interference: an 
interferogram. The recombined beam passes through the sample, which absorbs all the 
different wavelengths characteristic of its spectrum, and this subtracts specific 
wavelengths from the interferogram. A mathematical operation known as a Fourier 
transformation converts the interferogram (a time domain spectrum displaying intensity 
verses time within the mirror scan) to the final IR spectrum which is the frequency 
domain spectrum showing intensity versus frequency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2: Michelson interferometer 
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2.1.2 HgCdTe (MCT) Detector 
 
MCT (mercury cadmium tellurium) detector is a photon detector operating at liquid N2 
temperature. IR radiation excites the electrons to higher energy levels. This changes the 
electrical conductivity of the detectors. MCT detector is highly sensitive and used to 
obtain good quality spectra.  
 
2.2 Theory of Infrared (IR) Absorption Spectroscopy  
 
Photon energies associated with the infrared region of the electromagnetic spectrum are 
not large enough to excite electrons, but may induce vibrational excitation of covalently 
bonded molecules. At temperatures above absolute zero, all the atoms in molecules are 
in continuous vibration with respect to each other. When a beam of electromagnetic 
radiation is passed through a substance, it can be either absorbed or transmitted, 
depending upon its frequency and the structure of the molecule it encounters. Thus 
when a molecule absorbs radiation it gains energy as it undergoes a quantum transition 
from one energy state to another and excites molecular vibrations. The mode of 
excitation depends on the wavelength of the light. Electrons are promoted to higher 
orbitals by ultraviolet or visible light, molecular vibrations are excited by infrared light, 
and rotations are excited by microwaves.  
 
The spectrum of a molecule depends on its energy level structure and therefore the 
absorption spectra are useful for identification of compounds. Measuring the 
concentration of an absorbing species in a sample is accomplished by applying the 
Beer-Lambert Law (Lasch 2002).  
 
A = a b c         Eq. 1 
 
Where A is the intensity (the amount of radiation absorbed) of the band; a is the 
absorbitivity or extinction coefficient which depends on the nature of the absorbing 
species, b is the sample thickness and c is the concentration of the component of 
interest.    
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IR absorption information is presented in the form of a spectrum with wavenumber at 
the x-axis and the absorption intensity or % transmittance the y-axis. Transmittance is 
the ratio of radiant power transmitted by the sample to the radiant power incident on the 
sample. Absorbance is the logarithm to the base 10 of the reciprocal of the 
transmittance.  
 
Absorption of IR is restricted to compounds with small energy differences in the 
possible vibrational and rotational states. When the radiant energy matches the energy 
of the specific molecular vibration, absorption occurs. In order to absorb IR radiation 
the covalent bond of a molecule must undergo a net change in dipole moment as a 
consequence of its rotational or vibrational motion (Figure 2-3) (Siebert 2008). The 
vibrational wavenumber must also be identical to the wavenumber of the incident 
radiation. The dipole moment changes as the bonds expand and contracts. In contrast, if 
the vibration affects the polorisability of the molecule then the vibrational mode will be 
Raman active. 
 
 
 
Figure 2-3: Change in the dipole moment of a molecule. The symmetric stretch in 
carbon dioxide is not IR active because there is not change in the dipole moment. 
The asymmetric stretch is IR active due to a change in dipole moment. 
 
As the selection rules for Raman and IR are complementary, Raman can be used to 
detect vibrations missing in a compounds IR spectrum. Vibrations that are prominent in 
an infrared spectrum, those involving polar bond (e.g. C-H, C-Cl and C=O) and strong 
dipole moments are usually weak in a Raman spectrum. Likewise, non-polar vibrations 
that give very strong Raman bands usually result in weak infrared signals. For example, 
hydroxyl or amine stretching vibrations and the vibrations of carbonyl groups, are 
usually very strong in an FT-IR spectrum and usually very weak in a Raman spectrum. 
However, the stretching vibrations of carbon-carbon double or triple bonds and 
O C O 
No change in dipole  
O C O 
Change in dipole  
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symmetrical vibrations of aromatic groups are very strong in the Raman spectrum 
(McClain 2000). 
 
2.3 Vibrational Modes 
 
The absorption of IR radiation by a molecule is induced by changes in molecular 
dipoles associated with vibrations and rotations. Only a few compounds exhibit pure 
rotational bands and therefore are of little use. The vibrational absorption bands are of 
more interest. Vibrations can be subdivided into two types, depending on whether the 
bond length or angle is changing: stretching and bending. Stretching is a symmetric or 
antisymmetric rhythmical movement along the bond length. The bending vibration 
occurs when the bond angle between two atoms or a group of atoms change (Siebert 
2008). These motions are known as scissoring, wagging, rocking, and twisting as 
illustrated in Figure 2-4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4: Vibrational modes 
 
 33 
Asymmetrical stretching                    Scissoring (bending in  
                                   and out of the plane) 
  -         +          
- 
Symmetrical stretching               Scissoring (bending in  
                              the plane) 
According to group theory, a molecule consisting of n atoms has 3 n degrees of freedom 
(Lasch 2002). In a nonlinear molecule, 3 of these degrees are rotational and 3 are 
translational and the remaining corresponds to fundamental vibrations; in a linear 
molecule, 2 degrees are rotational and 3 are translational. Water, which is nonlinear, has 
three fundamental vibrations (Figure 2-5A) and carbon dioxide, CO2, is linear and 
hence has four fundamental vibrations (Figure 2-5B).  
 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5: a) Stretching and bending vibrational modes for H20 and b) Stretching 
and bending vibrational modes for C02 
 
A symmetrical vibration produces no change in the centre and therefore is infrared 
inactive resulting in weaker vibrations. In contrast, the unsymmetrical stretching gives a 
charge separation and thus is capable of interacting with radiation of the same 
frequency. Stretching frequencies are higher than corresponding bending frequencies. It 
is easier to bend a bond than to stretch or compress it. Bonds to hydrogen have higher 
Symmetrical            Asymmetrical stretching    Scissoring (bending) 
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stretching frequencies than those to heavier atoms. Triple bonds have higher stretching 
frequencies than corresponding double bonds, which in turn have higher frequencies 
than single bonds. 
 
2.4 Infrared spectrum of bio-molecules 
 
Molecular vibrations characterising different molecules can be found along the entire IR 
spectrum (Figure 2-6). The majority of analytical IR applications are confined to the IR 
region between 2000 and 650 cm
-1
. This is called the fingerprint region of the spectrum. 
As most of the functional groups have relatively sharp absorption bands in the 
fingerprint region, quantification of the components can be determined using data 
handling techniques.  
 
 
Figure 2-6: Correlation chart with functional groups in the IR fingerprint region 
from ranging between 2000–650 cm-1. Adapted from www.biomedcentral.com 
 
 
FT-IR spectroscopy probes the biochemical composition of a sample and determines the 
precise position and amplitude of infrared (IR) absorption by biochemical bonds. 
However, visual interpretation of IR spectra is very complex as the IR spectra results 
from various vibrational modes of molecules. Despite the complex molecular structure 
of cells, the major vibrational modes of molecules belong to lipids, proteins, nucleic 
acids and polysaccharides (carbohydrate). 
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2.4.1: Lipids  
 
Lipids provide sources of energy for cells and play a major role as components in 
biological membranes. Spectral absorptions of lipids are found within the 3000-2800 
cm
-1 
region. The bands at 2852, 2874 cm
-1 
are due to the symmetric CH2 stretching of 
the methylene chains in membrane lipids (Lasch 2002); peaks at 2922 and 2960 cm
-1 
is 
due to the asymmetric CH2 and CH3 stretch (Mourant 2003; Lasch 2002). Other lipid 
bands mentioned in literature have absorption at 1099,1742, 1468, 1171 and 1058 cm
-1 
were assigned to the C = O (ester) stretch, CH2 bend, C-O (ester) stretch and C-O 
stretch, respectively (Manoharan 1993). Lipids have long hydrocarbon chains and 
therefore their have peaks at 1352 cm
-1 
(CH3 vibration) and 1740 cm
-1
 (C=O (ester) 
stretch) (Lasch 2002 and Erukhimovitch 2002). 
 
2.4.2 Proteins 
 
Proteins within single cells catalyze chemical reactions; provide structural rigidity, 
control membrane permeability and provide the means for gene expression. Proteins are 
composed of individual units called amino acids. In the spectra of a cell, intensive bands 
due to amide I (1620-1690 cm
-1
) have been observed (Andrus 1998; Mourant 2003; 
Lasch 2002 and Gasparri 2003). These corresponds to the C=O stretching coupled to the 
N-H bending and the C-H stretching modes of peptide bonds (Sarver 1991; Chapman 
1989 and Mourant 2003). Amide I band frequencies have been correlated with the 
presence of α-helices, β-sheets, β-turns and random coils (Byler 1986). It is well 
documented that absorbance in the range from 1645 to 1662 cm
-1 
is generally associated 
with the presence of α-helices (Byler 1988). Absorption bands between 1613-1637 cm-1, 
1662-1682 cm
-1
 and 1637-1645 cm
-1 correspond to β-sheets, β-turns and random coils 
respectively. The amide II band between 1530-1570 cm
-1
 arises from the vibrational 
modes that involve the C-N-H bending and C-N stretching of peptidic bonds
 
(Andrus 
1998; Gasparri 2003 and Lasch 2002). The amide III band between 1240-1340 cm
-1
 is 
contributed by proteins arising from C-N stretching and N-H bending (Andrus 1998; 
Mourant 2003 and Gasparri 2003).  
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2.4.3 Nucleic Acids 
 
A single cell consists of two types of nucleic acids. DNA is found mainly in the nucleus 
of the cell, while ribose nucleic acid (RNA) is found mainly in the cytoplasm of the cell 
although it is usually synthesized in the nucleus. The DNA contains the genetic codes to 
make RNA and the RNA contains the codes for the primary sequence of amino acids to 
synthesize proteins .Both nucleic acids have infrared active vibration in the region 900-
1300 cm
-1
 (Benedetti 1997 and Omberg 2002). Nucleic acid signals contribute to the 
infrared spectra at 1091 cm
-1
 (sym PO2
-
), 1065 cm
-1
 (PO2
-
 and ribose groups) and 968-
972 cm
-1
 (phosphodiester group present in the DNA and RNA)
 
(Lasch 2002 and 
Benedetti 1997).  
 
2.4.4 Carbohydrates 
 
Carbohydrates collectively include sugars, starches, saccharides, and polysaccharides. 
The name "carbohydrate" means a “hydrate of carbon”. Sugars are present in single 
cells as glucose, which provides source of energy. Polysaccharides are either found in 
free-state or bound to proteins known as glycoproteins. Major absorption peaks are 
observed at 1028 cm
-1
 (C-OH, C-O stretch), 1080 cm
-1
 (C-OH, C-O stretch), 1095 cm
-1
 
(CH2, C-C stretch) and 1455 cm
-1
 (CH2, C-H bending) (Lasch 2002).  
 
2.5 Infrared spectroscopy in cell and tissues  
 
A large portfolio of research covering extensive FT-IR studies of malignant tissue has 
been established. A review of all tissue studies is beyond the scope of this thesis. 
However, important publications related to different disease sites are briefly 
summarised in Chapter 3. Advancement in infrared spectroscopy has permitted analysis 
at single cell level and extended the capabilities of this methodology to investigations 
based on cell morphology and supplementary biochemical information contained within 
the IR spectra. A review of single cell studies is also provided in Chapter 3.  
 
 37 
2.6 Limitations of FT-IR spectroscopy 
 
Limitations of FT-IR spectroscopy: 
1) It cannot detect single atoms as they do not contain chemical bonds. 
Consequently, they do not absorb infrared radiation and hence and do not possess any 
vibrational motion. Diatomic molecules, such as N2 and O2 also do not absorb infrared 
radiation and are also not detected. 
 
2) The spectra acquired from samples are complex with overlapping bands and can be 
difficult to interpret. Peaks often correspond to more than one molecule.  
 
3) Aqueous solutions have been proven to be difficult to measure. Water is a strong 
infrared absorber in specific wavenumber ranges (1270-2000 cm
-1
and 3200-4000 cm
-1
) 
and causes difficulty in infrared spectrum analysis. So FT-IR works best with solids, or 
films. 
 
4) FT-IR spectrometers are a single beam technique. The samples and the background 
are measured at different times. In order to eliminate the instrumental and 
environmental contributions to the spectrum, the sample spectrum is ratioed against the 
background spectrum 
 
5) The thickness of the sample has to be less than 10 microns for IR measurements.  
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IR spectroscopy is a powerful tool and is widely used for the study of bio-molecular 
structures. Being highly specific and sensitive, spectroscopy of molecular vibrations 
using mid-infrared has proven to be of great value in fields of biology and medicine for 
the analysis of biochemical compositions. This chapter reviews the application of 
infrared (IR) spectroscopy in various biomedical applications. The first Section (3.1) 
briefly summarises the diagnostic applications of in human malignant tissues. The 
spectroscopic study of biological cells is an
 
active area of research. Recent publications 
on single cell analysis are reviewed in Section 3.2. The analysis of analytes in bio-fluids 
is discussed in Section 3.3 and finally, Section 3.4 reviews the application of FT-IR 
spectroscopy in the field of Haematology. 
 
3.1 FT-IR spectroscopy in tissue diagnostics 
 
Several research groups have established that IR spectroscopy can distinguish normal 
from diseased (malignant) tissue in a variety of organs. The majority of groups have 
focused their analysis on FT-IR imaging using an array detector that permits 
simultaneous imaging of tissue areas as an objective method. By collecting infrared 
spectra at each sampling point (pixel), it has been possible to acquire infrared spectral 
maps for tissue sections obtained from biopsy samples. In all cases, the spectral dataset 
acquired as a result of FT-IR spectroscopic imaging has been subjected to various data 
pre-processing modalities and multivariate analytical techniques in order to detect 
spectral differences.   
 
FT-IR spectroscopic imaging technique has been applied to examine precancerous and 
cancerous tissue within biopsies from a variety of disease sites, such as cervical 
(Chiriboga 1998; Rigas 2000; Wood 2004); breast (Gao 1999; Dukor 1998; Eckel 2001; 
Fabian 2003); lung (Wang 1997; Yano 2000; Krafft 2008), oesophagus (Wang 2003; 
Wang 2007; Maziak 2007); Colon (Rigas 1990, Salman 2004; Lasch 2004), liver (Diem 
2000), thyroid (Lui 2003) and prostate (Paluszkiewicz 2001; German 2006).  
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The main target of these studies is development of a clinical diagnostic method for early 
cancer detection. All studies have reported biochemical differences between normal and 
malignant tissues, which have been shown to correlate well with diagnoses provided by 
pathologists. Due to the heterogeneous nature of biological tissue, the infrared spectrum 
obtained from these sources consists of several absorption bands.  Major peaks have 
been identified, corresponding to proteins, nucleic acids, lipids, and carbohydrates, 
which are the main constituents of biological tissues. RNA, DNA and protein levels 
were found to rise with proliferation and malignant grade while lipid levels remain 
constant with increasing malignant grade (Andrus 2006; Lasch 2002; Andrus 1998; 
Sahu 2004). 
 
3.2 FT-IR spectroscopy in single cells 
 
Spectroscopic studies of individual cells are more complicated than those of tissues. The 
initial work investigating the application of IR spectroscopy in detection of cancer cells 
was undertaken by Wong (1991). Several spectral differences were noted between 
normal and malignant cervical cells. However the results were based on visual 
inspection of spectra which is subject to bias. In addition, experimental method 
involving the use of pap smears (Papanicolaou test used to detect premalignant and 
malignant processes) is flawed, as pellets of cells were analysed rather than individual 
cells, contributing to variability in sample thickness and hence contributing to bias. 
Furthermore, pellets of cells generate grossly abnormal spectra. An extensive 
investigation into the potential confounding variables associated with cervical Pap 
smears was carried out by Wood (1998). Through analysis of different cell types and 
other variables and contaminants (mucous, blood and leukocytes) present in Pap smear 
by FT-IR spectroscopy it was found that visual inspection of spectra could potentially 
result in misdiagnosis.  
 
With the goal of developing a more robust and sensitive spectroscopic diagnostic 
method, a multitude of single cell studies have been embraced over time. A thin 
preparation approach was developed to filter out debris and spread cells uniformly on 
slides (Cohenford 1998).  
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Given a number a potential confounding variables associated with cell analysis (Wood 
1998), in most cases infrared spectroscopy has been coupled to multivariate analytical 
techniques to create effective and sensitive classification tools to determine spectral 
variance associated with cellular heterogeneity. Extensive studies using this combined 
approach have been conducted on cervical cancer cells (Wood 1996 and Cohenford 
1997). In a more recent study cervical cell samples screened by FT-IR spectroscopy was 
compared with histological diagnosis (gold standard). FT-IR results versus histology 
showed sensitivity of 96.3% and specificity of 96.4 % (Sindhuphak 2003). 
  
The characteristics of human cells have been studied by IR spectroscopy indicating 
significant differences between cellular cytosol and nuclear spectral signatures. Large 
differences are revealed in the spectral contributions of RNA, DNA and phospholipids 
in metabolically inactive cells (showing spectral signatures of proteins only) and 
dividing cells (showing spectral signatures of nucleic acids and phospholipids) (Diem 
2002). Boydston-White (1999), revealed differences
 
in FT-IR spectra between 
proliferating myeloid leukaemia (ML-1) cells in different phases
 
of the cell cycle as 
being due to alterations in DNA content
 
or amide I and II protein structure. Results 
show pronounced DNA detection in the S phase of cell cycle (DNA replication) and 
cytoplasmic RNA in the G1 a G2 phases of the cell cycle. Furthermore, cells in G2 
phase synthesis more RNA than cells in G1 phase, resulting in boarding of RNA 
absorption bands. In an extended study of HeLa cells by microspectroscopy, changes in 
the spectrum of a single proliferating cell were also observed. This study reported 
spectral changes due to drastic biochemical and morphological changes occurring due to 
state of maturation, differentiation and development during cell proliferation (Boydston-
White 2006). A similar study Mourant (2003) also assessed spectral differences in 
different proliferative states i.e. exponential (proliferating) or plateau (non-proliferating) 
phases
 
of growth of fibroblast cells and reported that cell proliferation plays an 
important role in cancer initiation and progression. The ratios of RNA/lipid and 
protein/lipid increased
 
when the cells were in the exponential phase compared to the
 
plateau phase of growth. For these studies, homogeneous cell fractions obtained through 
centrifugal separation were utilised.  
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Research on single cancer cells is ongoing and subsequently a study by Matthaus 2006 
reported the first IR microspectral imaging of mitotic human cells at different stages of 
mitosis. They report that variations in the intensities of protein and DNA spectral 
markers are dependent on chromatin density during the sub-phases of mitosis. It is well 
documented that distinct features differentiate between normal and malignant cells 
(Diem 2008). These include: 
 Morphology and size of malignant cells are more variable compared to normal 
cells 
 Malignant cells consists of larger and multiple nuclei than normal cells, 
therefore contain higher level of DNA and RNA 
 Reduced glycogen level in malignant cells. 
 
Single cell mapping at a sub-cellular level has been investigated on different types of 
cells. Studies have been conducted at a sub-cellular level revealing distinct variations 
between nuclear, heavy mitochondrial and light mitochondrial regions of a cell (Lasch 
2002). IR microspectroscopy studies for individual normal and cervical cancer cells are 
also reported that allows a distinction between nuclear and cytoplasmic regions. 
Metabolically inactive cells have revealed spectral signatures of prominently proteins. 
In contract actively dividing cells also show spectral signatures of nucleic acids and 
phospholipids. Jamin 2003 investigated biochemical heterogeneity in cell death as a 
result of apoptosis and necrosis in single cells. Changes were observed at different 
stages in cell death between spectral regions of 1044-1234 cm
-1
. The total absorbance 
intensity of nucleic acid is shown to be highly influenced by variations in the size of 
nucleus during necrosis and apoptosis.  
 
Most work conducted on the distinction between normal and malignant tissue has 
focused on spectral differences in the spectral region of 600-1800 cm
-1
. However, 
variations in the spectral region of 2800-3200 cm
-1 
have been reported (Sahu 2005). 
Results have shown alterations in lipid and fatty acid profile corresponding to cell 
membranes and organelles during multiplication of cancer cells.  
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Other references to single cell studies include investigations of oral mucosal cells 
(Romeo 2006), epithelial cells (Romeo 2006) and leukaemia cells (Boydston-White 
1999 and Schultz 1996). As investigation of leukaemia cells is the main focus of this 
thesis, detailed review of publications in this area is included in Section 3.4.  
 
3.3 FT-IR spectroscopy in biofluids  
 
Besides the application of FT-IR to the tissue diagnostics and single cell analysis, its 
role in the diagnostic aspects involving body fluids is gaining importance. Mantsch 
group reported the successful diagnosis of rheumatoid arthritis based on near infrared 
(NIR) analysis of synovial fluid (Shaw 1995). Other authors revealed IR determination 
of the lecithin/sphingomyelin ratios in amniotic fluid (Lui 1997). The practical use of 
mid-IR spectroscopy in quantitative clinical applications has been previously 
demonstrated for serum analysis (Shaw 1998) and urine analysis (Shaw 2000) using 
partial least squares to calculate concentration of different analytes. For example, it was 
found that at least six serum analytes, namely albumin, total proteins, glucose 
triglycerides, urea, and cholesterol may be quantified on the mid-IR spectra of dried 
serum films (Shaw 2000; Petibios 1999). Measurements of the concentrations of 
glucose, total protein and cholesterol in human plasma have also been performed 
(Deleris 2003). The feasibility of FT-IR spectroscopy for the quantification of serum 
LDL-cholesterol and HDL-cholesterol concentration has also been reported (Lui 2002). 
Partial least squares (PLS) was utilised in most bio-fluid analysis as both the dependent 
and independent variables (absorbance and concentration) are used in the development 
of the calibration model. Recently attenuated total reflection (ATR) FT-IR spectroscopy 
has been developed for the quantitative analysis of blood plasma, whole blood and urine 
constituents. PLS was used to construct a prediction model which can calculate the 
concentration of albumin, cholesterol, glucose, total protein, urea and triglyceride in 
whole blood or blood plasma samples. For urine samples a calibration model was 
constructed to predict concentrations of urea, uric acid and phosphate and creatinine 
(Hosafci 2007).  
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Whole blood samples are also used for screening different diseases and cancer 
diagnostics as blood is more homogenous and requires very little sample preparation. In 
most cases, quatification of analytes in whole blood by infrared spectroscopy is 
performed on isolated cells that are dried into a thin film (Low-Ying 2002). However, 
Shen 2003 determined the concentration of glucose in aqueous whole blood samples 
using FT-IR spectroscopy and PLS analysis. Furthermore, Khanmohammadi 2007 
distinguished between healthy subjects and those with basal cell carcinoma (BCC) by 
investigating the IR absorbance spectra from aqueous blood samples. Major spectral 
changes were observed in proteins and nucleic acids between the normal and BCC 
samples. Furthermore results revealed 96.7% of accuracy when compared to current 
clinical methods.  
 
3.4 Applications of FT-IR in Haematology 
 
It is only in recent years that IR spectroscopy has been adequately well-developed to 
enable spectroscopic studies of cells and molecules within blood. There are various 
contributions of IR spectroscopy to haematological malignancies, including studies of 
differentiation between normal leucocytes and leukaemic cells; classification and 
establishment of DNA modifications in leukaemia; chemotherapy assessments, 
determination of apoptosis in leukaemia cells and differentiation of clinico-pathological 
subdivisions of lymphoma. 
 
3.4.1 Differentiation of leukaemic cells from normal leukocytes 
 
An initial infrared study by Polli (1955) demonstrated no spectroscopic differences 
between the DNA isolated from normal and leukaemic human leukocytes. Following 
improvements in IR spectroscopic instrumentation and techniques, research carried out 
by Benedetti 1984 revealed various differences in the infrared spectra obtained from 
isolated normal and leukaemic cells. They used a group frequency concept and 
identified two DNA marker bands in the IR spectrum, at 966 cm
-1
 and 530 cm
-1
 
characteristic for lymphoid leukaemia. In addition, they showed that the ratio between 
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two integrated spectral areas (the symmetric PO
-2
 stretching absorption band at 1080 
cm
-1
 and the amide II absorption band at 1540 cm
-1
) discriminates between normal 
lymphocytes and leukaemic cells. Total DNA content was increased in leukaemic cells 
isolated from either CLL or from ALL cases, compared to that in normal mononuclear 
cells. 
 
Rather than relying on the classical group frequency approach to identify individual 
marker bands and interpret changes in the infrared spectra of leukaemic cells, Schultz 
(1996) alternated to pattern recognition algorithms that make better use of all the 
fingerprint-like characteristics of the infrared spectrum. Spectral characteristics of 
human lymphocytes isolated from the peripheral blood of normal and leukaemic (CLL) 
subjects were analysed. Multivariate statistical analysis has been used to classify spectra 
into intrinsic groups. Unsupervised multivariate analysis revealed that spectra from 
normal blood separated into two subgroups, due to variations in the proportion and 
degree of activation of lymphocytes and monocytes and differences in DNA and lipid 
content. In contrast, the CLL cells separated into three subgroups distinct from the 
normal cell grouping due to cytogenetical variations corresponding DNA content. 
Supervised multivariate analysis including LDA has been used to construct a 
classification model and to identify new samples. This method was successfully applied 
to discriminate between sensitive and multi-resistant human leukaemic K562 cells using 
cross validation (Gaigneaux 2002). 
 
FT-IR spectroscopy has also been applied to the analysis of human plasma samples for 
monitoring and identification of patients with chronic lymphocytic leukaemia 
(Erukhimovitch 2006). Results showed reduction of carbohydrate, Amide III and amino 
acid peaks in CLL patient plasma samples compared to plasma samples obtained from 
healthy persons to due to higher metabolic activity and lower levels of nutrients in 
leukaemia cells. 
 
These findings reveal that CLL cells can be differentiated from normal cells using FT-
IR spectroscopy, based on qualitative and quantitative differences at the DNA, protein 
and lipid levels. For example, leukaemic cells have increased DNA content, 
conformational alterations in DNA, and reduced lipid content signifying that infrared 
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spectra can contain valuable information to allow differentiation of the cell state that 
can be used for diagnostic purposes.  
 
3.4.2 Chemotherapy and sensitivity/resistance assessments 
 
A study by Lui (1997) extended the previous studies by Schultz (1997) from diagnosis 
to prognosis. They assessed whether variations observed in FT-IR spectra of CLL cells 
can be used to predict the ex vivo sensitivity/resistance to treatment with two common 
antileukaemic drugs, chloroambucil and cladribine. The spectral changes indicated that 
the main cellular changes responsible for differences in the drug-sensitive or drug-
resistant cells were: lipids, sugars/phosphates (DNA and RNA) and proteins.  
 
A further study by Schultz (1997) showed a new aspect of infrared diagnosis of CLL – 
patient monitoring. They revealed that utilising a differential of cell alteration in CLL 
(indicative for DNA base pairing), it seems to be possible to monitor the disease 
progression of patients over time and after drug treatment. A relative intensity of a DNA 
band seems to be indicative of the severity of the disease and may predict the outcome 
of drug-treatment (Schultz 1997). These promising results may also provide the 
foundation for a future diagnostic tool of blood cancer in haematology. 
 
In a recent publication, Ramesh (2002) employed FT-IR spectroscopy to follow-up 
chemotherapy treatment for B- and T-cell childhood leukaemia patients. Predominant 
spectral changes in the leukaemic cells occur in the region between 1000 and 1200 cm
-1
, 
which corresponds to the cellular nucleic acids. Good conformity was noted between 
reduced cellular nucleic acid content and reduction of blasts, due to chemotherapy 
treatment, in both B- and T-cell patients. Decreased levels of total carbohydrates, 
cholesterol, phospholipids and proteins level were also observed.  
 
A study by Sahu (2006) assessing the effectiveness of chemotherapy in leukaemia 
patients have also reported similar patterns in spectral difference in the WBC of an adult 
AML patient and a child ALL patient. Results reveal that phosphate absorbance from 
nucleic acids and the lipid-protein ratio in the WBC decreased immediately after 
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treatment (Sahu 2006). Understanding the molecular changes in cells following 
chemotherapy treatment could be used for monitoring of patients during chemotherapy. 
 
3.4.3 Determination of apoptosis in leukaemia cells 
 
The deregulation of apoptosis, a pre-programmed physiological mode of cell death, is of 
great importance in the pathogenesis and progression of cancer. As an active process, 
apoptosis is accompanied by profound biochemical changes to three essential cellular 
components, i.e. DNA, proteins and lipids simultaneously and may provide a new tool 
for monitoring the apoptotic process and its effect on the conventional anticancer drugs 
and irradiation therapy. Several research groups have demonstrated that IR spectroscopy 
can detect apoptosis induced by different reagents in various cell lines. Research by Lui 
2001 applied IR spectroscopy to estimate the percentage of apoptotic leukaemic cells in 
two different cell lines (CEM and 562) induced with etoposide (VP-16). Apoptotic 
changes in DNA were observed in the spectral region between 900-1300 cm
-1
. As the 
percentage of apoptosis increases, the protein structure of the treated cells shifts from ß-
sheets to unordered (random) coil, the overall lipid content increases and the amount of 
detectable DNA decreases.  
 
Similar findings were obtained in a recent study carried out by Gasparri 2003 who 
induced apoptosis in the human promyelocytic leukaemia cell line, HL60, with 
camptothecin, a cytotoxic drug over a period of time and analysed apoptotic cells by 
using a FT-IR approach based on an attenuated total reflection (ATR). A decrease in the 
overall spectral DNA in the apoptotic cells was observed.   
 
3.4.4 Differentiation of lymphoma clinico-pathological grades  
 
A study by Andrus (1998) has demonstrated that FT-IR can distinguish between 
clinically aggressive (high-grade) and clinically indolent (low-grade lymphomas) based 
on the nucleic acid absorbance ratio. They observed that absorbance ratio A1121/A1020 
increased, along with the emergence of an absorbance peak at 1121cm
-1
, with increasing 
clinico-pathological grade of malignant lymphoma. Furthermore, the absorbance profile 
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moves closer to that of RNA and further from that of DNA with increasing lymphoma 
clinico-pathological grade. This is because clinically aggressive neoplasms have more 
cycling cells in the G1 and S phases of the cell cycle and/or fewer apoptotic cells, and 
therefore greater absorbance at 1121cm
-1
 (RNA) relative to that at 1020cm
-1
 (DNA) 
when compared with indolent neoplasms. Absorbance attributable to collagen increased 
with lymphoma grade and was greater in benign inflammatory tumours than in low-
grade lymphomas. The A1121/A1020 trend observed may form the basis of a universal 
cancer grading to assist with cancer treatment decisions. FT-IR micro-spectral imaging 
of non-Hodgkin lymphoma is also reported using Focal Plane Array detector (Burattini 
2007). Spectral differences were reported between reactive and tumour lymph nodes. 
Major spectral differences between normal and malignant spectra were identified in the 
low frequency region. Spectral classification using principal component analysis (PCA) 
and hierarchical cluster analysis (HCA) between distinct compartments such as 
intrafollicular, interfollicular and mantle zones of healthy and tumoral lymph nodes 
were also reported. 
 
3.5 Summary  
 
This chapter has documented that a great deal of work has been done on various 
cancerous and precancerous tissue types. FT-IR spectroscopy has also shown to be 
feasible in single cells studies and bio-fluid analysis. However, due to the complexity of 
the leukaemia and lymphomas classification system and variations in the biochemical 
composition of different lineages of leukemic cells, there is a need for a more reliable 
classification algorithm to discover spectral patterns and characterise spectral 
differences among different cell progenitors.   
 
To date various research publications have focused their attention on detection of only 
one subtype of leukaemia, mostly comparing spectral signatures of normal and chronic 
lymphoblastic leukaemia (CLL) cells. Previous FT-IR spectroscopic studies have used 
only spectral differences between normal and abnormal cells, PCA or HCA to 
demonstrate potential causes contributing to the variance in spectra rather than 
classifying the biochemical and spectral variations.  
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This aspect has been ignored in previous studies, but needs to be understood for 
diagnostic applications of infrared spectroscopy. This research project investigates 
whether FT-IR spectroscopy can be applied in the classification of multiple sub-types of 
leukaemia and lymphoma cells. The focus of this thesis is to construct a classification 
model to classify cells derived from human T-cell lymphoma, B- cell lymphoid, and 
myeloid leukaemia cell lines by using a combination of spectroscopic measurements 
and powerful multivariate (supervised and unsupervised) statistical analysis. The focus 
of the research has also expanded to include the investigation of normal and CLL blood 
samples as well as blood fractions (plasma and buffy coat) in order to obtain more 
information on cellular composition. To date, no one to our knowledge has compared 
the biochemical composition of whole blood, plasma and buffy coat blood fractions 
with FT-IR spectroscopy. Understanding differences in the biochemical composition of 
various fractions of blood by FT-IR spectroscopy is fundamental to understanding 
disease progression as well as diagnostics and screening of different cancers. In an 
attempt to use valuable information from full blood count through laboratory 
investigations, partial least squares was utilised to develop a predictive model to 
determine concentrations of neutrophil, lymphocyte, monocyte, eosinophil and basophil 
in buffycoat samples. 
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This chapter reviews the techniques used for pre-processing spectral data and 
subsequent chemometric techniques used for developing a classification model. The 
main emphasis is on both univariate and multivariate analytical techniques.   
 
4.1 Data pre-processing 
 
Raw data acquired through FT-IR spectroscopy requires spectral manipulation to extract 
qualitative and quantitative information. Spectra are subjected to pre-processing 
methods to effectively suppress or eliminate unnecessary artefacts and noise. Noise can 
obscure important features within the IR spectra such as peaks or peak widths, therefore 
calculations of peak areas and peak widths can prove difficult. 
 
In this study, the methods of spectral manipulation employed include: smoothing, 
spectral derivative, normalization and mean-centring. The applications of either 
standard deviation or an absorption filter tool in order to further improve the quality of 
dataset were also investigated.  
 
4.1.1 Smoothing  
 
The Savitzky-Golay smoothing filter was applied using the “Savgol” function from the 
PLS toolbox in Matlab. The Savitzky-Golay smoothing filter was used to smooth a 
noisy signal (high frequency fluctuations) in spectra. The filter is defined as a weighted 
moving average with weighting given as a polynomial of a certain degree (Savitzky 
1964). The filter uses any number of points for the weighted average. However, over 
smoothing using a large number of points can distort band shapes and therefore; a nine-
point Savitzky-Golay zero-derivative filter was used in this study.  
 
 
 50 
4.1.2 Spectral Derivative  
 
Derivation is used to eliminate fluctuations in the baseline (first derivative) and slope 
(second derivative) of the absorption spectra. Calculating the derivative of a mean 
spectrum is a method of identifying peak frequencies of biochemical components and 
therefore provides qualitative and quantitative information. It also causes effective 
narrowing of spectral features, which may enhance the specificity of the method.  
 
An infrared spectrum can be described as a mathematical function; therefore one can 
calculate and determine the slope of such function by taking the derivative (Ng 1999). 
The resulting derivative spectrum contains important features. In the second derivate 
spectrum, the downward pointing peaks pinpoint the exact wavenumber of the 
maximum absorbance of the peak. These wavenumbers can be used to estimate the 
number of overlapping bands and locate their peak positions (Ng 1999).  
 
4.1.3 Normalization 
 
Normalisation removes the variations in absolute signal intensity as a result of thickness 
variations. Normalisation can either be carried out to a well defined peak, although 
overlapping bands can be difficult, or with the total area under the curve. 
 
4.1.4: Mean-centring 
 
Mean centring is a common approach to standardise data to ensure that spectral 
intensities of each spectrum could be statistically compared to the mean of the dataset.  
Mean-centring is achieved by calculating the mean of the dataset and subtracting that 
mean from each spectrum. 
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4.1.5 Standard deviation 
 
The standard deviation at each wavelength was calculated as a measure of the spread or 
variance of the spectra in a dataset about its mean. A low standard deviation indicates 
that the data points tend to be very close to the same value (the mean); while high 
standard deviation indicates that the data are “spread out” over a large range of values. 
Using standard deviation is an effective method of removing extreme spectra in the 
dataset. These may be likely to include spectra with low signal to noise levels and high 
signal levels indicating thin (or no sample) or excessively thick sample areas. The 
standard deviation used in this study is defined in the methodology Section 5.9.2. 
 
4.1.6 Absorption filter tool  
 
Absorbance filter tool filters out weak or low absorbance. All spectra outside a defined 
absorbance range are removed. The absorbance range used in this study is defined in the 
methodology Section 5.9.2. The absorbance filter tool in combination with other pre-
processing techniques such as normalisation are used to enhance the spectral features 
that incorporate information regarding biochemical composition and effectively 
suppresses or eliminate unnecessary artefacts, noise, calcium fluoride, water and CO2 
signals as well as variations in sample thickness.  
 
4.2 Chemometrics for spectral anlaysis  
 
Univariate analytical methods are the simplest ways of displaying the biochemical 
information and determining peak positions. Although this is a simple approach of 
spectral analysis, it only utilises a small part of the biochemical data. As the intricacy of 
the IR spectrum increases within and between sample types, unambiguous assignment 
of the spectral bands to specific molecular groups becomes more difficult. Therefore in 
complex biological samples, multivariate statistical techniques are employed as they 
utilise the entire spectra and all of the biochemical information contained within the 
spectra. It is therefore likely to provide a more rigorous approach at separating spectra 
by cell type. Two generic strategies of multivariate analysis namely, supervised and 
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unsupervised classification methods, were used to retrieve analytical information from 
the IR spectra.  
 
4.2.1 Univariate Analysis  
 
Univariate methods used in this study include: assignments of peaks for identification of 
specific spectral features; calculating difference spectra and measurements of absolute 
peak intensity and peak intensity ratios. 
 
4.2.1.1 Peak assignments 
 
In order to identify spectral signatures a “group frequency approach’ was used as an 
traditional univariate method of spectral analysis and assigning key peak positions to 
mean spectrum. This approach monitors vibrations due to pre-assigned specific 
functional groups (e.g. C=O, N-H, C-H, etc) and explores changes in these functional 
groups as potential disease biomarkers.  
 
4.2.1.2 Peak Intensity Ratio 
 
Absolute peak intensity of the mean spectrum was calculated to determine variation 
amongst spectra that are not identified visually and also to determine possible changes 
in peak positions and peak shifts. The intensities (height) of the most significant peaks 
in the mean IR spectra were measured relative to the baseline. The intensity values were 
then used to calculate peak ratios.  
 
Peak intensity ratio calculations reflect changes in the content and structures of proteins, 
nucleic acid and fat in cells, thus the diagnosis of cancer cells could be made at 
molecular level. This method of has been used for detailed spectral analysis by many 
groups (Wang 2003; Mordechai 2005; Bonnier 2006). In this study, peak intensity ratios 
corresponding to proteins, lipids and nucleic acids were used.  
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4.2.1.3 Difference spectra 
 
Spectra are often similar visually, with only subtle variations in peak height and peak 
position from one group to another. Calculating difference spectra emphasizes the 
variation between spectra. A difference spectrum was calculated by subtracting the 
mean normalized spectrum from one group from the mean normalized spectra from 
another group. 
 
4.2.2 Multivariate Analysis  
 
Combination of unsupervised and supervised multivariate techniques was employed in 
this study to construct a classification model based on variance between the spectra. 
Initially, an unsupervised classification method of principal component analysis (PCA) 
was employed. Supervised classification method, known as linear discriminant analyses 
(LDA) were used to construct a classification model. Many groups have used PCA-fed-
LDA for separation of FT-IR and Raman spectral data (Stone 2000; Kendall 2003; 
Pichardo-Molina 2007 and Lyng 2007) 
 
Furthermore cross validation was used to probe the quality of spectroscopic 
classification and performance of the classification model.  
 
4.2.2.1 Principal Component Analysis (PCA) 
 
PCA is an unsupervised classification method, where the spectra are separated solely on 
measure of their variance. It combines the advantages of both unequivocal classification 
and outlier detection (Bossart 2003). It is a well-established method ideally suited to 
distinguish and visualise small, reoccurring spectral variations in large datasets. These 
can include both spectral data and pseudo-colour PC score images. PCA reduces the 
number of parameters needed to represent the variance in the spectral dataset. It resolves 
a complete spectral dataset into a few key spectral components and can thus identify and 
isolate important trends within the dataset (Lasch 1998). The first principal component 
(PC) represents the highest variance in the spectral dataset; the second PC represents the 
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next highest variance. Noise is introduced in later PCs. ANOVA (“analysis of 
variance”) was used to identify the most significant principal components reflecting 
biochemical trends and differences. The ANOVA test calculates an F-value from the 
sum of the squares of the variance. The larger the F-value results in more effective 
clustering of spectra within a group. Fcrit is also calculated during ANOVA which is 
the cut-off value for 99% significance. 
 
The most significant PC scores for each individual spectrum in the dataset were plotted 
against one another to enable the natural clustering with cell line type or blood group to 
be visualised. This approach identifies natural clusters or grouping with no prior 
knowledge of their classification. Hence PCA is known as an unsupervised technique.  
 
Generally, PCA is not ideal for the separation of the groups. Therefore a multivariate 
technique that involves an external classification scheme to separate spectra must be 
applied.  
 
4.2.2.2 Linear Discriminant Analysis (LDA) 
 
LDA is a supervised method, since the number of classification groups (group identity) 
is dictated rather than discovered during the analysis. It uses PC scores (describing the 
greatest variance in the dataset) to calculate linear discriminant functions that 
maximises the variance between the different groups and minimises the variance within 
each group (Kraft 2006). To prevent over-fitting of data it is important to use minimum 
PCs. LDA has been used widely for classification of gastric biopsies (Wu 2005), 
Thalassemia (Mantsch 2003); oesophagus (Stone 2002; Kendall 2003) and laryngeal 
malignancies (Stone 2000). 
 
4.2.2.3 Leave-one-out Cross Validation (LOOCV) 
 
Preferably, a classification model must be tested using an independent dataset. In this 
study, due to limitations with patient and sample numbers this was not possible. To 
overcome this, leave-one-out cross validation was used. Similar approaches for 
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validating classification models have been used in investigation of synovial fluids from 
joints affected by rheumatoid arthritis and osteoarthritis
 
(Shaw 1995) and classification 
of gastric inflammation and malignancy on endoscopic biopsies
 
(Li 2005). 
 
Leave-one-out cross validation (LOOCV) is often used to test the accuracy of the 
predictions of the classification model. Classification accuracy is assessed whereby the 
class of spectra within a batch is predicted by holding out all of the spectra measured 
from a particular sample (the test set) and building an LDA model with the remaining 
data (the training set). This method is repeated so that each sample in the dataset is left 
out in turn and used once as the test data. Sensitivities and specificities were calculated 
as a measure of model accuracy and performance to evaluate the efficacy of 
classification systems. Sensitivity is defined as the ratio of the number of true positives 
to the sum of true positives and false negatives and the specificity is defined as the ratio 
of the number of true negatives to the sum of true negatives and false positives. See 
equations 2 and 3. 
 
Sensitivity =          No. of True Positives     ×        100%    Eq.2  
   No. of True Positives + No. of False Negatives 
 
 
 
Specificity =          No. of True Negatives     ×        100%    Eq.3 
   No. of True Negatives + No. of False Positives 
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4.2.2.4 Partial Least Squares (PLS) 
 
PLS is useful to extract information from complex spectra and is quantitative spectral 
decomposition technique. It utilizes the spectral data and concentration information 
during the decomposition process. PLS takes advantage of the correlation relationship 
between the spectral data and the concentration of cellular analytes. Two sets of scores 
are produced as a result; one set for the spectral data and the other for the analyte 
concentration which enables a construction of calibration model.  
 
When applied to spectra, PLS analysis finds a mathematical relationship between a set 
of independent variables, the X matrix (Nobjects x Kwavelenghts), and set of dependent 
variables, the Y matrix (Nobjects x Mmeasurements). The resulting model has the form:  
    
Y = XB + E         Eq.4 
 
where B is the matrix of regression coefficients obtained from PLS analysis and E is the 
matrix of residuals (Osborne 1997). PLS is also a regression technique, which utilises 
latent variables (LV). These variables are independent variables. Latent variables, like 
PCs are calculated to determine the most of the variance in the dataset. The first LV 
describes most of the variance in the independent set, the second LV the next largest 
amount of variance and so on. The aim is to obtain most of the concentration 
information into the first few latent variables that account most of the variation to 
include in the model. Cross validation is performed in the construction of PLS model to 
estimate the number of LV required and estimate prediction error. The error is 
determined by fitting a PLS model to n-1 samples and making a prediction value for the 
omitted sample. This was carried for each sample in the dataset and a predictive sum of 
squares (PRESS) was calculated. The CUMPRESS was also calculated, which is the 
cumulative error.  
 
There are two types of PLS algorithms: PLS 1 and PLS 2. PLS 2 calibrate for all 
cellular analytes simultaneously and as a result one set of scores are produced. In PLS 1 
separate scores are calculated for each cellular analyte and therefore separate sets of 
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scores are calculated for each analyte. This gives a more accurate prediction. Since 
separate scores are generated for individual analytes, the speed of calculations is 
considerably increased. In this study PLS 1 was used. 
 
PLS analysis has been used in various studies for the quantification of total proteins, 
cholesterol, high and low density lipoproteins, triglyceride, glucose, urea and uric acid 
(Rohleder 2005; Low-Ying 2002; Petiois 1999) in fluids, cells and tissues (Petiois 
2006).  
 
4.3 Summary  
 
The main analytical techniques used in this study for data analysis have been briefly 
reviewed in this section. It is important that univariate and multivariate analytical 
techniques to create a statistical method to extract the relevant biochemical information 
buried in the spectrum and convert this experimental data to useful diagnostic 
information. Application of these statistical methods has been discussed in Chapter 5. 
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The first Section (5.1) in this chapter begins by defining the pathological classification 
of cell lines used for the preliminary phase of the study. Detailed description regarding 
cell line origin and culture conditions are also discussed in this section. Section 5.1.1 
describes the procedures involved in preparation of cell line samples. Section 5.2 
describes the procedures involved in collection of normal blood specimens from healthy 
subjects and leukemic blood specimens from patients with chronic lymphocytic 
leukaemia (CLL). Isolation of whole blood, plasma and buffycoat and procedures of 
sample preparation are discussed in Section 5.2.3.  
 
Section 5.3 covers the key components of the FT-IR spectrometer, followed by 
sampling techniques in Section 5.4. Sections 5.5 and 5.6 focus on the principles of 
infrared microspectroscopy and FT-IR imaging respectively. Optimised parameters for 
spectral measurements are discussed in Section 5.8. Technical issues such as the effects 
of aperture size and number of co-added scans on the signal-to-noise ratio of spectral 
measurements have been investigated prior to conducting spectral measurements on 
both cell line and blood samples. The final Section 5.9 in this chapter looks in greater 
detail at the spectral measurements as well as the order of statistical and analytical 
methods used in this study.  
 
5.1 Cell lines  
 
The preliminary studies carried out as part of this research project, rely on measuring 
FT-IR spectra from cell line samples. Cell lines as a rich resource of abundant, 
accessible and manipulable living cells were used to better understand the 
pathophysiology of haematopoietic malignancies and identify potential biomarkers. The 
major advantages of using cell lines are the unlimited supply and availability of 
identical (homogenous) cell material unlike real tissues. It is important to use 
homogenous cell material in order to evaluate the potential of spectroscopic methods 
before implementing them on complex cellular material and blood specimens. Another 
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advantage of using cell lines is the possibility to control growth rate and the infinite 
viable storability in liquid nitrogen. 
Leukaemia and lymphoma cell lines used in this study are characterized generally by: 
monoclonal origin i.e. derived from one malignant precursor cell; differentiation arrest 
at a discrete stage during maturation; sustained autonomous proliferation of the cultured 
cells. Leukaemia and lymphoma cell lines originate from different cell lineages based 
on their immunophenotype, genotype and functional features and grow as single or 
cultured cells in suspension. 
 
For the purpose of this study five different cell lines were supplied by the Institute of 
Cancer Research, Sutton. These included: Karpas 299 (Human T-cell lymphoma cell 
line) cells, REH (Human acute lymphoid cell line) cells, RCH-ACV (Human acute 
lymphoid cell line) cells, HL60 (Human acute myeloid leukaemia cell line) cells and 
Meg01 (Human chronic myeloid cell line) cells. A total of 5 sets of the same cell types 
were supplied as separate batches (25 cell samples in total). The cells were grown as a 
suspension in 80-90% RPMI 1640 medium containing 10-20% fetal bovine serum 
(FBS). Cells were maintained at 37ºC in a humidified atmosphere with 5% CO2.  Table 
5-1 gives detailed information regarding cell line origin and culture conditions. This 
information was provided by the Institute of Cancer Research. 
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Cell 
Line  
Cell Type Origin  Medium  Incubation 
 
REH Human B-cell 
precursor 
leukaemia  
Established from the 
peripheral blood of a 15-
year-old North African 
girl with ALL in 1973. 
90% RPMI 
1640 + 10% 
FBS 
at 37 °C with 
5% CO2 
RCH-
ACV 
Human B-cell 
precursor 
leukaemia 
Established from the bone 
marrow cells taken at 
relapse of common ALL, 
7 months after diagnosis, 
from an 8-year-old girl 
treated with 
chemotherapy. 
80-90% 
RPMI 1640 + 
10-20% FBS 
at 37 °C with 
5% CO2 
HL60 Human acute 
myeloid 
leukaemia 
Established from the 
peripheral blood of a 35-
year-old woman with 
AML FAB M2 in 1976; 
90% RPMI 
1640 + 10% 
FBS 
at 37 °C with 
5% CO2 
Meg 01 Human chronic 
myeloid 
leukaemia in 
megakaryocytic 
blast crisis 
Established from the bone 
marrow of a 55-year-old 
man with CML in 
megakaryocytic blast 
crisis in 1983 
90% RPMI 
1640 + 10% 
FBS 
at 37 °C with 
5% CO2 
Karpas 
299 
Human T cell 
lymphoma 
Established from the 
peripheral blood of a 25-
year-old man with T cell 
non-Hodgkin lymphoma 
in 1986; now classified as 
"CD30+ anaplastic large 
cell lymphoma"; cells 
carry the NPM-ALK 
fusion gene 
90% RPMI 
1640 + 10% 
FBS 
at 37 °C with 
5% CO2 
 
Table 5-1: Cell line characteristics and culture conditions. Source: Institute of 
Cancer Research, London 
 
5.1.1 Sample Preparation 
 
Prior to spectroscopic measurements the cells were washed and diluted (1:5) in cold, 
sterile saline (0.9% NaCl) solution. The samples were pelleted by centrifugation at 
3000rpm for 3 mins to concentrate the cells. The pellet was re-suspended in 0.9% 
phosphate buffer saline solution and the washing cycle was repeated twice more. 
Typically 200µL of the final diluted cell samples was transferred onto CaF2 slides by 
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Shandon Cytospin® Cytocentrifuge (1500 rpm for 5 min), a method formerly developed 
for cytology as described below. The cytospin produces a sparse monolayer of cells so 
that cells are separated. Deposition of cellular material using a cytospin has been 
previously used by other groups for FT-IR spectral measurements (Romeo 2006; 
Romeo 2006 and Crow 2005). 
 
Cells were transferred onto two sets of slides for each sample. Both sets of slides were 
then allowed to air-dry at room temperature under airflow for 30 min as thin circular 
disk films (diameter of 5 mm).  The air-drying approach overcomes the difficulties 
associated with strong water absorptions by simply eliminating water from the 
specimen. This also eliminates the spectral inference of water and provides better 
spectral resolution by reducing the water/solute interactions. One of the two sets of 
slides was frozen at -80°C. Prior to FT-IR measurements, the frozen slides were allowed 
to defrost at room temperature. Infrared spectroscopic measurements on dried films 
have been reported by various groups (Boydston-White 1999; Ramesh 2001 and Cohen 
1998).  
 
The Shandon Cytospin® Cytocentrifuge is a thin-layer cell preparation system. It 
consists of Cytofunnel® and a layer of filter paper with a 5 mm diameter hole, which is 
clamped against a CaF2 slide using a Cytoclip™ slide clip (Figure 5-1). The entire 
assembly is placed into a special rotor of a centrifuge, and spun. The centrifugal force 
separates and deposits a thin-layer of cells onto a clearly defined area of the CaF2 slide 
while maintaining cellular integrity. The residual fluid is absorbed into the sample 
chamber’s filter card. 
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Figure 5-1: Assembly of the Cytofunnel and Cytoclip slide clip. Adapted from 
www.thermo.com  
 
5.2 Normal and CLL Blood Samples 
 
5.2.1 Ethical Approval  
 
All experimental procedures of the study were assessed and approved by the 
Gloucestershire Local Research and Ethics Committee prior to commencement. This 
process included review of study design, protocols, patient information and consent 
forms. All study subjects gave informed consent prior to participation. The project REC 
reference number for the study is 06/Q2005/17.  
 
 
5.2.2 Sample Collection  
 
Blood samples were collected from 10 healthy subjects through voluntary 
participitation. 12 chronic lymphocytic leukaemia (CLL) blood samples were collected 
for this study during routine check-up procedures and redundant samples were used for 
research purposes. Full Blood Count (FBC) was carried on both normal and CLL blood 
samples prior to further sample preparation. The FBC reports were reviewed by the 
Consultant Haematologists involved in the research. Subjects with normal FBC (healthy 
volunteers) and those with a high FBC (CLL patients) were included in the study in 
accordance with the study protocol. 
Cytospin Slide Clip 
CaF2 Slide 
Filter Card 
Sample Chamber 
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5.2.3 Isolation of whole blood, plasma and buffycoat   
 
Blood samples from healthy volunteers and CLL patients were collected in 9 ml vials 
containing ethylene diamine tetra-acetic acid (EDTA) an anticoagulant agent at 25ºC. 
Approximately 3ml was transferred into another EDTA vials as a representative whole 
blood sample. 3 ml of blood was loaded over the 3 ml of histopaque in the Accuspin
TM
 
Histopaque®-1077 tubes (purchased from Sigma-Aldrich, UK) and centrifuged (3000 
rpm for 10 min) at 23ºC. Histopaque tubes were used to isolate lymphocytes and 
mononuclear cells as well as plasma from whole blood with the aid of a separation 
medium, HISTOPAQUE-1077. This is an aqueous solution of a high molecular weight 
polysaccharide and sodium diatrizoate with density of 1.077 g/ml. The separation of 
blood components using the HISTOPAQUE-1077 medium avoids the possibility of red 
blood cell contamination.  
 
On centrifugation of blood, three fractions were generated: fraction A, the red blood cell 
layer (bottom layer), which descends through the “frit” (porous high density 
polyethylene barrier); fraction B, a clear and yellow plasma fraction (top layer) and 
fraction C, the so-called “buffy-coat” (middle layer) mainly consisting lymphocytes and 
mononuclear cells as shown in Figure 5-2. The dense buffycoat layer and the plasma 
fraction were extracted using a pipette into separate glass tubes. For each blood sample, 
3 glass tubes were labelled 1) whole blood, 2) plasma and 3) buffycoat.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: Separation of blood components using HISTOPAQUE-1077 
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5.2.4 Sample Preparation 
 
Approximately 200µl of whole blood, buffycoat and plasma samples were transferred 
onto CaF2 slides by Cytospin® Cytocentrifuge (1500 rpm for 5 min) as described in 
Section 5.1.1 without any sample preparation.  
 
In order to isolate cells from the buffy coat samples, cells were centrifuged (1000rpm 
for 5 min) to concentrate the cells into a pellet. The pellet was washed twice with 
physiological sterile saline (0.9% NaCl) and re-suspended in 100 µL saline to remove 
any adhering media and organic compounds. Buffy coat samples were then deposited 
onto CaF2 slides. Only one slide was prepared per sample which was subsequently 
frozen at -80°C. Prior to FT-IR measurements, the frozen slide was allowed to defrost at 
room temperature. Small volumes of EDTA and Histopaque were also transferred onto 
CaF2 slides to assess any biochemical contribution from these agents on the spectra 
obtained from a blood sample. 
 
5.3 Components of the Spectrum Spotlight FT-IR Imaging System 
 
The infrared spectral data presented in this study were collected using a Perkin-Elmer 
Spectrum One/Spotlight FT-IR Imaging 300 System as shown in Figure 5-3. This 
instrument is incorporated with a computerised microscope x-y-z stage, visual image 
capture software and a highly sensitive, liquid nitrogen-cooled 1 x 16 element HgCdTe 
(MCT) array detector with a step scanning interferometer.  
 
The Spectrum Spotlight FT-IR Imaging System enables the collection of images or 
spectra from small areas of samples either in transmission or reflectance mode. The 
imager includes a camera and viewing system that magnifies the visible light image of 
the sample so that a position of interest can be isolated. The motorised stage, controlled 
by a joystick and the Spotlight software, enables the identification of points of interest 
on the sample and focus the imager.  
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Figure 5-3: PerkinElmer Spectrum Spotlight FT-IR Imaging 300 System 
 
5.4 Sampling techniques 
 
The analysis of cell lines and blood specimens involved a combination of point mode 
measurements and IR image mode studies. The two main techniques generally 
employed for FT-IR spectroscopy are transmission and reflectance. In this study the 
transmission technique was applied, in which the IR radiation passes through the 
sample. This technique generates spectra of high signal-to-noise and can be used for 
solid and liquid samples. However, it is unfeasible to measure samples thicker than 20 
µm as they display a no signal. Samples that are thinner than 1 µm are also difficult to 
measure due to weak absorbance signals.  
 
Prior to any spectral measurements, a background spectrum must be obtained from a 
region of no sample. The background spectrum is used to ratio out the instrument’s 
inbuilt response from sample spectra (Figure 5-4). The transmittance T can be 
calculated as: 
 
 
PC  
Stage controller 
and Joystick 
Spectrum One  
Imager 
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T = I/IO         Eq.5 
where T is the transmittance, IO is the intensity entering the sample, and I the intensity 
passed through the sample at each wavenumber. 
 
The absorbance spectrum can be calculated from the transmittance spectrum using the 
following equation. 
 
A = -log 10 T          Eq.6 
 
 
 
 
 
Figure 5-4: The FT-IR measuring sequence. The final absorbance spectra is 
truncated to highlight fingerprint region between 900-1800cm
-1 
 
Sample 
Interferogram 
Interferogram 
Background 
Transmittance spectra 
Absorbance spectra - log 
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5.5 Infrared Microspectroscopy 
 
In microspectroscopy, an IR microscope is coupled to infrared spectrometer. It permits 
both visual and infrared examination of different parts of the sample. The infrared 
microscope works in visible transmission, visual reflection, infrared transmission and 
infrared reflection. In this study cell line and blood samples mounted on the transmitting 
CaF2 slide were examined in visible mode. Visual images were collected via a CDD 
camera under white light LED illumination and quilted together to produce an image of 
the entire sample deposition area. Various cellular regions were selected from this 
sample image for each cell line and blood sample. 
 
Subsequent to visual examination using visible light, IR point spectra was then obtained 
from cell line and blood samples in transmission mode. Prior to acquiring IR point 
spectra for a sample background spectra was obtained using the same number of scans 
and spectral resolution. The background spectrum was ratioed against the sample 
spectrum.  
 
 
A       B 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5:  A) An example of visual light image obtained from a cell line sample 
and B) zoomed area of cell line sample to enable visualisation of individual cells 
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5.6 FT-IR Imaging  
 
FT-IR spectral image data can be obtained using an FT-IR spectrometer that 
incorporates a step scan transform interferometer, a microscope and a multi element 
Focal Plane Array (FPA) detector. In this study, a 16 x 1 linear array which allowed 16 
spectra to be measured simultaneously. The stage is then moved and 16 more pixels are 
measured and so on until all pixels are measured in the defined area. FT-IR imaging 
data are obtained in the format of a spectral hypercube as shown in Figure 5-6. This is a 
4-dimensional data array consisting of two spatial dimensions, i.e. X-spatial dimension 
(pixels) and Y-spatial dimension (pixels) (Shaw 2000). For each pixel point an 
interferogram is acquired which is then Fourier transformed to obtain an absorption 
spectrum consisting of thousands of data points, depending on the resolution and size of 
the area probed. Infrared micro-spectroscopic imaging has previously been employed in 
various studies including; analysis of lymph node tissue (Romeo 2005); liver tissue 
(Diem 2000); benign breast tumour tissue (Fabian 2003) and aortic tissue (Bonnier 
2006) as well as single cell analysis (Romeo 2006 and Lasch 2002).  
 
High spectral (4 cm
-1
) and spatial (6.25 µm) resolution was used in the study as detailed 
in Section 5.8.3. Resolution is defined as the ability to separate two adjacent features. In 
the case of spectral resolution, this refers to the specific wavelength intervals in the 
electromagnetic spectrum. Narrower bands with minimum intervals within FT-IR 
spectra along the x axis (wavenumber) require a higher spectral resolution. This is often 
difficult in overlapping peaks.  
 
Spatial resolution is the ability to sharply and clearly define the features within an 
image. The selection of pixel size (6.25 or 25µm) is an important consideration.  
Decreasing the pixel size on an image increases the spatial resolution. Therefore using a 
6.25µm is better than 25µm. Spatial resolution has been investigated for spectral 
imaging applications for FT-IR spectroscopy (Wood 2000; Collet 2004; Lasch 2006; 
Kuimova 2009).  
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Figure 5-6: Spectral hypercube displaying intensity values at a given wavenumber. 
Raw spectral data in which the dimension for each pixel point is pixel coordinate 
X, the wavenumber axis and the pixel coordinate Y, the intensity axis. The 
intensity value of each spectrum is assigned a colour and displayed against the X 
and Y coordinates of the spectral element. The intensities at different spectral 
elements show variations in the biochemical composition for each pixel in the 
hypercube. 
 
5.7 Software 
 
Conversion of spectral hypercube into a useable format and conversion of raw FSM 
files into ASCII format was performed using Matlab version 7.4.0 (The MathWorks, 
USA) and the PLS Toolbox (Eigenvector, USA). All spectral pre-processing and data 
analysis was also performed in Matlab. In-house developed tools were used to pre-
process the spectral data and conduct univariate and multivariate analysis.  
 
 
 
 
Pixel X Co-ordinate 
Pixel Y Co-ordinate 
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5.8 Optimisation of spectral measurement parameters 
 
5.8.1 Optimisation: Choice of aperture size 
 
Optimum aperture size was selected by collecting 20 point spectra from pure glucose 
compound over the 720-4000 cm
-1
 spectral region. Figure 5-7 shows the averaged 
spectra obtained with decreasing aperture size from 50 x 50µm to 5 x 5µm. Aperture 
size at 5 x 5µm and 10 x10µm demonstrate a low signal to noise ratio. Increasing the 
size of aperture to 30 x 30µm and 50 x 50µm improves the signal to noise ratio. 
Aperture size of 30 x 30µm was selected for this study as an optimum parameter for 
collecting point mode spectra from all cell line samples and blood specimens. This 
aperture gives better quality spectra with the best signal to noise ratio. 
 
 
 
Figure 5-7: Effects of increasing aperture size on the signal-to-noise ratio of 
glucose spectral measurements 
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5.8.2 Optimisation: Choice of co-added scans 
 
The optimum number of co-added scans was selected by collecting 20 point spectra 
from pure glucose compound over the 720-4000 cm
-1
 spectral region. Each spectrum 
was taken as an average of increasing number of co-added scans. Figure 5-8 shows the 
averaged spectra obtained with increasing the number of co-added scans from 16 to 128. 
Spectra taken as an average of 64 co-added scans was selected for this study as an 
optimum parameter for collecting point mode spectra from all cell line samples and 
blood specimens due to high signal to noise ratio. 
 
 
 
Figure 5-8: Effects of increasing co-added scans on the signal-to-noise ratio of 
glucose spectral measurements 
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5.8.3 Optimisation: Choice of spectral resolution  
 
Spectral resolution refers to the width of the spectral band at each wavenumber. It 
determines the accuracy of separating different wavelength of radiation in the 
absorption spectrum. Applying spectral resolution ranging from 4 to 64 cm
-1 
has 
significant visual impact on the quality of spectra as demonstrated in Figure 5.9. 
However, it is important to use high spectral resolution in order to identify the precise 
position of narrow absorbance bands and retain all data points. Spectral resolution of 4 
cm
-1 
was selected for this study as an optimum parameter for collecting point mode 
spectra from all cell line samples and blood specimens as it will identify overlapping 
peaks.  
 
 
 
Figure 5-9: Effects of increasing co-added scans on the signal-to-noise ratio of 
glucose spectral measurements 
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5.9 Spectral Measurements 
 
In this study, the type of spectral measurements obtained varies with the type of 
biological and clinical samples analysed. There are three main objectives outlined for 
investigation in this thesis as discussed in Section 1.3. The means of collecting and 
analysing spectral data vary amongst the three sections. Combinations of point and 
image mode spectral measurements were obtained. The parameters for acquiring 
spectroscopic data have been divided into 3 main sections for explanatory purposes:  
Method 1: Classification of B-cell lymphoid leukaemia, myeloid leukaemia and T-cell 
lymphoma derived cell lines 
Method 2: Optimisation of the PCA-fed-LDA classification model 
Method 3: Classification of normal and CLL blood specimens.  
 
5.9.1 Method 1: Classification of leukaemia and lymphoma derived cell lines 
 
Spectral data was obtained for all leukaemia (RCH-ACV, REH, HL60 and Meg01) and 
lymphoma (Karpas) derived cell lines using both point mode and image mode 
measurements. Measurements of each cell type were repeated five times with 
subsequent batch sets (1-5) prepared at different times to test for reproducibility. In total 
50 samples were measured, out of which 25 samples were frozen and the other 25 were 
air-dried samples. 
 
Prior to point mode measurements of air-dried and frozen cell line samples, a 
background spectrum was obtained from a blank area of the CaF2 slide and ratioed 
against the sample spectrum each time. The optimised point measurement parameters of 
64 scans per pixel (spp), with a spectral resolution of 4 cm
-1
 using an aperture of 30 µm 
over the wavenumber range 1800 to 800 cm
-1 
were used to measure FT-IR spectra of 
leukaemia and lymphoma cell line samples. Point spectra obtained in transmission 
mode from cell line samples at different regions were averaged. Univariate analytical 
methods were used to compare the individual mean spectra representing leukaemia and 
lymphoma cell lines and comparing spectra from air-dried and frozen cell line samples. 
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This involved assignments of peaks to identify specific spectral features and calculating 
difference spectra.  
 
IR imaging data was also obtained for both air-dried and frozen cell line samples in the 
format of a spectral hypercube as described in Section 5.6. Regions of high cellular 
content from the visual image map were selected for all cell line samples. The average 
size of the area probed was approximately 200-400µm. Image mode spectral data was 
collected by scanning the computer controlled microscope stage in an x-y direction in 
increments corresponding to the 6.25µm step size, using a spectral resolution of 4 cm
-1 
and 64 scans per pixel (spp) to increase the signal-to-noise ratio. Individual spectra from 
each pixel point were extracted from the spectral hypercube. Background scans were 
obtained from a region of no sample and rationed against the sample spectrum. 
Absorption Spectra extracted in the wavenumber range of 4000 to 720 cm
-1
 were 
converted to ASCII files using PS convert (Perkin Elmer). Similar imaging techniques 
have been employed by other groups in investigation of aortic tissue (Bonnier 2006), 
liver tissue (Yee 2000) as well as single cells (Lasch 2002) 
 
Raw spectral data contained within the spectral hypercube were compared with 
published spectral assignments to provide information on the biochemical composition 
across the sample in visual form. Data analysis was carried out using Matlab. Principal 
components (PCs) were calculated and pseudo-colour PC score maps were generated to 
identify major biochemical differences. Three regions (approximately 20µm x 10µm) of 
high cellular content were selected from the chosen PC score image. The spectra from 
the selected regions of the PC score map were then combined and subjected to data pre-
processing methods described in chapter 4. The pre-processed spectral dataset was used 
to construct a PCA-fed-LDA classification model and further unsupervised and 
supervised classification algorithms were used to discover spectral patterns and 
grouping spectra that share common features. The first 25 PC scores (describing the 
greatest variance in the dataset) were used to calculate linear discriminant functions that 
maximises the variance between the different groups and minimises the variance within 
each group. These are techniques are discussed in Sections 4.2.2.1 and 4.2.2.2 
respectively. The prediction accuracy of the classification model was tested using cross 
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validation procedure described in Section 4.2.2.3. The proposed sequence for spectral 
measurements and data analysis is shown in Figure 5-10.  
 
Image maps were collected for all five cell lines from five subsequent batches (25 air-
dried and 25 frozen samples) to obtain a large spectral dataset for multivariate analysis 
as point spectra are not sufficient. The number and quality of spectra in the dataset have 
a considerable impact on the reliability of multivariate analysis. The performance of 
multivariate techniques improve with increased dataset size.  
 
 
 
Figure 5-10: Overview of spectral measurements and data analysis process 
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 76 
5.9.2 Method 2: Optimisation of the PCA-fed-LDA classification model 
 
Raw imaging spectral data collected for the five air-dried and frozen leukaemia and 
lymphoma cell lines was used to optimise the PCA-fed LDA classification model. 
Firstly, the effects of increasing the PCs from 5 to 25 input into the PCA-fed-LDA 
classification model were investigated. Savitsky-Golay derivative was tested as a pre-
processing tool on the PCA-fed-LDA classification model to obtain the optimal 
performance. Spectral dataset was subjected to a range of 0
th
, 1
st
 and 2
nd
 order Savitsky-
Golay derivative calculated using 9-points. The application of standard deviations and 
absorption filter tool on the spectral dataset were also assessed. These were only used to 
filter out poor quality spectra from a dataset separately and not in combination. 
 
Standard deviation filtering was only applied to cell line spectra obtained from the 
selection of different cellular regions on the PC score maps for all 5 cell samples from 5 
subsequent batches. The combined spectral dataset was then normalised and smoothed. 
In this study a measure of 1.5 standard deviations as an optimal limit was used to 
identify any outliers. In this case, outliers are referred to as spectra that are more than 
1.5 standard deviations either side of the mean of the dataset (Figure 5-11). Any outlier 
spectra beyond the standard deviation range were removed to improve the quality of 
spectral dataset and obtain a stable model. The remaining spectra were collated to create 
a new improved dataset.  
 
The absorption filter tool was only applied to raw FSM (binary) files for all 5 cell 
samples from 5 subsequent batches. Prior to application of the absorption filter tool, the 
raw FSM file was imported into Matlab
 
using a combination of in-house functions and a 
PerkinElmer data plugin script which converted and truncated (1800–900 cm-1) the raw 
binary data into an ASCII format which can then be processed by Matlab. This loading 
process also converted the data from transmittance into absorbance values.  
 
Prior to the application of the in-house absorbance spectral filter tool, the dataset was 
normalised by calculating the area under the curve. The in-house absorbance spectral 
filter tool was applied to the loaded hyperspectral data cube filters out weak or low 
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absorbance. All spectra outside the absorbance range of 0.2 (upper absorbance limit) 
and 0.15 (lower absorbance limits) are removed. In this study, this absorbance range 
was chosen to optimise the stability of the classification model.  
 
 
 
Figure 5-11: Spectral dataset with mean, + and – 1.5 standard deviation 
highlighted in the bold black lines 
 
5.9.3 Method 3: Classification of normal and CLL blood specimens 
 
Spectral measurements for normal and CLL blood specimens were acquired in point 
mode only from different regions of the sample. Prior to spectral measurements of 
blood components, a background spectrum were obtained from a blank area of the CaF2 
slide and ratioed against the sample spectrum each time. Spectra for EDTA and 
Histopaque were also obtained to assess any spectral contributions. The optimised 
standard point measurement parameters of 64 scans per pixel (spp), with a spectral 
resolution of 4 cm
-1
 using an aperture of 30 µm over the wavenumber range 1800 to 800 
cm
-1 
were used to measure FT-IR spectra of the blood component samples as well as 
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EDTA and Histopaque. Figure 5-12 shows that there is relatively low contribution from 
EDTA and Histopaque in the overall spectra obtained from blood samples.  
 
Univariate analytical methods were used to compare the individual mean spectra 
between: 
 Normal whole blood, plasma and buffy coat samples 
 CLL whole blood, plasma and buffy coat samples 
 Normal and CLL whole blood, plasma and buffy coat samples 
 
Univariate methods involved assignments of peaks to identify specific spectral features, 
calculating difference spectra and measurements of absolute peak intensity and peak 
intensity ratios. 
 
Further analysis of spectra from different blood components was carried out by 
multivariate analysis using an in-house Matlab programme. Initially, PCA is used to 
generate data for linear discriminant analysis. Three PCA-fed-LDA classification 
models were constructed using 1) normal and CLL whole blood spectra, 2) normal and 
CLL plasma spectra and 3) normal and CLL buffy coat spectra. The performance of 
these classification models was tested using a cross validation procedure. PLS was 
performed on buffycoat spectra from normal and CLL blood samples. It was used to 
construct a linear predictive model for each cellular analyte amount based on the 
spectrum obtained from normal and CLL buffycoat samples. 
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Figure 5-12: Spectra of blood components, EDTA and Histopaque 
 
5.10 Summary 
 
The section summaries the procedures involved in preparation of cell line samples and 
leukemic blood specimens from normal healthy volunteers and patients with chronic 
lymphocytic leukaemia (CLL). It also provides details on sampling techniques using 
FT-IR spectroscopy. Through various experimental measurments, the optimised 
parameters for spectral measurements used in this study are comprised of 64 scans per 
pixel (spp), with a spectral resolution of 4 cm
-1
 using an aperture of 30 µm over the 
wavenumber range 1800 to 800 cm
-1 
for both cell line and blood sample mesurements.  
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This chapter has been compiled to outline the results of FT-IR spectral measurements 
from various biological and clinical samples and has been divided into 3 main sections. 
The results from a preliminary study, which reviews the spectra obtained from B-cell 
lymphoid leukaemia, myeloid leukaemia and T-cell lymphoma derived cell lines are 
discussed in the first Section (6.1). The effects of air-drying and freezing cell samples 
are also evaluated in this section. Section 6.1.2 determines the efficiency and sensitivity 
of the PCA-fed-LDA classification model to distinguish cell line groups using 
multivariate techniques. The second Section (6.2) evaluates methods of optimising the 
PCA-fed-LDA classification model for distinguishing different cell lines. The second 
phase of the study (Section 6.3) investigates the clinical application of FT-IR 
spectroscopy on blood specimens. Section 6.3.1 reviews the spectra obtained from 
blood samples from normal healthy subjects. Results obtained through detailed 
empirical analysis of the different components of normal blood including whole blood, 
plasma and buffy-coat are discussed in Sections 6.3.1.1 and 6.3.1.2. Section 6.3.2 
reviews the spectra obtained from blood samples from patients with chronic 
lymphocytic leukaemia (CLL) with detailed empirical analysis of the different 
components of CLL blood in Sections 6.3.2.1-6.3.2.3. Detailed comparison of normal 
vs CLL spectra through empirical analysis are discussed in Section 6.3.3. The efficiency 
and sensitivity of the PCA-fed-LDA classification model to classify normal and CLL 
spectra using multivariate techniques are discussed in Section 6.3.4. Finally section 
briefly investigates the application of Partial Least Square (PLS) analysis to construct a 
prediction model to calculate the concentration of cellular analytes in buffy coat 
samples.  
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6.1 Empirical and Multivariate Analysis for Classification of leukaemia and 
lymphoma cell lines 
 
6.1.1 Empirical analysis of leukaemia and lymphoma cell lines 
 
Point spectra obtained in transmission mode from cell line samples at different regions 
were averaged using an in-house Matlab programme. The optimised standard point 
measurement parameters are described in Section 5.8 and 5.9.1. The mean spectra were 
plotted as intensity (arbitrary units) against wavenumber (cm
-1
). A plot of the mean FT-
IR spectra of the five cell line groups is shown in Figure 6-1 for comparison. The 
spectra have a degree of similarity. However, subtle differences between the spectra 
from the different cell line groups are observed due to slight variations in peak positions 
and intensities. The peak positions of the major vibrational modes are labelled. The full 
list of peak assignments are summarised in Appendix D.  
 
Despite the minor spectral differences, all five cell types were found to display 
prominent characteristic spectral features. The most distinctive peaks in the IR 
absorption spectra are assigned to the absorption modes of proteins: the most intense is 
the amide I band, centred near 1655 cm
-1
, which corresponds to the C=O stretching 
coupled to the N-H bending and the C-H stretching modes of peptide bonds (Cecilia
 
2008 and Ami 2003). It has been reported previously that the shape of the amide I band 
is influenced by the overall secondary structure of cellular proteins
 
(Liu 2001). In 
particular, the peaks assigned to α-helices, β-sheets, β-turns and random coils have 
absorption maxima between 1645-1662 cm
-1
, 1613-1637 cm
-1
, 1662-1682 cm
-1
 and 
1637-1645 cm
-1
 respectively. The amide II band at 1549 cm
-1
 arises from the vibrational 
modes that involve the C-N-H bending and C-N stretching of peptidic bonds (Gasparri 
2003). The amide III at 1242 cm
-1
 is contributed by proteins arising from C-N stretching 
and N-H bending (Liu 1997 and Gasparri 2003).  
 
The peaks at 1400-1460 cm
-1 
are attributed to CH2 and CH3 deformation vibrations 
primarily due to lipid contribution. Nucleic acid signals contribute to the infrared 
spectra at 1091 cm
-1
 (sym PO2
-
), 1065 cm
-1
 (PO2
-
 and ribose groups) and 972 cm
-1
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(phosphodiester group present in the DNA and RNA) (Ami 2003). Lipids have long 
hydrocarbon chains and therefore have their peaks at 1352 cm
-1 
(CH3 vibration). The 
peak at 1740 cm
-1
 (C=O bending) corresponds to ester carbonyl (Bonnier 2006), 
although this peak at 1787 cm
-1 
emerges somewhat as a shoulder (Figure 6-1). 
Phosphate bands of phospholipids are also found between 1080-1230 cm
-1
. 
 
 
 
Figure 6-1: Mean FT-IR spectra for B-cell lymphoid (REH and RCH-ACV), 
myeloid leukaemia (HL60 and Meg01) and T-cell lymphoma (Karpas 299) in the 
range 800-1800cm
-1
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6.1.1.1 Difference Spectra  
 
To further emphasise and extract the spectral variations between the cell line groups, 
difference spectra, were calculated by subtracting the mean spectrum from one cell line 
group from another as described in Section 4.2.1.3. The difference spectrum was 
calculated using an in-house Matlab programme. In order to calculate difference 
spectra, all spectra belonging to REH and RCH-ACV cell line groups were combined 
and the mean was calculated to obtain a mean representative spectrum for the B-cell 
lymphoid cell line group. This was done subsequently for all spectra belonging to HL60 
and Meg01 cell line group to obtain a mean representative spectrum for the myeloid cell 
line group. Mean representative spectrum for T-cell lymphoma (Karpas 299) was also 
calculated. A plot of the mean FT-IR spectra of the three cell line groups normalised to 
the intensity at 1655 cm
-1
 is shown in Figure 6-2 for comparison.  
 
Figures 6-3 – 6-5 shows the resulting spectra obtained from taking the difference 
between mean normalised spectra from each cell line group in turn. The positive peaks 
in the difference spectra plot with an intensity greater than zero represent biochemical 
constituents in abundance in that specific cell line group. In contrast, negative peaks 
represent a lower concentration of that biochemical constituent comparative to that 
present in the spectrum of the subtracted cell line group. Variations in the concentration 
of biochemical constituents between the lymphoid, myeloid and lymphoma are seen 
throughout the fingerprint region (Figure 6-1). The complicated band patterns in the 
difference spectra as shown in Figures 6-3 – 6-5 are composed of peaks arising from 
changes of vibrational modes, to changes of the protein structures (Amide I, II and III), 
and to changes of specific nucleic acids, amino acid side chains and fatty acids. Table 6-
1 lists the biochemical constituents in high concentrations as positive peaks in certain 
cell line groups and those with lower concentrations as negative peaks in other cell line 
groups.  
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Figure 6-2: Mean representative spectrum for T-cell lymphoma (Karpas 299), B-
cell lymphoid (RCH-ACV and REH) and myeloid (HL60 and Meg01) cell lines 
 
 
Figure 6-3: Difference spectra obtained by subtraction of B-cell lymphoid cell line 
spectrum from the spectrum obtained from myeloid cell line 
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Figure 6-4: Difference spectra obtained by subtraction of B-cell lymphoid cell line 
spectrum from the spectrum obtained from T-cell lymphoma cell line 
 
 
Figure 6.5: Difference spectra obtained by subtraction of myeloid cell line 
spectrum from the spectrum obtained from T-cell lymphoma cell line 
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 Lymphoid - Myeloid Lymphoid - Lymphoma Myeloid - 
Lymphoma 
Peak Assignment  Peak  Assignment Peak Assignment 
Positive  
Peaks 
960 
1009 
1056 
1086 
1217 
1496 
1650 
1709 
DNA 
Nucleic acids 
Nucleic acids, -
CO-O-C str 
P=O str of >PO2
- 
PO2
- 
str 
CH2 bending 
Amide I 
C=O in nucleic 
acids 
961 
1086 
1217 
1497 
1514 
1644 
1708 
 
1738 
DNA 
P=O str of 
>PO2
- 
PO2
- 
str 
CH2 
bending 
Tyrosine 
Amide I 
C=O in 
nucleic 
acids 
Lipid,  
amino acid 
side chains, 
C=O str in 
esters 
1085 
1121 
 
1520 
1629-
1698 
1710 
 
1745 
P=O str of 
>PO2
- 
Carbohydrat
es, C-O, C-
OH str 
Tyrosine 
Amide I 
 
C=O in 
nucleic 
acids 
Lipid,  
amino acid 
side chains, 
C=O str in 
esters 
Negative  
Peaks 
1125 
1321 
1402 
 
1439 
1585 
 
1629 
Carbohydrates, C-
O, C-OH str 
Amino acid, CH 
vib 
Lipid, CH2 
wagging vib,  C-
O str in 
carbohydrates 
Lipid (CH3 sym 
bending vib) 
Amide II, NH 
vib, CN str 
NH3
+ 
, def vib 
Amide I, C=O str 
993 
 
1028 
 
1277 
1322-1350 
1407 
 
1438 
 
1585 
 
1761-1784 
Phosphoryla
ted proteins, 
RNA 
C-OH 
carbohydrat
es,  
Amide III 
Amino 
acids, COO
- 
Lipid (CH3 
sym 
bending vib) 
Lipid (CH3 
sym 
bending vib) 
Amide II, 
NH vib, CN 
str 
Liids, esters, 
C=O str 
986 
1157 
1280 
1415-
1441 
 
1767-
1790 
 
 
RNA 
Glycogen 
Amide III 
Fatty acids, 
phospholipi
ds and 
triglycerides 
Lipids, 
esters, C=O 
str 
 
 
Table 6-1: Lists positive and negative peaks obtained from the difference spectra 
between B-cell lymphoid, myeloid and T-cell lymphoma cell lines with peak 
assignment  
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6.1.1.2 FT-IR spectral comparison of air-dried and frozen cell lines 
 
The optimised standard point measurement parameters (described in Section 5.8) were 
used to collect 20 FT-IR spectra each from both air-dried and frozen cell line samples at 
different sites. Figures 6-6 illustrate the comparison of mean air-dried and frozen 
spectra taken as an average of 20 different measurements at various sites of the 
leukaemia (RCH-ACV, REH, HL60 and Meg01) and lymphoma (Karpas 299s) cell 
lines sample.  
 
Table 6-2 compares the effects of air-drying and freezing cell line samples on the 
intensity of major peaks in the fingerprint region. Subtle changes are observed in peaks 
corresponding to DNA and lipids; 972 cm
-1
, 1092 cm
-1
, 1240 cm
-1
, 1400 cm
-1
and 1456 
cm
-1
. The intensity of these peaks generally tends to decline in frozen spectra compared 
to that of air-dried spectra. Significant changes in intensity are observed in the major 
protein peaks at 1548 cm
-1
 and 1655 cm
-1 
corresponding to amide II and amide I 
proteins. The intensity of these peaks generally tends to intensify in the spectra 
belonging to frozen samples compared to the spectra belonging to the air-dried samples. 
A recent study coincides with these finding and reveals that proteins (amide I and II) are 
relative stable during freezing with an abrupt decrease in α-helical structures. Freezing 
tend to have greater effect on the behaviour of liposomes and biological membrane 
lipids of cells by changing the hydrophobic and hydrophilic interactions (Wolkers 
2007). Study by Mourant (2003), also observed a reduced intensity of the Amide II peak 
and a change in position for the spectra of dried M1 fibroblast cells. Alterations in the 
secondary structure of proteins are suggested to cause this change in position when the 
cells are dried, introducing artefacts. Changes in amplitude and shifts in absorption 
bands corresponding to proteins and nucleic acids as a result of hydration (air-drying) 
have also been reported due to changes in conformation (Pevsner 2003). Major changes 
in the peak intensity of amide I and amide II bands and the shape of the amide III band 
have been noted.  
 
Table 6-3 further support these results, as area under the curve for the major peaks 
enlarge in all frozen spectra compared to that of air-dried spectra. These findings 
 88 
suggest that freezing cell line samples preserves cellular composition and reduces rate 
of cellular damage. As a result, stable and high quality spectra can be obtained. 
 
 
 
Figure 6-6: Comparison of mean air-dried and frozen cell line spectra  
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972 1092 1240 1400 1456 1548 1655
Mean ACV dry spectra 0.024 0.061 0.059 0.054 0.05 0.123 0.181
Mean ACV frozen spectra 0.032 0.065 0.059 0.051 0.05 0.133 0.203
Mean REH dry spectra 0.035 0.069 0.062 0.05 0.048 0.12 0.203
Mean REH frozen spectra 0.029 0.062 0.056 0.052 0.052 0.128 0.206
Mean HL60 dry spectra 0.027 0.056 0.053 0.054 0.056 0.129 0.198
Mean HL60 frozen spectra 0.023 0.056 0.053 0.05 0.05 0.129 0.213
Mean Meg01 dry spectra 0.025 0.055 0.056 0.054 0.053 0.126 0.203
Mean Meg01 frozen spectra 0.023 0.055 0.052 0.051 0.05 0.129 0.211
Mean Karpas dry spectra 0.024 0.056 0.056 0.055 0.055 0.128 0.196
Mean Karpas frozen spectra 0.027 0.059 0.053 0.053 0.052 0.128 0.206
                                 Intensity of paticular peaks (cm-1)
 
Table 6-2: Comparison of peak intensities between air-dried and frozen spectra for 
B-cell lymphoid (RCH-ACV and REH), myeloid leukaemia (HL60 and Meg01) and 
T-cell lymphoma (Karpas 299) cell lines  
 
 
972 1092 1240 1400 1456 1548 1655
Mean ACV dry spectra 0.21 3.02 1.14 0.51 0.28 3.96 11
Mean ACV frozen spectra 0.69 1.37 4.3 2.23 1.19 15.4 40.1
Mean REH dry spectra 0.16 2.49 1.08 0.43 0.22 3.39 9.47
Mean REH frozen spectra 0.19 2.98 1.25 0.51 0.27 3.72 10.5
Mean HL60 dry spectra 0.07 1.84 0.73 0.4 0.25 3.35 8
Mean HL60 frozen spectra 0.12 2.99 1.29 0.63 0.35 4.78 12.5
Mean Meg01 dry spectra 0.07 2.74 1.2 0.59 0.35 4.34 12.1
Mean Meg01 frozen spectra 0.13 4.08 1.68 0.91 0.55 7.02 18.7
Mean Karpas dry spectra 0.12 2.71 1.07 0.55 0.32 4.09 10.6
Mean Karpas frozen spectra 0.13 2.68 1.04 0.55 0.3 4.27 10.9
                                               Area under the curve
 
Table 6-3: Comparison of area under the curve between air-dried and frozen 
spectra for B-cell lymphoid (RCH-ACV and REH), myeloid leukaemia (HL60 and 
Meg01) and T-cell lymphoma (Karpas 299) cell lines 
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6.1.2 Multivariate Analysis  
 
To further identify spectral variations and develop a classification model to distinguish 
cell line groups with a view to diagnostic spectral analysis, multivariate analysis in form 
of principal component analysis (PCA), linear discriminant analysis (LDA) and leave-
one-out cross validation (LOOCV) was employed. PCA and LDA are described in 
Sections 4.2.2.1 and 4.2.2.2 respectively. LOOCV is explained in Section 4.2.2.3. All 
multivariate analysis was performed using in-house Matlab scripts.   
 
Many different cell line datasets were constructed in order to obtain optimal datasets 
and have been presented in the thesis. The original dataset consists of both dry and 
frozen spectra from five different cell line groups taken from five subsequent batches, 
with a total of 50 samples. The five cell line group datasets consists of individual 
spectral datasets for RCH-ACV, REH, HL60, Meg01 and Karpas 299. Dry and frozen 
spectra obtained from 50 cell line maps were further combined into three clinically 
significant subsets to obtain the second, three cell line group dataset. Spectra belonging 
to REH and RCH-ACV cell lines were combined to obtain a B-cell lymphoid group. 
This was done subsequently for all spectra belonging to HL60 and Meg01 cell lines to 
obtain a myeloid group. All Karpas 299 spectra represented the T-cell lymphoma group. 
For explanatory purposes, the five cell line model is defined as dataset 1a and the three 
cell line model as dataset 2a throughout the subsequent results and discussion Sections. 
These datasets were further sub-divided into either air-dried dataset or frozen dataset.  
 Five cell line group dataset comprised of only frozen spectra with 25 samples in 
and 9929 spectra total. This dataset is defined as spectral dataset 1c. 
 Three cell line group dataset comprised of both air-dried and frozen spectra with 
50 samples and 19690 spectra in total. This dataset is defined as spectral dataset 
2a. 
 Three cell line group dataset comprised of only air-dried spectra with 25 
samples in and 9929 spectra total. This dataset is defined as spectral dataset 2b. 
 Three cell line group dataset comprised of only frozen spectra with 25 samples 
in and 9929 spectra total. This dataset is defined as spectral dataset 2c. 
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6.1.2.1 Principal component analysis 
 
This initial section evaluates the results of PCA, LDA and LOOCV on the following 
datasets: 
 Five cell line group dataset comprised of both air-dried and frozen spectra with 
50 samples and 19690 spectra in total. For explanatory purposes, this dataset is 
defined as spectral dataset 1a throughout the subsequent result sections.  
 Five cell line group dataset comprised of only air-dried spectra with 25 samples 
and 9929 spectra in total. This dataset is defined as spectral dataset 1b. 
 
White light images as well as their corresponding pseudo-colour maps, of total 
absorbance at each point, in transmission mode were obtained from 50 dry and frozen 
cell line samples (dataset 1a and 2a). From the visual image, an area of high cellular 
content was selected for spectral imaging. The average size of the area probed was 
approximately 200-400µm for each cell line sample. Pseudo-colour map show 
absorbencies of varying intensities, where the blue indicates low and red indicates high 
absorbance values. For explanatory and visual purposes, Meg01 frozen cell line 
obtained from batch 5 is used as an example. The white light image and pseudo-colour 
map for Meg01 cell line is shown in Figure 6-7. 
 
A      B 
 
 
Figure 6-7: A) White light image of Meg01 cell line, B) pseudo-colour map of 
frozen Meg01 cell line (batch 5) in transmission mode. Red box highlights the 
region of interest 
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To establish biochemical changes in the spectral dataset across the pseudo-colour map, 
PCA was employed. PCA reduces a complete spectral dataset into a few spectral 
components and reveals maximal biochemical variance over the whole spectral dataset. 
As a result of PCA, 25 PC scores and PC loads are produced in order of variance. 
Figures 6-8 and 6-9 show the PC scores and loads of the first 10 principal components 
for the frozen Meg01 cell line sample. PC loads are the spectral components and PC 
scores relates to the abundance of that spectral component in the sample. The PCs were 
used as the input into a linear discriminant analysis (LDA) model as described in 
Section 6.1.24. Analysis of variance (ANOVA) was performed on the PCs to identify 
the most significant PCs, which were then used to develop LDA models. Leave-one-out 
cross validation (LOOCV) procedure was applied to indicate the accuracy of the 
predictions of the LDA classification model as described in Section 6.1.2.5.  
 
Figure 6-8: PC scores of the first 10 PCs for the Meg01 cell line (batch 5). Top left 
(1) to bottom right (10) 
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Figure 6-9: PC loads of the first 10 PCs. Top left (1) to bottom right (10) 
 
The first few PC loads account for most of the spectral variance. Noise is introduced 
and more subtle variations are observed as the number of PC loads increase. Peaks 
within the same PC loads can be represented as positive or negative. Therefore, 
labelling PC loads can prove to be difficult. Major peaks have been identified, using 
assignments from the literature as listed in Appendix D to determine the key changes in 
the biochemical constituents across the sample.  
 
Positive peaks indicate high contribution of a particular biochemical constituent when 
the PC score is high in a spectrum. In contrast, negative peaks indicate low contribution 
of a particular biochemical constituent when the PC score is high in a spectrum. PC 1 is 
shown inverted, indicating high levels of proteins, with protein peaks assigned at 1654 
and 1549 cm
-1 
(Figure 6-10). PC2 and PC3 also describe protein features, which account 
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for the highest variance in the dataset (Figure 6-11 and 6-12). Two sharp positive peaks 
at 1661 cm
-1 
and 1552 cm
-1 
assigned to Amide I and Amide II proteins are prominent in 
both PC2 and PC3. PC8 has positive peaks that are common to carbohydrates at 1025 
and 1159 cm
-1 
along with contribution from Amide II at 1556 cm
-1
 (Figure 6-13). PC 8 
has negative peaks at 969, 1072, 1096, 1231, 1617 and 1715 cm
-1
. Peaks at 969, 1072 
and 1093 are contributed by nucleic acids (P=O stretch of >PO2
-
). 1715 cm
-1 
is also 
close to assignment for nucleic acids (C=O stretch). Negative peaks at 1231 cm
-1 
is 
assigned for Amide III protein. The other PCs are statistically less significant as they 
account for less of the variance in the data and therefore are not shown. 
 
 
Figure 6-10: Principal component 1 
 
 
 
Figure 6-11: Principal component 2 
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Figure 6-12: Principal component 3 
 
 
Figure 6-13: Principal component 8 
 
6.1.2.2 Region selection and data collection 
 
PC scores were used to identify major biochemical differences across the map and to 
select spectral data for the five and three cell line group classification models. Three 
regions (approximately 20µm x 10µm) of high cellular content were selected from each 
PC score for each of the 50 cell line samples (dataset 1a and 2a). The spectra from the 
selected regions of the PC score map were then combined and normalised to remove 
intensity variations. The normalised dataset was then used to construct and test 
classification models to enable the biochemical changes to be classified according to the 
defined cell line group. An example of selection of spectra for the classification model 
is shown in Figure 6-14. An in-house Matlab programme was used to select regions of 
interest. Averaged spectra from the three regions of interest were plotted for comparison 
and identification of spectral differences as shown in Figure 6-15.  
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Figure 6-14: PC 2 score map for Meg01cell line. Red boxes represent three selected 
regions of interest. Each pixel on the pseudo-colour map represents the spectrum 
for that point 
 
 
 
 
Figure 6-15: Mean normalized IR spectra from three selected areas, region 1 (blue 
line), region 2 (green line) and region 3 (red line) for Meg01cell line in the range 
900-1800 cm
-1
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6.1.2.3 ANOVA and scatter plots for PC scores 
 
To interpret biochemical variations within the PC scores, ANOVA was performed on 
the dataset to demonstrate and assist in the selection of important principal components 
with maximal variance. The AVOVA F-values corresponding to each PC describes the 
ability of that PC to differentiate between the spectra obtained from the different cell 
line groups. With higher F-value; the better the principal component is at distinguishing 
the different cell line groups. The ANOVA F-value for the first 25 PCs for dataset 1a, 
1b, 1c, 2a, 2b and 2c are tabulated in Table 6-5. The most significant PCs with the 
highest F-values are highlighted in red. The Fcrit for spectral dataset 1a, 1b, 1c, 2a, 2b 
and 2c are tabulated in Table 6-4. The Fcrit is the "threshold" value at the level of 
significance to classify a difference among group. 
 
Dataset Fcrit Value 
1a 3.34 
1b 3.20 
1c 3.18 
2a 4.25 
2b 4.57 
2c 4.54 
 
Table 6-4: Fcrit for spectral datasets 1a, 1b, 1c, 2a, 2b and 2c 
 
The percentage of variance corresponding to the 25 PCs for datasets 1a, 1b, 1c, 2a, 2b 
and 2c are shown in Table 6-6. The first 11-12 PCs were seen to have the greatest 
variation ranging from 67% to 99% for the separation of cell line groups. The 
percentage variance does not exceed beyond 99% from 12 to 25 PCs. This may suggest 
that not all 25 PCs are necessary as an input into the LDA classification model. The 
effects of changing the numbers of PCs fed into the LDA classification model are 
discussed in Section 6.2.1.  
 
The most significant principal components were plotted against one another in a two-
dimensional scatter plot to visualise the natural clustering of cell line populations. The 
position of each spectrum is marked on the scatter plot and assigned a different colour 
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and symbol depending on cell line type and whether the spectrum belongs to frozen or 
air-dried sample. Direct comparison between the B-cell lymphoid and myeloid 
leukaemia and T-cell lymphoma cell lines for datasets 1a, 1b, 1c, 2a, 2b and 2c are 
presented in Figures (6-16 – 6-21). 
 
Principal 
Components 
                                                  F-values 
 
Dataset 
1a  
Dataset 
1b 
Dataset 
1c 
Dataset 
2a 
Dataset 
2b 
Dataset 
2c 
1 333.4367 426.0863 945.3188 282.2076 34.887 778.9605 
2 1265.421 1890.23 218.9316 1284.78 1076.793 270.6211 
3 178.787 209.0607 886.359 234.1255 21.7052 766.5517 
4 125.0908 839.7597 441.5297 182.7099 476.1455 816.7263 
5 132.5464 699.0236 247.6401 64.3828 1291.844 326.1484 
6 496.684 191.6305 52.7868 12.4013 330.0801 47.1793 
7 684.0582 87.9959 779.8272 800.4704 102.0099 841.4965 
8 4563.345 970.1663 132.6321 4319.519 1508.761 233.0032 
9 103.0531 699.3829 409.3716 581.7895 1246.058 799.5467 
10 202.2829 296.2329 327.3016 365.1057 6.0466 207.1826 
11 669.7159 713.7848 528.3819 1044.695 42.7936 151.9631 
12 278.2888 364.625 907.4002 321.1413 270.8251 423.8928 
13 575.6955 133.9266 173.2946 519.5837 75.0516 341.8803 
14 846.5202 388.3044 284.2646 803.6753 494.2436 553.5807 
15 345.0524 75.614 219.4749 181.0117 75.3162 203.2445 
16 1013.595 225.5205 46.3369 582.854 425.7424 29.897 
17 394.5588 135.2361 100.0457 412.1973 76.722 24.6149 
18 278.8043 99.3136 96.5434 126.9333 60.7738 685.9887 
19 603.4616 57.7737 289.6301 101.0662 135.7848 374.7447 
20 358.5668 38.6438 223.394 866.908 15.4326 30.6186 
21 150.7639 83.3247 149.6214 95.5624 169.6881 244.592 
22 46.9908 143.2041 259.0123 10.4237 50.2406 192.958 
23 416.9666 85.6689 96.5434 779.0291 148.1598 32.7953 
24 32.5906 226.433 84.158 126.9333 184.4157 87.6579 
25 399.9253 53.4608 84.1769 286.1001 82.174 89.5393 
 
Table 6-5: ANOVA F-value for the first 25 PCs for datasets 1a, 1b, 1c, 2a, 2b and 
2c 
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Principal 
Components 
                                                  % Variance 
 
Dataset 
1a 
Dataset 
1b 
Dataset 
1c 
Dataset 
2a 
Dataset 
2b 
Dataset 
2c 
1 66.0239 66.4409 70.3406 66.3645 66.4409 70.3406 
2 79.2583 78.7431 81.1373 79.6075 78.7431 81.1373 
3 87.2333 87.6249 88.8913 87.4908 87.6249 88.8913 
4 90.445 91.0243 91.8063 90.6503 91.0243 91.8063 
5 93.0744 94.1781 93.9453 93.2816 94.1781 93.9453 
6 94.8718 95.6509 95.9391 95.0769 95.6509 95.9391 
7 95.9941 96.9023 97.0282 96.1969 96.9023 97.0282 
8 96.9008 97.592 97.879 97.0668 97.592 97.879 
9 97.6839 98.166 98.4396 97.8484 98.166 98.4396 
10 98.2604 98.6362 98.8858 98.4148 98.6362 98.8858 
11 98.6383 99.0441 99.1444 98.7851 99.0441 99.1444 
12 98.9265 99.2744 99.3254 99.0587 99.2744 99.3254 
13 99.167 99.4429 99.4714 99.2657 99.4429 99.4714 
14 99.3111 99.5614 99.5661 99.4057 99.5614 99.5661 
15 99.4376 99.6585 99.6497 99.5189 99.6585 99.6497 
16 99.5541 99.7406 99.7195 99.6207 99.7406 99.7195 
17 99.6365 99.7944 99.7691 99.6987 99.7944 99.7691 
18 99.7092 99.8269 99.8117 99.7521 99.8269 99.8117 
19 99.7498 99.8562 99.8414 99.7911 99.8562 99.8414 
20 99.7879 99.8775 99.8682 99.8266 99.8775 99.8682 
21 99.8165 99.8941 99.8884 99.8539 99.8941 99.8884 
22 99.8405 99.9094 99.9026 99.8746 99.9094 99.9026 
23 99.8591 99.9207 99.9133 99.891 99.9207 99.9133 
24 99.8756 99.931 99.9222 99.9059 99.931 99.9222 
25 99.8883 99.9384 99.9301 99.9168 99.9384 99.9301 
 
Table 6-6: The percentage of variance corresponding to the 25 PCs for datasets 1a, 
1b, 1c, 2a, 2b and 2c 
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Figure 6-16: PC scores scatter plot (PC2 vs. PC8) represents clustering of cell lines 
for dataset 1a. Each symbol represents one spectrum. RCH-ACV dry= blue stars, 
RCH-ACV frozen= blue circles, REH dry= green stars, REH frozen= green circles, 
HL60 dry= red stars, HL60 frozen= red circles, Meg01 dry= magenta stars, Meg01 
frozen= magenta circles and Karpas 299 dry= cyan stars, Karpas 299 frozen= cyan 
circles 
 
Figure 6-17: PC scores scatter plot (PC2 vs. PC8) represents clustering of cell lines 
for dataset 1b. RCH-ACV dry= blue stars, REH dry= green stars, HL60 dry= red 
stars, Meg01 dry= magenta stars, and Karpas 299 dry= cyan stars 
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Figure 6-18: PC scores scatter plot (PC1 vs. PC12) represents clustering of cell 
lines for dataset 1c. RCH-ACV frozen= blue circles, REH frozen= green circles, 
HL60 frozen= red circles, Meg01 frozen= magenta circles and Karpas 299 frozen= 
cyan circles 
 
 
 
Figure 6-19: PC scores scatter plot (PC2 vs. PC8) represents clustering of cell lines 
for dataset 2a. Lymphoid group (RCH-ACV and REH) dry= blue stars; lymphoid 
group (RCH-ACV and REH) frozen= blue circles; myeloid group (HL60 and 
Meg01) dry= red stars; myeloid group (HL60 and Meg01) frozen= red circles; 
lymphoma (Karpas 299) dry= green stars and lymphoma (Karpas 299) frozen= 
green circles 
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Figure 6-20: PC scores scatter plot (PC5 vs. PC8) represents clustering of cell lines 
for dataset 2b. Lymphoid group (RCH-ACV and REH) dry= blue stars; myeloid 
group (HL60 and Meg01) dry= red stars and lymphoma (Karpas 299) dry= green 
stars 
 
 
 
Figure 6-21: PC scores scatter plot (PC4 vs. PC7) represents clustering of cell lines 
for dataset 2c. Lymphoid group (RCH-ACV and REH) frozen= blue circles; 
myeloid group (HL60 and Meg01) frozen= red circles and lymphoma (Karpas 299) 
frozen= green circles 
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6.1.2.4 Linear Discriminant Analysis (LDA) 
 
All 25 of the calculated PCs were used as input into an LDA classification model to 
maximise the variance between the cell line groups and minimise the variance within 
the groups. This required four linear discriminant functions for optimal separation of the 
cell line groups in datasets 1a, 1b and 1c. Two linear discriminant functions were 
required for optimal separation of the cell line groups in datasets 2a, 2b and 2c. A two-
dimensional scatter plot of the linear discriminant scores from dataset 1a, 1b, 1c, 2a, 2b 
and 2c are displayed in Figures 6-22 – 6-27. Figure 6-24A – 6-26L shows subplots of 
linear discriminant scores in various combinations only for dataset 1c for visual 
purposes. Each dataset produced various combinations of LD subplots as a result of 
LDA and due to the sheer volume of data not all have been included in the thesis. 
 
 
Figure 6-22: LDA scatter plot (LD1 vs. LD2) represents clustering of cell lines for 
model 1a. Each symbol represents one spectrum. RCH-ACV dry= blue stars, 
RCH-ACV frozen= blue circles, REH dry= green stars, REH frozen= green circles, 
HL60 dry= red stars, HL60 frozen= red circles, Meg01 dry= magenta stars, Meg01 
frozen= magenta circles and Karpas 299 dry= cyan stars, Karpas 299 frozen= cyan 
circles 
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Figure 6-23: LDA scatter plot (LD1 vs. LD2) represents clustering of cell lines for 
dataset 1b. RCH-ACV dry= blue stars, REH dry= green stars, HL60 dry= red 
stars, Meg01 dry= magenta stars, and Karpas 299 dry= cyan stars 
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Figure 6-24: LDA scatter plots for dataset 1c. A) LDA scatter plot (LD1 vs. LD2) 
represents clustering of cell lines. RCH-ACV frozen= blue circles, REH frozen= 
green circles, HL60 frozen= red circles, Meg01 frozen= magenta circles and 
Karpas 299 frozen= cyan circles. B) LD1 vs. LD3, C) LD1 vs. LD4, D) LD2 vs. 
LD1, E) LD2 vs. LD3, F) LD2 vs. LD4, G) LD3 vs. LD1, H) LD3 vs. LD2, I) LD3 
vs. LD4, J) LD4 vs. LD1, K) LD4 vs. LD2, L) LD4 vs. LD3 
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Figure 6-25: LDA scatter plot (LD1 vs. LD2) represents clustering of cell lines for 
dataset 2a. Lymphoid group (RCH-ACV and REH) dry= blue stars; lymphoid 
group (RCH-ACV and REH) frozen= blue circles; myeloid group (HL60 and 
Meg01) dry= red stars; myeloid group (HL60 and Meg01) frozen= red circles; 
lymphoma (Karpas 299) dry= green stars and lymphoma (Karpas 299) frozen= 
green circles 
 
 
Figure 6-26: LDA scatter plot (LD1 vs. LD2) represents clustering of cell lines for 
dataset 2b. Lymphoid group (RCH-ACV and REH) dry= blue stars; myeloid 
group (HL60 and Meg01) dry= red stars and lymphoma (Karpas 299) dry= green 
stars 
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Figure 6-27: LDA scatter plot (LD1 vs. LD2) represents clustering of cell lines for 
dataset 2c. Lymphoid group (RCH-ACV and REH) frozen= blue circles; myeloid 
group (HL60 and Meg01) frozen= red circles and lymphoma (Karpas 299) frozen= 
green circles 
 
6.1.2.5 Leave one out cross validation (LOOCV) 
 
The efficiency of the PCA-fed LDA classification model was evaluated using leave-
one-sample-out cross validation as described in Section 4.2.2.3. This method is ideal to 
determine the initial accuracy of the predictions of the PCA-fed LDA classification 
model if independent data is not available.  
 
The PCA-fed LDA classification model was constructed with 25 PCs as previously 
mentioned calculated with 18,556 spectra for dataset 1a and 19,903 spectra for dataset 
2a. For datasets 1b and 2b the PCA-fed LDA classification model was constructed with 
25 PCs calculated collected from 25 dry cell line samples with 9168 spectra for dataset 
1b and 9983 spectra for dataset 2b. For datasets 1c and 2c, the PCA-fed LDA 
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classification model was also constructed with 25 PCs calculated collected from 25 
frozen cell line samples with 9398 spectra for dataset1c and 9920 spectra for dataset 2c. 
 
The classification results, reflecting the number of spectra correctly classified for each 
cell line group in datasets 1a, 1b, 1c, 2a, 2b and 2c as well as their sensitivity and 
specificity are presented in Tables 6-7 – 6-12 . The results show that the percentage of 
spectra correctly predicted in the three cell line group (datasets 2a and 2c) is 
considerably higher than the five cell line group model. 
 
The percentage of correctly classified spectra reflects a poor measure of the PCA-fed 
LDA classification model performance. The possible factors that contribute to the large 
number of spectra misclassified may be associated with: 
 Unbalanced number of spectra contributed by each cell line group. 
 Inhomogeneties in cellular sample as may contain cells at different stages of the 
cell cycle and variation in degree of cell differentiation and maturation 
 Inclusion of saturated spectra. 
 Inclusion of poor quality spectra introduced through air-drying or freezing of 
cell line samples.  
 Intersample spectral variability within the same cell line group. 
 
Despite a consistent method of spectral imaging, the number of spectra collected per 
map may have varied due to small inconsistencies in the size of the area probed during 
region selection. Ideally the number of spectra per cell line samples in the model should 
be equal for the leave one out cross validation procedure (LOOCV) in order to avoid 
poor prediction results. In addition, contributions from calcium fluoride spectra during 
region selection may also influence the quality of the spectral dataset. Methods of 
improving the PCA-fed LDA classification model are evaluated in Section 6.2.  
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Cell line group Cell type classification  
RCH-
ACV 
HL60 Karpas 
299  
Meg01 REH Total No. 
RCH-ACV 1367 253 628 4 1448 3700 
Hl60 39 2256 482 42 399 3218 
Karpas 299 35 294 2169 47 382 2927 
Meg01 0 612 611 2821 845 4889 
REH 306 112 1007 900 1497 3822 
Number correct 1367 2256 2169 2821 1497  
      18556 
      Average 
Sensitivity (%) 78.2 63.9 44.3 73.9 32.7 58.6 
Specificity (%) 84.2 86.3 78.7 80.5 68.4 79.6 
 
Table 6-7: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1a. 54% spectra are correctly classified 
 
 
 
 
Cell line group Cell type classification  
RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH Total No. 
RCH-ACV 424 284 875 0 25 1608 
Hl60 32 807 147 465 99 1550 
Karpas 299 7 0 1256 13 264 1540 
Meg01 0 33 888 1109 303 2333 
REH 100 57 1060 895 25 2137 
Number correct 424 807 1256 1109 25  
      9168 
      Average 
Sensitivity (%) 75.3   68.3       29.7    44.6     3.5 44.3 
Specificity (%)    84.8  86.6   58.8   67.7    69.3 73.4 
 
 
Table 6-8: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1b. 39.5% spectra are correctly 
classified 
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Cell line group Cell type classification  
RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH Total No. 
RCH-ACV 1095   66 214 11 714 2100 
Hl60 6 1256 370 0 34 1666 
Karpas 299 16 381 674 4 312 1387 
Meg01 0 201 130 1765 464 2560 
REH 0 3 213 0 1469 1685 
Number correct 1095 1256 674 1765 1469  
      9398 
      Average 
Sensitivity (%) 98.0   65.8   42.1  99.2    49.1 70.8 
Specificity (%) 87.6  86.9    81.2       89.4    78.1 84.6 
 
Table 6-9: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1c. 66.5% spectra are correctly 
classified 
 
 
 
Cell line group Cell type classification  
Lymphoid 
 
Myeloid Lymphoma Total No. 
Lymphoid 6308 908 935 8151 
Myeloid 1164 6911 568 8643 
Lymphoma 262 723 2124 3109 
Number correct 6308 6911 2124  
    19903 
    Average 
Sensitivity (%) 77.5 79.6 68.4 75.3 
Specificity (%) 87.9 85.6 91.4 88.2 
 
Table 6-10: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2a. 77.1% spectra are correctly 
classified 
 
 
6.1.3 Summary 
The raw FT-IR spectra acquired from T-cell lymphoma, B- cell lymphoid, and myeloid 
leukaemia cell lines reveal that peak shapes and positions are similar, although the peak 
intensities tend to vary between air-dried and frozen samples. The initial imaging 
experiments of the B-cell lymphoid, myeloid leukaemia and T-cell lymphoma cell lines 
have demonstrated problems associated with poor region selection and contributions 
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from CaF2 which possibly result in poor quality spectral datasets. The preliminary five 
cell line group classification model using 50 frozen and air-dried samples correctly 
classified only 50% of the spectra. Furthermore, results show that the use of only frozen 
spectra improves the performance of classification model considerably.  
 
 
 
Cell line group Cell type classification  
Lymphoid 
 
Myeloid Lymphoma Total No. 
Lymphoid 1299 954 1901 4154 
Myeloid 1108 1715 1384 4207 
Lymphoma 124 372 1126 1622 
Number correct 1299 1715 1126  
    9983 
    Average 
Sensitivity (%) 31.3 40.8 69.4 47.1 
Specificity (%) 78.9 77.0 60.7 72.2 
 
Table 6-11: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2b. 41.5% spectra are correctly 
classified 
 
 
 
 
Cell line group Cell type classification  
Lymphoid 
 
Myeloid Lymphoma Total No. 
Lymphoid 3411 160 426 3997 
Myeloid 626 3055 757 4438 
Lymphoma 266 418 801 1485 
Number correct 3411 3055 801  
    9920 
    Average 
Sensitivity (%) 85.3 68.8 53.9 69.3 
Specificity (%) 84.9 89.4 85.9 86.8 
 
Table 6-12: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2c. 73.3% spectra are correctly 
classified 
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6.2 PCA-fed LDA classification model optimisation  
 
In order to optimise the PCA-fed LDA classification model, firstly, the effects of 
increasing the principal components used for the PCA-fed-LDA classification model 
was investigated on the five cell line group model using datasets 1a, 1b and 1c. The cell 
line groups in these datasets are RCH-ACV, REH, HL60, Meg01 and Karpas299. PCA-
fed-LDA was also preformed with variations of an additional factor to assess impact on 
results. Savitsky-Golay derivatives were tested as a pre-processing tool on the PCA-fed-
LDA classification model to obtain the optimal performance. Futher details on 
methodology are described in Section 5.9.2. The results from these investigations are 
shown in Sections 6.2.1 and 6.2.2 respectively. 
 
Other data pre-processing methods used prior to multivariate analysis (PCA-fed-LDA) 
were considered to achieve an optimal and stable classification model. Two distinct 
methods of data pre-processing were employed to enhance spectral features and 
effectively suppress or eliminate unnecessary artefacts and noise. The initial method 
exploits standard deviation filtering as a measure to identify outliers and determine 
spectral variability. The second method utilizes the application of an absorption filter 
tool. These data pre-processing methods are described in Sections 4.1.5 and 4.1.6.The 
outcome of using standard deviation filter and absorption filter tool on the above 
mentioned four datasets are discussed in Sections 6.2.3 and 6.2.4 respectively.  
 
6.2.1 Effect of increasing PCs input for LDA 
 
The number of PCs fed into the PCA-fed-LDA classification model was varied to 
exploit its ability to separate the five cell line groups as well as to improve on the 
prediction results. The number of PCs fed into the classification model were increased 
from 5 PCs to 25 PCs. PCs 5, 10, 15 and 25 have a percentage variance of 93.3%, 
98.4%, 99.5% and 99.9% respectively as shown in Table 6-6. The percentage of spectra 
correctly classified for each of the cell line groups using spectral datasets 1a, 1b and 1c 
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are presented in Figures 6-28 – 6-30. The overall performances of the classification 
models developed with varying numbers of PCs are shown in Table 6-13. 
 
The correct prediction of spectra is dependent of the number of PCs used in the 
analysis. Fewer PCs input into the PCA-fed-LDA classification model are shown to 
reduce the prediction achieved. This is seems to be the case particularly for spectra from 
spectral dataset 1a (dry and frozen spectra) and spectral dataset 1b (only dry spectra). 
Using cross validation on spectral dataset 1b (only frozen spectral dataset) more spectra 
are correctly classified (Figure 6-29). The percentage of spectra correctly classified 
increases when data from higher of PCs is entered into LDA as demonstrated in Figure 
6-28 and 6-30. Although this is not the case for some cell line groups (RCH-ACV, 
Meg01 and REH) in spectral dataset 1b.  
 
Overall, the highest percentage correct classification is seen when the data from the first 
25 PCs entered using spectral dataset 1c. This may indicate lesser degree of inter-
sample spectral variation within the same cell line group in the frozen spectral dataset. 
Sensitivity and specificity achieved by a PCA fed LDA model developed with 5, 10, 15 
and 25 PCs are tabulated in Table 6-13. 
 
0
10
20
30
40
50
60
70
80
ACV HL60 Karpas Meg01 REH
Cell Line Group
%
 s
p
ec
tr
a 
co
rr
ec
tl
y 
cl
as
si
fi
ed
5 PCs
10 PCs
15 PCs
25 PCs
 
Figure 6-28: percentage of spectra correctly classified by leave-one-sample-out 
cross validation model developed with increasing numbers of PC for the separation 
of the five cell line groups in spectral dataset 1a 
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Figure 6-29: percentage of spectra correctly classified by leave-one-sample-out 
cross validation model developed with increasing numbers of PC for the separation 
of the five cell line groups in spectral dataset 1b 
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Figure 6-30: percentage of spectra correctly classified for each of the cell line 
groups developed with increasing numbers of PC for spectral dataset 1c 
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5 PCs 
                    % RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH 
Dataset 
1a 
Sensitivity 7.4 10.9 17.2 25.9 21.1 
Specificity 63.4 70.9 68.0 62.9 70 
Dataset 
1b 
Sensitivity 22.6 18.8 22.1 45.4 34.0 
Specificity 80.1 75.1 58.3 64.3 74.4 
Dataset 
1c 
Sensitivity 32.3 32.8 49.5 91.4 37.5 
Specificity 65.9 78.3 84.1 81.3 70.9 
10 PCs 
Dataset 
1a 
Sensitivity 31.9 21.3 37.9 69.6 16.9 
Specificity 73.8 73.9 75.8 79.3 62.1 
Dataset 
1b 
Sensitivity 0 20.6 33.3 57.6 34.6 
Specificity 76.6 71.9 70.2 74.8 72.1 
Dataset 
1c 
Sensitivity 28.4 40.1 32.7 91.8 30.9 
Specificity 73.9 77.1 75.8 81.9 62.8 
15 PCs 
Dataset 
1a 
Sensitivity 61.0 26.8 38.8 57.7 30.2 
Specificity 82.3 74.9 76.1 73.7 67.9 
Dataset 
1b 
Sensitivity 33.5 48.9 51.0 52.9 3.2 
Specificity 74.9 81.8 81.2 71.2 67.9 
Dataset 
1c 
Sensitivity 94.1 49.2 45.1 96.6 44.1 
Specificity 85.2 79.1 82.1 81.8 74.4 
25 PCs 
Dataset 
1a 
Sensitivity 78.2 63.9 44.2 73.9 32.7 
Specificity 84.2 86.3 78.7 80.5 68.4 
Dataset 
1b 
Sensitivity 75.3 68.3 29.7 44.7 3.5 
Specificity 84.9 86.6 58.9 67.8 69.3 
Dataset 
1c 
Sensitivity 98 65.9 42.1 99.2 49.1 
Specificity 87.6 86.9 81.2 89.4 78.1 
 
Table 6-13: Sensitivity and specificity achieved by a PCA fed LDA model 
developed with 5, 10,15 and 25 PCs 
 
6.2.2 Effects of Savitsky-Golay filters on PCA-fed-LDA classification model 
 
In an attempt to achieve an optimal performance of the 5 cell line group classification 
model, spectral dataset was subjected to a range of 0
th
, 1
st
 and 2
nd
 order Savitsky-Golay 
derivative calculated using a 9-points. The derivative Savitsky-Golay filters were tested 
on PCA-fed-LDA model developed with 25 PCs, calculated with 9398 spectra from 
spectral dataset 1c. Spectral dataset 1c was chosen, as it has been proven to contain a 
better quality spectral dataset as demonstrated in Section 6.2.1. 
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The application of derivative Savitsky-Golay filters on a spectral dataset has significant 
impact on the performance of the PCA-fed-LDA classification model as shown in 
Figure 6-31. 1
st
 derivative and in particular 2
nd
 derivative reduce the percentage of data 
correctly classified. Higher percentages of the spectra were correctly classified using 0
th
 
derivative. This significantly differs from findings in the literature, as 1st order 
Savitsky-Golay derivative is often used as a pre-processing procedure. Table 6-14 
demonstrates the overall performance of the classification model with varying Savitsky-
Golay derivatives. The PCA-fed-LDA classification model achieves the highest 
sensitivity and specificity using 0
th
 order Savitsky-Golay derivative on the spectral 
dataset.  
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Figure 6-31: Percentage of spectra correctly classified for each of the cell line 
groups achieved with 0th, 1st and 2nd derivative Savitsky-Golay filters for spectral 
dataset 1c.  
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                    % RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH 
0
th
  Derv Sensitivity 93.0 65.8 42.0 99.2 49.1 
Specificity 87.6 86.9 81.2 89.4 78.1 
 
1
st
  Derv Sensitivity 80.7 78.5 21.6 80.9 44.7 
Specificity 83.4 90.8 59.9 72.8 75.1 
 
2
nd
 Derv Sensitivity 67.7 82.5 19.4 35.7 45.8 
Specificity 81.4 91.6 59.9 72.6 76.2 
 
Table 6-14: Sensitivity and specificity achieved by testing 0
th
, 1
st
 and 2
nd
 order 
Savitsky-Golay derivative on the PCA fed LDA classification model 
 
6.2.3 Application of standard deviation filtering on spectral dataset 
 
Standard deviation filtering was used as a measure to identify outliers (poor quality 
spectra) and applied to the spectral datasets of all individual five cell line groups. A 
range of standard deviation multiples were applied to the raw dataset prior to PCA-fed-
LDA. Mean spectra were calculated for all cell line groups and the number of standard 
deviation was reduced from +/- 5 to +/- 1.5 to identify outliers. Outliers are referred to 
as spectra that are more than the defined number of standard deviation either side of the 
mean of the dataset. Any outlier spectra beyond the standard deviation range were 
removed to improve the quality of spectral dataset and obtain a stable model. The 
remaining spectra for all cell line groups were collated to create a new, improved 
dataset and input into the PCA-fed-LDA classification model. Figure 6-32 shows the 
superimposed mean +/- 1.5 standard deviations of the infrared absorbance of the 
different cell line groups. 
 
As before, for explanatory purposes, standard deviation filtering was applied to spectral 
dataset 1c as it has been proven to contain a better quality spectral dataset as 
demonstrated in previous sections. The application of standard deviation filtering on a 
spectral dataset has significant impact on the performance of the PCA-fed-LDA 
classification model (using 25 PCs and 0
th
 derivative) as shown in Table 6-15. Higher 
percentages of the spectra were correctly classified using a standard deviation of +/-1.5 
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for all cell line groups compared to that of when no standard deviation filter is applied. 
The PCA-fed-LDA classification model achieves the highest sensitivity and specificity 
using standard deviation of +/- 1.5 on the spectral dataset (Table 6-16).  
 
 
 
Figure 6-32: Shows the superimposed +/- 1.5 standard deviations of the infrared 
absorbance of the different cell types 
 
 Percentage of spectra correctly classified  
Standard 
deviation 
RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH Total No. of 
spectra 
None applied 52 75 49 79 87 9398 
+/- 5 53 75 49 73 88 9285 
+/- 4 52 75 48 73 90 9143 
+/- 3 53 71 42 28 88 8387 
+/- 2 69 62 47 75 89 7132 
+/- 1.5 88 86 62 73 96 4037 
 
Table 6-15: Percentage of spectra correctly classified for each of the cell line 
groups achieved using a range of standard deviations for spectral dataset 1b. 
Those highlighted in red show that using standard deviation of +/- 1.5 has the most 
significant impact on the prediction results 
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                    % RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH 
No std Sensitivity 93.0 65.8 42.0 99.2 49.1 
Specificity 87.6 86.9 81.2 89.4 78.1 
 
+/- 5 Sensitivity 98.2 66.6 41.6 99.6 51.6 
Specificity 87.9 87.2 80.6 90.7 79.6 
 
+/- 4 Sensitivity 97.9 68.1 38.8 99.7 53.2 
Specificity 87.8 87.6 79.6 90.9 80.5 
 
+/- 3 Sensitivity 96.7 67.6 34.2 99 51.7 
Specificity 87.5 87.2 78.0 91.8 79.6 
 
+/- 2 Sensitivity 51.2 67.8 34.1 99.8 54.8 
Specificity 74.4 87 78.2 76.6 83.5 
 
+/- 1.5 Sensitivity 71.7 80.8 65.2 99.7 72.9 
Specificity 82.5 94.5 94.6 85.7 93.9 
 
Table 6-16: Sensitivity and specificity achieved by applying +/- 5, +/- 4, +/- 3, +/- 2 
and +/- 1.5 standard deviations on the performance of the PCA fed LDA 
classification model compared to when no standard deviation is applied 
 
Although using a standard deviation of +/- 1.5, has improved the quality of the spectral 
dataset with outliers removed, it has a huge impact on the number of spectra eliminated. 
In this case, 5361 of the spectra has been removed from the original spectral dataset 
comprised of 9398 spectra. This is more than half of the spectra being eliminated which 
account for 57% as demonstrated in Table 6-17. This suggests that there is large inter-
sample variability within the spectral dataset. This is significantly a large number of 
spectra being removed from the original dataset and is not statistically valid. Although 
standard deviation is an effective method of eliminating poor quality spectra and 
retaining those of high-quality with little variability, detecting outliers using this 
approach could be flawed. An alternative method to improve the quality of spectral 
dataset is discussed in Section 6.2.4. 
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Standard 
deviation (std) 
Total No. of spectra 
after std 
No. of spectra 
eliminated  
% of spectra 
eliminated 
None applied Original dataset (9398) 0 0 
+/- 5 9285 113 1.2 
+/- 4 9143 255 2.7 
+/- 3 8387 1011 10.8 
+/- 2 7132 2266 24.1 
+/- 1.5 4037 5361 57 
 
Table 6-17: Total number of spectra and percentage of spectra eliminated from the 
original dataset after applying a range of standard deviations 
 
6.2.4 Application of an absorption filter tool on spectral dataset 
 
White light images as well as their corresponding average absorbance image were 
obtained from 25 dry and 25 frozen cell line samples. An in-house Matlab programme 
was used to convert the data from transmittance into absorbance values from the 
captured regions as explained in Section 5.9.2. The average absorbance image shows 
absorbencies of varying intensities, where blue indicates low and red indicates high 
absorbance values. For explanatory and visual purposes, the Meg01 frozen cell line 
obtained from batch 5 is used as an example. The white light image and the 
corresponding average absorbance image for Meg01 cell line is shown in Figure 6-33. 
 
An in-house absorbance spectral filter tool was applied to the loaded hyperspectral data 
cube to filter out weak or low absorbance. All spectra outside the absorbance range of 
0.2 (upper absorbance limit) and 0.15 (lower absorbance limits) were removed. Figure 
6-34 represents the average absorbance image after the absorbance spectral filter tool 
was applied to filter out weak and saturated spectra. As demonstrated in Figure 6-34, 
blue regions indicating low absorbance values corresponding to regions of calcium 
fluoride have been eliminated. The spectral dataset in Figure 6-35 represents the 
original unfiltered dataset and the remaining good quality filtered spectra.  
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A 
 
B 
 
Figure 6-33: A) White light image of Meg01 cell line, B) average absorbance image 
of frozen Meg01 cell line (batch 5). Red box (200x300µm) highlights the region of 
interest 
 
A      B 
Figure 6-34: A) Average absorbance image of frozen Meg01 cell line (batch 5), B) 
Filtered average absorbance image. White areas represent weak or saturated 
spectra that have been filtered out 
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A       B 
 
 
Figure 6-35: A) Unfiltered normalised spectral dataset and B) Remaining good 
quality normalised filtered spectra. All spectra outside the absorbance range of 0.2 
(upper absorbance limit) and 0.15 (lower absorbance limits) were removed 
 
The new filtered dataset with most weak absorbance and saturated spectra removed was 
divided into separate datasets: 
 Five cell line group dataset comprised of both air-dried and frozen spectra from 
50 samples. This dataset is defined as spectral dataset 1a. 
 Five cell line group dataset comprised of only air-dried spectra from 25 samples. 
This dataset is defined as spectral dataset 1a. 
 Five cell line group dataset comprised of only frozen spectra from 25 samples. 
This dataset is defined as spectral dataset 1c. 
 Three cell line group dataset comprised of both air-dried and frozen spectra from 
50 samples. This dataset is defined as spectral dataset 2a. 
 Three cell line group dataset comprised of only air-dried spectra from 25 
samples. This dataset is defined as spectral dataset 2b. 
 Three cell line group dataset comprised of only frozen spectra with 25 samples. 
This dataset is defined as spectral dataset 2c. 
 
The improved dataset was inputted into PCA-fed-LDA classification model to assess its 
ability to distinguish between the cell line groups. The application of absorbance filter 
tool on the various spectral datasets has significant impact on the performance of the 
PCA-fed-LDA classification model (using 25 PCs and 0
th
 derivative). The classification 
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results, reflecting the number of spectra correctly classified for each cell line group in 
datasets 1a, 1b, 1c, 2a, 2b and 2c as well as their sensitivity and specificity are presented 
in Tables 6-18 – 6-23. 
 
Cell line group Cell type classification  
RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH Total No. 
RCH-ACV 618 55 127 19 225 1044 
Hl60 0 499 0 14 91 604 
Karpas 299 0 188 555 75 69 887 
Meg01 0 38 1 105 58 202 
REH 180 281 72 58 926 1517 
Number correct 618 499 555 105 926 4254 
      Average 
Sensitivity (%) 59.2 82.6 62.6 51.9 61.0 63.5 
Specificity (%) 94.4 84.6 94.0 95.9 83.8 90.5 
 
Table 6-18: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1a. 63.5% spectra are correctly 
classified 
 
 
 
 
Cell line group Cell type classification  
RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH Total No. 
RCH-ACV 373 0 0 0 25 398 
Hl60 0 94 16 61 0 171 
Karpas 299 0 1 91 4 1 97 
Meg01 0 0 0 166 5 171 
REH 311 18 196 94 33 652 
Number correct 373 94 91 166 33 1489 
      Average 
Sensitivity (%) 93.7 54.9 93.8 97.0 5.06 68.9 
Specificity (%) 71.5 98.5 84.7 87.9 96.2 87.8 
 
Table 6-19: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1b. 50.1% spectra are correctly 
classified 
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Cell line group Cell type classification  
RCH-
ACV 
HL60 Karpas 
299 
Meg01 REH Total No. 
RCH-ACV 545 0 23 0 36 604 
Hl60 0 658 1 0 7 666 
Karpas 299 0 74 543 0 8 625 
Meg01 0 0 0 646 0 646 
REH 3 83 81 0 475 642 
Number correct 545 658 543 646 475 3183 
      Average 
Sensitivity (%) 90.2 98.8 86.9 100 73.9 89.9% 
Specificity (%) 99.9 93.8 95.9 100 97.9 97.5% 
 
Table 6-20: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1c. 90.0% spectra are correctly 
classified 
 
 
 
 
 
Cell line group Cell type classification  
Lymphoid 
 
Myeloid Lymphoma Total No. 
Lymphoid 1730 360 265 2355 
Myeloid 1 1253 85 1339 
Lymphoma 3 251 898 1152 
Number correct 1730 1253 898 4846 
     
    Average 
Sensitivity (%) 77.5 93.6 77.9 81.7 
Specificity (%) 99.8 82.6 90.5 90.9 
 
Table 6-21: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2a. 80.1% spectra are correctly 
classified 
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Cell line group Cell type classification  
Lymphoid 
 
Myeloid Lymphoma Total No. 
Lymphoid 774 12 85 871 
Myeloid 0 432 83 515 
Lymphoma 2 4 191 197 
Number correct 774 432 191 1583 
     
    Average 
Sensitivity (%) 88.9 83.9 96.9 89.9 
Specificity (%) 99.7 98.5 87.9 95.7 
 
Table 6-22: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2b. 83.6% spectra are correctly 
classified 
 
 
 
 
Cell line group Cell type classification  
Lymphoid 
 
Myeloid Lymphoma Total No. 
Lymphoid 808 94 128 1030 
Myeloid 15 954 139 1108 
Lymphoma 20 91 723 834 
Number correct 808 954 723 2972 
     
    Average 
Sensitivity (%) 78.4 86.1 86.7 83.7 
Specificity (%) 98.2 90.1 87.5 91.9 
 
Table 6-23: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2c. 88.1% spectra are correctly 
classified 
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6.2.5 Summary 
 
Increasing the numbers of PCs input into the PCA-fed-LDA classification model from 5 
PCs to 25 PCs is shown to increase the prediction accuracy achieved. Furthermore, the 
application of 1
st
 and 2
nd
 derivative reduces the percentage of spectra correctly classified 
in the frozen spectral dataset. 0
th
 derivative has a significant impact on the performance 
of the PCA-fed LDA classification model with higher percentages of the spectra 
correctly classified. Using a standard deviation of +/- 1.5 improved the performance of 
classification model resulting with highest sensitivity and specificity values. The use of 
an absorbance spectral filter tool to filter out weak/ low absorbance or saturated spectra 
is a better approach of identifying poor quality spectra. The spectra retained after the 
application of the absorbance spectral filter tool is of better quality and more stable.  
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6.3 Empirical and Multivariate Analysis for Classification of Normal and CLL 
Blood Specimens 
 
6.3.1 Empirical analysis: Normal Blood  
 
10 blood samples were collected from healthy subjects. Blood components such as 
plasma and buffy-coat (containing white blood cells) were isolated using standard 
procedures as described in Sections 5.2.3 and 5.2.4. White light images and spectral 
measurements were obtained for whole blood (containing red blood cells), plasma and 
buffycoat. An example of a white light image obtained from a buffy-coat sample is 
shown in Figure 6-36. Several regions were probed (marked in red) for their IR 
signature to evaluate spectral variations as shown in Figure 6-36. Point spectra obtained 
in transmission mode were obtained from whole blood, plasma and buffy-coat samples 
at different regions were averaged using an in-house Matlab programme. Due to lack of 
viscosity, the transfer of some whole blood, buffy-coat and plasma samples onto CaF2 
slides proved to be difficult. Hence, there are unbalanced numbers of spectra 
contributed by each blood component. The total number of point spectra collected for 
whole blood, buffy-coat and plasma are 829, 437 and 78 respectively. 
 
A plot of the mean FT-IR spectra of the 3 separate blood components is shown in 
Figure 6-37 for comparison. Significant spectral differences were noted between the 
three blood components. These were identified using a standard empirical method of 
assigning key peak positions. Spectrum for individual blood component is sited in 
Appendix E. The peak positions of the major vibrational modes are labelled. The full 
list of peak assignments are summarised in Appendix D.  
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Figure 6-36: White light image from a buffy-coat sample. Point measurements 
were taken from areas marked in red 
  
 
Figure 6-37: Represents the average IR spectra for whole blood, plasma and buffy-
coat in the range 900-1800 cm
-1 
for normal blood 
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The representative mean spectra for whole blood and buffy-coat have a degree of 
variations in peak positions and intensities as shown in Figure 6-37. The most 
distinctive peaks in the IR absorption spectra for whole blood and buffy coat are 
assigned to the absorption modes of proteins the most intense is the amide I band, 
centred near 1658 cm
-1 
for whole blood spectra and 1651 cm
-1 
for buffy-coat spectra. 
The amide I corresponds to the C=O stretching coupled to the N-H bending and the C-H 
stretching modes of peptide bonds
 
(Cecilia 2008 and Ami 2003). The amide II band at 
1546 cm
-1
 for both whole blood and buffy coat spectra arises from the vibrational 
modes that involve the C-N-H bending and C-N stretching of peptidic bonds
 
(Gasparri 
2003). The amide III peak at 1241 cm
-1 
for whole blood and 1235 cm
-1 
for buffycoat 
spectra is contributed by proteins arising from C-N stretching and N-H bending
 
(Gasparri 2003 and Liu 1997).  
 
The peaks at 1453-1455 cm
-1 
are attributed to CH2 and CH3 deformation vibrations 
primarily due to lipid contribution in both whole blood and buffycoat spectra. Peaks at 
1393-1396 cm
-1 
(CH3 vibration) also correspond to lipids. A small peak at 1742 cm
-1 
was observed in the case of buffy-coat spectra, which may correspond to C=O 
stretching vibrations from phospholipids in membranes. This peak is absent in the 
spectra for whole blood.  
 
Symmetric and anti-symmetric stretching vibrations from the phosphate group are seen 
in the FT-IR spectra of whole blood and buffy-coat in the region between 950 and 1280 
cm
-1
. Apart from phospholipids and phosphorylated proteins, nucleic acids are the main 
contributors of these bands in cells. For buffy-coat spectra, nucleic acid signals 
contribute at 1083 cm
-1
 (sym PO2
-
), 1051cm
-1
  (PO2
-
 and ribose groups) and 969 cm
-1
 
(phosphodiester group present in the DNA and RNA)
 
(Ami 2003). For whole blood 
spectra, nucleic acid signals contribute at 1106 and 1172 cm
-1
. The peak at 969 cm
-1 
is 
absent in the spectra for whole blood.  
 
The representative mean FT-IR spectrum for plasma differs considerably, with 
significant variations in peak positions and vibrational modes as shown in Figure 6-37. 
The spectrum for plasma is dominated by peaks mainly corresponding to lipids, 
carbohydrates, amino acids and lactate. Main peaks arise at 1003 cm
-1
 (C-OH of 
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carbohydrates, C-O-P of lipids), 1372 cm
-1
 (CH3) and 1455 cm
-1
 (CH2 and CH3 
deformation vibrations). These vibrations in the low molecular weight biomolecular 
components are more prevalent in plasma compared to whole blood and buffy-coat. 
There are also minor peaks that contribute to Amide I (1660 cm
-1 
with a shoulder at 
1641 cm
-1
) and Amide II (1546 with a shoulder at 1538 cm
-1
).  
 
6.3.1.1 Difference Spectra: Normal Blood 
 
To further emphasise and extract the spectral variations between the blood components, 
difference spectra, was calculated by subtracting the mean spectrum from blood 
component from another. The difference spectrum was calculated using an in-house 
Matlab programme. Figure 6-38 shows the resulting spectra obtained from taking the 
difference between mean whole blood from plasma. Figure 6-39 shows the resulting 
spectra obtained from subtracting the mean whole blood spectra from mean buffy-coat 
spectra. The difference spectra obtained subtracting the mean plasma spectra from mean 
buffy-coat spectra is represented in figure 6-40. The complicated band patterns in the 
difference spectra are composed of peaks arising from changes of vibrational modes, to 
changes of the protein structures and to changes of specific nucleic acids, amino acid 
side chains and fatty acids. Table 6-24 lists the biochemical constituents in high 
concentrations as positive peaks in a certain blood component and those with lower 
concentrations as negative peaks in other blood component.  
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Figure 6-38: Difference spectra obtained by subtraction of whole blood spectrum 
from the spectrum obtained from plasma 
 
 
Figure 6-39: Difference spectra obtained by subtraction of whole blood spectrum 
from the spectrum obtained from buffy-coat 
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Figure 6-40: Difference spectra obtained by subtraction of plasma spectrum from 
the spectrum obtained from buffycoat 
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 Whole blood - Plasma Whole blood - Buffycoat Plasma - Buffycoat 
Peak Assignment  Peak  Assignment Peak Assignment 
Positive  
Peaks 
 
1654 
1542 
Amide I 
Amide II 
 
1660 
1546 
 
 
 
 
Amide I 
Amide II 
948 
999 
 
1070 
 
1134 
 
 
1273 
1373 
1428-
1477 
 
 
 
 
1597 
??? 
Phosphorylated 
proteins, RNA 
P=O str of >PO2
- 
Carbohydrates,  
Carbohydrates, C-
O, C-OH str 
Carbohydrates, 
??? 
Lipids (CH3) 
Lipids (C-H, CH2 
wagging vib, CH3 
sym bending vib 
and C-O str in 
carbohydrates) 
Amino acids 
 
Negative  
Peaks 
1003 
1072 
1173 
 
1272 
1373 
1426- 
1480 
 
1597 
 
Carbohydrates, C-O, C-OH str 
P=O str of >PO2 
Carbohydrates, C-O, C-OH, C-C, 
C-O-C 
??? 
Lipids (CH3) 
Lipids (C-H, CH2 wagging vib, 
CH3 sym bending vib and C-O str 
in carbohydrates) 
Amino acids 
 
968 
 
1071 
1139 
 
 
1222 
 
1361 
 
 
1374  
1413- 
1482 
 
 
 
 
Phosphorylated 
proteins, RNA 
P=O str of >PO2 
Carbohydrates, C-
O, C-OH str 
Carbohydrates, C-
O, C-OH, C-C, C-
O-C 
Amino acids, Lipid 
(COO, CH3) 
 Lipids, CH3 
Lipids (C-H, CH2 
wagging vib, CH3 
sym bending vib 
and C-O str in 
carbohydrates) 
1654 
1542 
Amide I 
Amide II 
 
 
 
 
 
 
 
 
 
 
Table 6-24: Lists positive and negative peaks obtained from the difference spectra 
between whole blood, plasma and buffy-coat samples with peak assignment 
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6.3.1.2 Peak Intensity Ratio: Normal Blood 
 
In order to analyse the distribution of biochemical constituents in whole blood, plasma 
and buffy-coat spectra and consider variations in overall spectral intensities, peak 
intensity ratios were calculated in the range 900-1800 cm
-1
. Specific peaks assigned to 
proteins, lipids, carbohydrates and nucleic acids have been used to calculate peak 
intensity ratio. Figure 6-41 shows, the relative peak intensity ratio of the bands assigned 
to proteins (amide I, II and III) and lipids (1454, 1390 and 1372 cm
-1
) in various 
combinations. It has been found that the ratio of peak intensity corresponding to all 
proteins and lipids peaks differ greatly between whole blood, plasma and buffy-coat 
spectra. All combinations of protein/lipid peak intensity ratios are very similar and 
indicate a strong correlation with higher protein distribution in buffy-coat and whole 
blood compared to that in plasma. These findings are in agreement with the difference 
spectra represented in Section 6.3.1.1 indicating that whole blood and buffy-coat spectra 
have higher distribution of protein compared to the plasma spectra.  
 
Figure 6-42 shows, the relative peak intensity ratio of the bands assigned to 
carbohydrates (1005 and 1140 cm
-1
) and proteins (amide I, II and III) in different 
combinations. In this case, such ratios indicate changes between carbohydrate and 
protein distribution in different blood components. All combinations of 
carbohydrate/protein peak intensity ratios are very similar and indicate a strong 
correlation with higher carbohydrate distribution in whole blood and plasma compared 
to that in buffy-coat. These findings are in agreement with the difference spectra 
represented indicating that plasma spectra have higher distribution of carbohydrates 
compared to the spectra for whole blood and buffy-coat.  
 
The relative peak intensity ratio of the bands assigned to nucleic acids (967, 1079 and 
1236 cm
-1
) and proteins (amide I, II and III) in different combinations are demonstrated 
in Figure 6-43. The ratio of peak intensity corresponding to all nucleic acid and 
proteins, differ greatly between whole blood, plasma and buffy-coat. All combinations 
of nucleic acid/protein peak intensity ratios are very similar and indicate a strong 
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correlation with higher nucleic acid distribution in buffy-coat compared to that in whole 
blood and plasma. 
 
 
Figure 6-41: Correlation between protein (amide I, II and III) and lipid (1454, 
1390 and 1372 cm
-1
) peak intensity ratios 
 
 
Figure 6-42: Correlation between carbohydrate (1005 and 1140 cm
-1
) and protein 
(amide I, II and III) peak intensity ratios 
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Figure 6-43: Correlation between nucleic acid (967, 1079 and 1236 cm
-1
) and 
proteins (amide I, II and III) peak intensity ratios 
 
6.3.2 Empirical analysis of chronic lymphocytic leukaemia (CLL) blood specimens 
 
6.3.2.1 Empirical analysis: CLL Blood  
 
12 blood samples were collected from patients with chronic lymphocytic leukaemia 
(CLL). Blood components such as plasma and buffy-coat were isolated using standard 
procedures as described in Section 5.2.3. White light images and spectral measurements 
were obtained for whole blood, plasma and buffycoat as described in Section 5.5 and 
5.9.3. 
 
A background spectrum was obtained from a blank area of the CaF2 slide and ratioed 
against the sample spectrum each time. The optimised standard point measurement 
parameters described in Section 5.8 were used to measure FT-IR spectra from whole 
blood, plasma and buffycoat samples. Point spectra obtained in transmission mode 
obtained from the blood component at different regions were averaged using an in-
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house Matlab programme. The total number of point spectra collected for whole blood, 
buffy-coat and plasma are 711, 623, and 338 respectively.  
 
A plot of the mean FT-IR spectra of the 3 separate blood components from CLL blood 
normalised to the intensity at 1656 cm
-1
 (amide I) is shown in Figure 6-44 for 
comparison. Significant spectral differences are noted between the three blood 
components.  These were identified using a standard empirical method of assigning key 
peak positions. Spectrum for individual blood component is sited in Appendix E. The 
peak positions of the major vibrational modes are labelled. The full list of peak 
assignments are summarised in Appendix D.  
 
The representative mean spectra for CLL whole blood, plasma and buffy-coat are very 
similar. However, there is a degree of variations in peak positions and intensities as 
shown in Figure 6-44. The most distinctive peaks in the IR absorption spectra for whole 
blood, plasma and buffy coat are assigned to the absorption modes of proteins the most 
intense is the amide I band, centred near 1656 cm
-1 
for buffycoat and plasma spectra and 
1658 cm
-1 
for whole blood spectra. The amide II peak are assigned at approximately 
1546/1547 cm
-1
 for whole blood, plasma and buffy coat spectra The amide III band 
arise at 1233-1242 cm
-1
. Lipid contributions in whole blood, plasma and buffycoat 
spectra are attributed at 1452-1467 cm
-1 
and 1307- 1399 cm
-1
 bands. A small peak at 
1741 cm
-1 
observed in the buffy-coat spectra may correspond to C=O stretching 
vibrations from phospholipids in membranes. This peak is absent in the spectra for 
whole blood and plasma.  
 
Symmetric and anti-symmetric stretching vibrations from the phosphate group are seen 
in the FT-IR spectra of whole blood and buffy-coat in the region between 950 and 1280 
cm
-1
. For buffy-coat spectra, nucleic acid signals contribute at 1084 cm
-1
, 1056cm
-1
 and 
972 cm
-1
. For whole blood spectra, nucleic acid signals contribute at 1106 and 1170 cm
-
1
. The peak at 968/972 cm
-1 
is absent in the spectra for whole blood. Nucleic acid 
contributions are attributed at 1086cm
-1
, 1055cm
-1
 and 968 cm
-1
. 
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Figure 6-44: Represents the average IR spectra for whole blood, plasma and buffy-
coat in the range 900-1800 cm
-1 
for CLL blood 
 
6.3.2.2 Difference Spectra: CLL Blood 
 
The difference spectrum was calculated using an in-house Matlab programme. Figure 6-
45 shows the resulting spectra obtained from taking the difference between mean whole 
blood from plasma. Figure 6-46 shows the resulting spectra obtained from subtracting 
the mean whole blood spectra from mean buffy-coat spectra. The difference spectra 
obtained subtracting the mean plasma spectra from mean buffy-coat spectra is 
represented in Figure 6-47. Table 6-25 lists the biochemical constituents in high 
concentrations as positive peaks in a certain blood component and those with lower 
concentrations as negative peaks in other blood component. 
 
 
 
 140 
 
Figure 6-45: Difference spectra obtained by subtraction of whole blood spectrum 
from the spectrum obtained from plasma 
 
 
Figure 6-46: Difference spectra obtained by subtraction of whole blood spectrum 
from the spectrum obtained from buffycoat 
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Figure 6-47: Difference spectra obtained by subtraction of plasma spectrum from 
the spectrum obtained from buffycoat 
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 Whole blood - Plasma Whole blood - 
Buffycoat 
Plasma - Buffycoat 
Peak Assignment  Peak  Assignment Peak Assignment 
Positive  
Peaks 
 
 
 
 
 
 
 
1660 
1546 
Amide I 
Amide II 
 
1660 
1548 
Amide I 
Amide II 
1660 
1552 
1733-
1751 
1409 
 
1239 
1183 
Amide I 
Amide II 
Lipids, 
esters, C=O 
str 
Lipids (C-
H, CH2) 
PO2
- 
str 
Carbohydrat
es, C-O, C-
OH str 
Negative  
Peaks 
967 
1063-
1086 
1222 
1357 
 
1411-
1482 
 
1602 
1716 
Phosphorylated 
proteins, RNA 
P=O str of >PO2 
 
C-O, C-OH, C-C, 
C-O-C 
Amino acids, Lipid 
(COO, CH3) 
Lipids (C-H, CH2 
wagging vib, CH3 
sym bending vib 
and C-O str in 
carbohydrates) 
???? 
C=O in nucleic 
acids 
 
 
 
 
972 
 
1009 
 
1073 
1137 
 
 
1225 
 
 
1374 
1424- 
1484 
 
 
 
 
1602 
1714 
Phosphoryla
ted proteins, 
RNA 
Carbohydrat
es, C-O, C-
OH str 
P=O str of 
>PO2 
Carbohydrat
es, C-O, C-
OH str 
 
Carbohydrat
es, C-O, C-
OH, C-C, 
C-O-C 
Lipids, CH3 
Lipids (C-
H, CH2 
wagging 
vib, CH3 
sym 
bending vib 
and C-O str 
in 
carbohydrat
es) 
???? 
C=O in 
nucleic 
acids 
920 
949 
1007 
 
1135 
 
1270 
1376 
1449 
 
 
 
 
 
1507 
1600 
??? 
??? 
Carbohydrat
es, C-O, C-
OH str 
Carbohydrat
es, C-O, C-
OH str 
Amide III 
Lipids, CH3 
Lipids (C-
H, CH2 
wagging 
vib, CH3 
sym 
bending vib 
and C-O str 
in 
carbohydrat
es) 
??? 
??? 
 
 
 
 
Table 6-25: Lists positive and negative peaks obtained from the difference spectra 
between whole blood, plasma and buffy-coat samples with peak assignment 
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6.3.2.3 Peak Intensity Ratio: CLL Blood 
 
Figure 6-48 shows, the relative peak intensity ratio of the bands assigned to proteins 
(amide I, II and III) and lipids (1452 and 1393 cm
-1
) in various combinations. It has 
been found that the peak intensity ratio corresponding to all proteins and lipids peaks; 
differ greatly between whole blood, plasma and buffy-coat spectra. Most combinations 
of protein/lipid peak intensity ratios are very similar and indicate a strong correlation 
with higher protein distribution in buffy-coat and whole blood compared to that in 
plasma. This is not the case in peak ratios at 1236/1452 cm
-1 
and 1236/1393 cm
-1
. This 
could be due to the peak assigned at 1236 cm
-1 
has overlapping vibrational modes 
corresponding to lipids and amide III protein.  
 
The relative peak intensity ratio of the bands assigned to nucleic acid (967, 1079 and 
1236 cm
-1
) and protein (amide I, II and III) in different combinations are demonstrated 
in Figure 6-49. The ratio of peak intensity corresponding to all nucleic acid and 
proteins, differ greatly between whole blood, plasma and buffy-coat. All combinations 
of nucleic acid/protein peak intensity ratios are very similar and indicate a strong 
correlation with higher nucleic acid distribution in buffy-coat compared to that in whole 
blood and plasma. 
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Figure 6-48: Correlation between protein (amide I, II and III) and lipid (1452 and 
1393 cm
-1
) peak intensity ratios 
 
 
Figure 6-49: correlation between protein (amide I, II and III) and nucleic acid 
(967, 1079 and 1236 cm
-1
) peak intensity ratios 
 
 
 145 
6.3.3 Empirical analysis: Normal Blood vs CLL Blood Comparison 
 
The comparison between the FT-IR spectra of normal whole blood and CLL whole 
blood is shown in Figure 6-50. Figure 6-51 represent the comparison between the FT-IR 
spectra of normal plasma and CLL plasma. The comparison between the FT-IR spectra 
of normal buffycoat and CLL buffycoat is shown in Figure 6-52. The full list of peak 
assignments are summarised in Appendix D.  
 
The representative mean spectra for normal whole blood and CLL whole blood are very 
similar with very little variations in peak intensities as shown in Figure 6-50. A degree 
of variation throughout the fingerprint region (900-1800 cm
-1
) for spectra belonging to 
normal and CLL plasma is demonstrated (Figure 6-51). Significant band shifts and 
changes in peak intensity are observed. Major band shifts are seen in peak at 1078 cm
-1 
to 1082 cm
-1
 and 1371 cm
-1 
to 1401 cm
-1
 in the CLL plasma spectra. The significant 
reduction in the intensity of various peaks corresponding to lipids, carbohydrates, amide 
III and amino acids indicate a general reduction in plasma metabolites, higher metabolic 
activity and lower levels of nutrition in leukaemia cells. These finding coincide with a 
study by Erukhimovitch 2005, which reported reduction in the intensity of peak 
assigned at 1056 cm
-1 
(carbohydrates), 1270 cm
-1 
(Amide III) and 1592 cm
-1 
(amino 
acids) in plasma samples from patients suffering from CLL compared to healthy 
subjects.  
 
Changes in peak intensities are also seen between normal buffycoat and CLL buffycoat 
spectra as represented in Figure 6-52. The most significant changes are seen in the 900-
1200 cm
-1 
region, corresponding to the vibrational modes of nucleic acids. This 
indicates that the concentration of nucleic acids increase in leukaemia cells due to DNA 
replication. The increase in the nucleic acid in CLL buffycoat coincides with study by 
Boydston-White 1999, which suggest that concentration of nucleic acids increase in 
leukaemia cells during the replication of DNA. Changes in intensities are also observed 
in Amide I and II peaks. 
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Figure 6-50: Represents the average IR spectra for normal whole blood and CLL 
whole blood in the range 900-1800 cm
-1 
 
 
 
Figure 6-51: Represents the average IR spectra for normal plasma and CLL 
plasma in the range 900-1800 cm
-1 
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Figure 6-52: Represents the average IR spectra for normal buffycoat and CLL 
buffycoat in the range 900-1800 cm
-1 
 
6.3.3.1 Difference Spectra: Normal vs CLL Blood 
 
The difference spectrum was calculated using an in-house Matlab programme. Figure 6-
53 shows the resulting spectrum obtained from subtracting the mean normal whole 
blood spectrum from mean CLL whole blood spectrum. Figure 6-54 shows the resulting 
spectra obtained from taking the difference between mean normal plasma spectrum and 
mean CLL plasma spectrum. The difference spectra obtained subtracting the mean 
normal buffycoat spectra from mean CLL buffy-coat spectra is represented in Figure 6-
55. Table 6-26 lists the biochemical constituents in high concentrations as positive 
peaks in a certain blood component and those with lower concentrations as negative 
peaks in other blood component. 
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Figure 6-53: Difference spectra obtained by subtraction of normal whole blood 
spectrum from the spectrum obtained from CLL whole blood 
 
 
Figure 6-54: Difference spectra obtained by subtraction of normal plasma 
spectrum from the spectrum obtained from CLL plasma  
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Figure 6-55: Difference spectra obtained by subtraction of normal buffycoat 
spectrum from the spectrum obtained from CLL buffycoat   
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 Normal–CLL whole blood Normal–CLL Plasma Normal–CLL buffycoat 
Peak Assignment  Peak  Assignment Peak Assignment 
Positive  
Peaks 
 
 
 
 
 
 
 
 
929 
954 
989 
1011 
1022 
1042 
1079 
1141 
1203 
1263 
 
1306 
1321 
1438- 
1490 
 
1555- 
1565 
1627 
1640 
1653 
1737-
1773 
??? 
??? 
Phosphorylated proteins, RNA 
Carbohydrates, C-O, C-OH str 
??? 
Carbohydrates, C-OH 
P=O str of >PO2 
Carbohydrates, C-O, C-OH str 
??? 
Carbohydrates, C-O, C-OH, C-C, 
C-O-C 
??? 
Lipids (CH3) 
Lipids (C-H, CH2 wagging vib, 
CH3 sym bending vib and C-O str 
in carbohydrates) 
Amide II 
 
??? 
??? 
Amide I 
Lipids, esters, C=O str 
1655 
1546 
Amide I 
Amide II 
974- 
997 
1008 
 
1057 
 
1066- 
1084 
1136 
 
1214 
1272 
 
 
1383- 
1372 
1484 
 
 
 
 
 
1597 
1715 
Phosphorylated 
proteins, RNA 
Carbohydrates, C-
O, C-OH str 
Carbohydrates, C-
OH 
P=O str of >PO2 
 
Carbohydrates, C-
O, C-OH str 
??? 
Carbohydrates, C-
O, C-OH, C-C, C-
O-C 
Amino acids (C-O 
of COO-) 
Lipids (C-H, CH2 
wagging vib, CH3 
sym bending vib 
and C-O str in 
carbohydrates) 
Amide II 
C=O in nucleic 
acids 
Negative  
Peaks 
916 
1336 
1385 
1453 
1507 
1515 
1529 
1540 
1675 
1688 
1728 
 
 
??? 
Lipids (CH3) 
Amino acids (C-O of COO-) 
Lipid (CH def of >CH2) 
??? 
??? 
??? 
??? 
Amide I 
??? 
Lipids, esters, C=O str 
955 
 
1004 
 
1074 
1138 
 
 
1272 
 
 
1373 
1429- 
1481 
 
 
 
 
1599 
Phosphorylated 
proteins, RNA 
Carbohydrates, C-
O, C-OH str 
P=O str of >PO2 
Carbohydrates, C-
O, C-OH str 
 
Carbohydrates, C-
O, C-OH, C-C, C-
O-C 
Lipids, CH3 
Lipids (C-H, CH2 
wagging vib, CH3 
sym bending vib 
and C-O str in 
carbohydrates) 
??? 
1245 
 
 
1311 
1413 
 
1438 
 
 
 
1547 
1644 
1741 
Carbohydrates, C-
O, C-OH, C-C, C-
O-C 
??? 
Amino acid C-O of 
sym COO- 
Carbohydrates, C-
O, C-OH str 
Carbohydrates, C-
O, C-OH str 
Amide II 
Amide I 
Lipids, esters, C=O 
str 
 
Table 6-26: Lists positive and negative peaks obtained from the difference spectra 
between normal and CLL whole blood spectrum; normal and CLL plasma 
spectrum and normal and CLL buffycoat spectrum with peak assignment 
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6.3.3.2 Peak Intensity Ratio: Normal vs CLL Blood 
 
Figure 6-56 shows, the relative peak intensity ratio of the bands assigned to proteins 
(amide I, II and III) and lipids (1454 and 1390 cm
-1
) in various combinations for the 
three blood components of normal and CLL blood. It has been found that the peak 
intensity ratios corresponding to all proteins and lipids peaks; differ greatly between; 
normal and CLL whole blood, normal and CLL plasma and normal and CLL buffy-coat 
spectra. In general, a slightly higher protein/lipid distribution is seen in normal whole 
blood spectra compared to that of CLL whole blood spectra. The protein/lipid 
distribution in normal plasma spectra is significantly higher than in spectra of CLL 
plasma. The reduction in the protein/lipid peak intensity ratio in CLL plasma coincides 
with study by Erukhimovitch 2005 as previously discussed in Section 5.3.3. A slightly 
higher protein/lipid distribution is seen in CLL buffycoat spectra compared to that of 
normal buffycoat spectra. This is not evident in the protein/lipid peak ratios at 
1272/1454, 1658/1390 and 1272/1390 cm
-1
.  
 
 
 
Figure 6-56: correlation between protein (amide I, II and III) and lipid (1454 and 
1390 cm
-1
) peak intensity ratios in the three blood components (whole blood, 
plasma and buffycoat) of normal and CLL blood 
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Figure 6-57 shows, the relative peak intensity ratio of the bands assigned to nucleic 
acids (967, 1079 and 1236 cm
-1
) and proteins (amide I, II and III) in various 
combinations for the three blood components of normal and CLL blood. In general, a 
higher nucleic acid/protein distribution is seen in CLL whole blood spectra compared to 
that of normal whole blood spectra. The nucleic acid/protein distribution in normal 
plasma spectra is higher than in spectra of CLL plasma. There is a significant increase 
in the nucleic acid/protein distribution in CLL buffycoat compared to that of normal 
buffycoat spectra. The increase in the nucleic acid/protein peak intensity ratio in CLL 
buffycoat coincides with study by Boydston-White 1999 as previously discussed in 
Section 5.3.3.The observed results suggest that concentration of nucleic acids increase 
in leukaemia cells during the replication of DNA. 
 
 
 
Figure 6-57: correlation between nucleic acid (967, 1079 and 1236 cm
-1
) and 
protein (amide I, II and III) peak intensity ratios in the three blood components 
(whole blood, plasma and buffycoat) of normal and CLL blood 
 
 
 
 153 
6.3.4 Multivariate Analysis  
 
All point spectra were combined into clinically significant groups for the construction 
of a multivariate linear discriminant model. Initially, PCA was used to generate data for 
linear discriminant analysis as described in Section 4.2.2.1. LDA is explained in Section 
4.2.2.2. All multivariate analysis is performed using in-house Matlab programmes. 
Samples from the normal and CLL pathological groups were rearranged into the three 
clinically significant subsets: 
1) Dataset 1 comprised of only whole blood point spectra from the normal and 
CLL groups. 
2) Dataset 2 comprised of only plasma point spectra from the normal and CLL 
groups. 
3) Dataset 3 comprised of only buffycoat point spectra from the normal and CLL 
groups. 
 
Subsequently classification models were constructed using these three clinical subsets. 
To interpret biochemical variation, ANOVA was performed on all datasets to 
demonstrate principal components with maximal variance. Table 1 situated in Appendix 
F reports principal components with highest F values after ANOVA of the first 25 PC 
for datasets 1, 2 and 3. Table 1 also reflect the corresponding % variance. The most 
significant PC are plotted against each other in Figures 1-3 located in Appendix F to 
observe the degree of natural separation between blood groups. Fcrit for datasets 1, 2 
and 3 are 6.69, 6.72 and 6.61 respectively.  
 
All 25 of the calculated PCs were used as input into an individual LDA model to 
maximise the variance between the normal and CLL blood groups and minimise the 
variance between two blood groups. This required one linear discriminant function for 
optimal separation of the blood groups. Two-dimensional scatter plot of the linear 
discriminant scores from subsets 1, 2 and 3 are displayed in Figures 6-58 – 6-60. The 
efficiency of the PCA-fed LDA classification model was evaluated using leave-one-
sample-out cross validation. The classification results, reflecting the number of spectra 
correctly classified into either normal blood or CLL blood group in datasets 1, 2 and 3 
as well as their sensitivity and specificity are presented in Tables 6-27 – 6-29.  
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Figure 6-58: Histogram of LDA results for dataset 1 
 
 
Figure 6-59: Histogram of LDA results for dataset 2 
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Figure 6-60: Histogram of LDA results for dataset 3 
 
 
 
 
Blood Group                             Blood Group Classification 
Normal whole blood CLL whole 
blood 
Total No. 
Normal whole blood 545 366 911 
CLL whole blood 170 655 825 
Number correct 545 655  
   1736 
   Average 
Sensitivity (%) 59.8 79.3 69.6 
Specificity (%) 79.4 59.8 69.6 
 
Table 6-27: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 1. 70% spectra are correctly classified 
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Blood Group                             Blood Group Classification 
Normal plasma CLL plasma Total No. 
Normal plasma 32 64 96 
CLL plasma 0 235 235 
Number correct 32 235  
   331 
   Average 
Sensitivity (%) 33.3 100 66.7 
Specificity (%) 100 33.3 66.7 
 
Table 6-28: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 2. 80.6% spectra are correctly 
classified 
  
 
Blood Group                             Blood Group Classification 
Normal buffycoat CLL buffycoat Total No. 
Normal buffycoat 473 7 480 
CLL buffycoat 1 958 959 
Number correct 473 958  
   1438 
   Average 
Sensitivity (%) 98.5 99.9 99.2 
Specificity (%) 99.9 98.5 99.2 
 
Table 6-29: Summary of leave-one-sample-out cross validation results and 
sensitivity and specificity values for dataset 3. 99.5% spectra are correctly 
classified 
 
6.4 PLS Analysis 
 
In this study prior to spectroscopic measurements, Full Blood Count (FBC) was taken at 
the Haematology Laboratory for each buffycoat sample as a standard procedure for 
measuring concentration of cellular analytes. Concentrations of six cellular analytes 
were measured as a result of full blood count as shown in Table 6-30. These include 
neutrophils, lymphocytes, monocytes, eosinophils and basophils. After spectroscopic 
measurements and the pre-processing of spectra, partial least squares (PLS) regression 
was performed on buffycoat spectra from normal and CLL blood samples. It was used 
to construct a linear predictive model for each cellular analytes amount based on the 
spectrum obtained from normal and CLL buffycoat samples. 
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Table 6:30: Concentrations of 6 cellular analytes for normal buffycoat samples and 
CLL buffycoat samples determined by standard full blood count assessment 
 
 
The spectral data and analyte concentrations were mean-centred prior to calibration of 
the training set. Example of a root mean square error as a result of PLS analysis of 
infrared spectra is illustrated in Table 6-31 for all five cellular analytes. Figure 6-61 and 
Table 6-31 shows variance captured by 20 latent variables (LV). The optimum number 
of LVs required to capture variance is determined through calculating the PRESS 
values. The first 10 LV’s capture most of the variance. The X-Block (predictor variable) 
captured higher % variance compared to that captured by the Y-Block (predicted 
variable). 
                          Cellular Analyte  [10^9 /L] 
Sample Number Neutrophil   Lymphocyte Monocyte Eosinophil Basophil 
Normal Buffy 
Coat 
     
1 3.04 2.87 0.41 0.18 0.07 
2 3.83 2.37 0.38 0.52 0.02 
3 3.99 1.71 0.83 0.08 0.01 
4 2.46 1.96 0.4 0.2 0.01 
5 7.02 2.36 0.55 0.2 0.02 
6 5.71 3.14 0.51 0.15 0.02 
7 3.65 2.58 0.39 0.07 0.02 
8 4.24 2.14 0.31 0.07 0.02 
9 2.14 1.82 0.41 0.13 0.02 
10 2.49 2.07 0.49 0.21 0.03 
11 6.55 2.53 0.56 0.16 0.05 
12 3.13 2.91 0.41 0.1 0.05 
CLL Buffycoat      
1 7.31 0.39 0.88 0.23 0.01 
2 0.68 3.36 0.51 0.08 0.01 
3 3.2 1.72 0.86 0.5 0.1 
4 2.22 0.56 0.07 0.06 0.01 
5 2.05 35.22 0.59 0.03 0.04 
6 4.46 20.83 0.44 0 0.02 
7 0 0 0 0.19 0.03 
8 0 0 0 0.47 0.22 
9 0 0 0 0.35 0.24 
10 3.17 3.41 0.7 0.09 0.01 
11 4.04 21.2 1.19 0.29 0.05 
12 0.09 272.6 5.99 0.13 2.4 
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 X Block Y Block 
LV This LV Total This LV Total 
1 44.19 44.19 9.89 9.89 
2 14.62 58.81 13.44 23.34 
3 11.15 69.96 14.65 37.99 
4 11.55 81.52 4.46 42.45 
5 6.55 88.06 6.93 49.37 
6 2.94 91.01 10.18 59.55 
7 2.00 93.01 5.05 64.6 
8 2.56 95.57 2.83 67.43 
9 1.15 96.72 4.76 72.2 
10 0.36 97.08 3.14 75.33 
11 0.33 97.42 3.24 78.58 
12 0.30 97.72 2.59 81.17 
13 0.27 97.99 2.39 83.57 
14 0.16 98.15 2.06 85.62 
15 0.33 98.48 0.57 86.19 
16 0.09 98.57 1.57 87.77 
17 0.15 98.72 0.73 88.49 
18 0.07 98.79 1.24 89.73 
19 0.06 98.85 0.97 90.7 
20 0.11 98.96 0.44 91.14 
 
Table 6-31: Percent Variance Captured by PLS Model by 20 LVs 
 
After the training had been performed on the calibration set and the LV’s had been 
determined, the spectra of the validation set were subjected to cross validation. Data 
was divided into contiguous blocks during the cross-validation i.e. normal (the 
calibration/training dataset) and leukaemia (the validation dataset) so that data is serially 
correlated. The calibration (training) dataset comprised of 437 spectra (10 normal 
buffycoat samples) and the validation dataset consisted of 627 spectra (12 CLL blood 
samples). The cellular analyte concentrations of the 12 CLL samples investigated by 
FT-IR spectroscopy were predicted using PLS analysis. The difference between the 
predicted and the actual concentration is illustrated for all 5 cellular analytes in Figure 
6-62.  Each symbol on the plot shows the samples in the test set only.  The cumulative 
error for each analyte is represented as a) 0.6949, b) 0.6600, c) 0.8534, d) 0.8424 and e) 
0.9158. The average sum squared error is 1.411. 
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Figure 6-61: Shows trends in RMSECV and RMSEC with increasing number of 
latent variables for neutrophil, lymphocyte, monocyte, eosinophil and basophil 
qualitative model. The first 10 LVs capture most of the variance and chosen as 
optimal 
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Figure 6-62: Scatterplots comparing blood a) neutrophil, b) lymphocyte, c) 
monocyte, d) eosinophil and e) basophil concentrations predicted on the basis of 
the infrared spectra of dry buffycoat films to actual concentration. Each circle 
corresponds to the validation test set and the solid line is the line of identity 
 
The preliminary PLS analysis used in this study used concentrations obtained from full 
blood count (FBC) measurements. FBC values obtained from both normal and CLL 
buffycoat samples show very little variations in concentration values. Hence, PLS in 
this case is not accurate and has not been able to predict the true concentration values. 
Many studies have made use of PLS for quantitative clinical applications in predicting 
concentration of proteins, glucose triglycerides, urea, and cholesterol in serum (Shaw 
2000; Petibios 1999) and plasma (Deleris 2003). The quantification of cellular analytes 
such as neutrophil, lymphocyte, monocyte, eosinophil and basophil in dried buffycoat 
film is a new concept investigated in this thesis, which has not been addressed in the 
literature to date.  
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The idea behind this initial sub-study was to determine whether concentrations of 
different cellular analytes including neutrophil, lymphocyte, monocyte, eosinophil and 
basophil can be predicted in CLL samples. This may reveal important characteristic 
features including: 
 origin: whether the leukaemia or lymphoma arise from a lymphoid progenitor 
or myeloid progenitor 
 
 Type of cell that is involved in differentiation and maturation: whether the cells 
involed are lymphocytes (T cells and B cells) or myeloids (basophils, 
megakaryocytes, neutrophils, monocytes, and esinophils). 
 
These characteristic features may further help clinicians to accurately screen cellular 
profile of blood samples and classify the type of leukaemia or lymphoma depending on 
cell lineages; determine the stage cell differentiation and maturation and further 
understand disease progression. It can be concluded that the quantitative analysis of 
cellular analytes in dried buffycoat films based on FT-IR spectroscopy and PLS analysis 
cannot as yet compete with present day laboratory diagnostics. Currently, the PLS 
model constructed is not complete due to time restrictions and is imperfect. Much work 
is required in understanding the concept of PLS. This is briefly outlined in the future 
work section. 
 
6.5 Summary 
 
Significant spectral differences were noted between the three blood components of 
normal and CLL blood including whole blood, buffycoat and plasma. Further spectral 
variations between the different blood components were emphasised using difference 
spectra. Peak intensity ratios were found to be in agreement with the difference spectra 
indicating higher protein distribution in buffy-coat and whole blood spectra compared to 
that in plasma in both normal and CLL blood. Higher nucleic acid distribution is seen in 
buffy-coat spectra compared to that in whole blood and plasma. The spectra of plasma 
mainly comprised of lipids, carbohydrates, amino acids and lactate contributions.  
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Multivariate analysis reveals that PCA-fed-LDA classification model constructed using 
spectra from buffycoat samples shows better performance compared to that using whole 
blood or plasma with higher sensitivity and specificity values. The prediction of the five 
most frequently occurring cellular components of blood was attempted with PLS 
regression, which was applied to buffycoat spectra. FBC values obtained from both 
normal and CLL buffycoat samples show very little variations in concentration values. 
Hence, PLS in this case is not accurate and has not been able to predict the true 
concentration values.  
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The scope of this thesis was to investigate the application of FT-IR spectroscopy as a 
potential diagnostic tool for the detection of leukaemia and lymphoma. This mainly 
consisted of accurate spectral measurements the target cell line and blood samples; 
extracting the relevant biochemical information buried in the spectrum and application 
of multivariate statistical methods to convert experimental data to useful diagnostic 
information. A combination of spectral amalysis and multivariate statistical analysis 
was used for both quantification of biochemical constituents and classification of cell 
lines derived from human T-cell lymphoma, B- cell lymphoid and myeloid leukaemia as 
well as blood samples from healthy subjects and patients with CLL. The spectral data 
were subjected to both unsupervised and supervised methods of multivariate analysis; in 
particular principal component analysis fed linear discriminate analysis (PCA-fed 
LDA). Leave one out cross validation (LOOCV) was also used to examine the quality 
of spectroscopic classification. Cellular analyte concentrations were predicted by means 
of multivariate methods such as partial least-squares (PLS) regression.  
 
7.1 Leukaemia and lymphoma cell line classification model performance 
 
The FT-IR spectra acquired from T-cell lymphoma, B- cell lymphoid, and myeloid 
leukaemia cell lines reveal that peak shapes and positions are repeatable although the 
peak intensities tend to vary due to differences in the bio-chemical constituents. Most 
significant changes in peak intensities occur in the fingerprint region between the 900-
1800 cm
-1 
corresponding to the proteins (Amide I, II and III), nucleic acids, amino 
acids, lipids and carbohydrates. Overall, the data showed that the relative intensities of 
DNA and amide III modes increase in malignant cells, indicating increased cellular 
nuclear content. Although these findings are consistent with those described in various 
publications (Boydston-White 1999; Boydston-White 2005 and Beekes 2007), these can 
not solely be used as a diagnostic algorithm. 
 
Significant differences have been demonstrated between the spectra from air-dried and 
frozen cells in terms of peak intensities and area under the curve. Findings suggest that 
freezing cell line samples preserves cellular composition and reduces the rate of cellular 
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damage. This is consistent with other studies conducted by Wolkers 2007 and Mourant 
2003. Visual inspections reveal that the IR absorption spectra of cell lines are complex, 
with hundreds of data points due to the sheer number of contributing bio-molecules and 
therefore contain many overlapping bands. In addition, the spectral homogeneity of 
spectra from cells belonging to similar lineage makes the visual interpretation of 
individual spectra nearly impossible. It is therefore essential that univariate methods are 
combined with both supervised and unsupervised methods of multivariate analyses for a 
meaningful interpretation.  
 
The initial imaging experiments of the B-cell lymphoid, myeloid leukaemia and T-cell 
lymphoma cell lines have demonstrated problems associated with poor region selection 
and contributions from CaF2 possibly resulting in poor quality spectral datasets. A 
preliminary unfiltered five cell line group classification model using 50 frozen and air-
dried samples correctly classified 54% of 18556 spectra. The three cell line group model 
also using 50 frozen and air-dried samples correctly classified 77.1% of 19903 spectra. 
This demonstrates that higher numbers of spectra are classified correctly in the three 
cell line group models compared to the five cell line group models using LOOCV. The 
highest sensitivity was achieved for three cell line group datasets ranging between 47-
75% compared to that achieved by five cell line model 44 -71%. The highest specificity 
was also achieved for three cell line group datasets ranging between 72-88% compared 
to that achieved by five cell line model 74-85%.  
 
Furthermore, the use of the frozen spectra improves the performance of classification 
model considerably. Finding show that 73.3% of 9920 spectra are correctly classified in 
the frozen three cell line group datasets, whereas in the air-dried three cell line group 
only 41.5% of 9983 spectra are correctly classified. The frozen three cell line model 
achieved sensitivity and specificity of 47.1% and 72.2% respectively. In contract the 
dried three cell line model achieved sensitivity and specificity of 69.3% and 86.8% 
respectively. These findings confirmed the feasibility of using FT-IR spectroscopy to 
measure and discriminate between different cell lines groups, covering the range of 
haematological malignancies. The use of FT-IR spectral classification models for the 
discrimination of leukaemia and lymphoma have not been demonstrated to date. 
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However, similar methods employing PCA-fed-LDA and LOOCV have been used 
previously in investigation of synovial fluids from joints affected by rheumatoid 
arthritis and osteoarthritis
 
(Shaw 1995) and classification of gastric inflammation and 
malignancy on endoscopic biopsies
 
(Li 2005). 
 
7.2 PCA-fed-LDA Classification Model Optimisation  
 
Various modalities were investigated in order to optimise the PCA-fed-LDA 
classification model. These include assessing the 
 effects of increasing PCs input for LDA 
 effects of Savitsky-Golay filters  
 application of standard deviation to filter outliers from the spectral dataset 
 application of an absorption filter tool on spectral dataset 
 
Optimisation of the PCA-fed-LDA classification model is important for the accurate 
classification of leukaemia and lymphoma derived cell lines. Findings reveal that 
methods of optimisation have significant improvements on the performance of the PCA-
fed LDA classification model. Increasing the numbers of PCs input into the PCA-fed-
LDA classification model from 5 PCs to 25 PCs is shown to increase the prediction 
achieved. In addition, using the only the frozen spectral dataset significantly improved 
the performance of the PCA-fed LDA classification model. Furthermore, the application 
of 1
st
 and 2
nd
 derivative reduces the percentage of spectra correctly classified in the 
frozen spectral dataset. 0
th
 derivative has a significant impact on the performance of the 
PCA-fed LDA classification model with higher percentages of the spectra correctly 
classified.  
 
Applying a range of standard deviation filtering (+/- 5 to +/- 1.5) to the frozen spectral 
dataset has shown to have a considerable impact. Standard deviation of +/- 1.5 
improved the performance of classification model resulting with highest sensitivity and 
specificity values. Although this an effective method of identifying poor quality spectra 
(outliers), a large number of spectra are eliminated from the dataset. The use of 
absorbance spectral filter tool to filter out weak/ low absorbance or saturated spectra is a 
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better approach of identifying poor quality spectra. The spectra retained after the 
application of the absorbance spectral filter tool is of better quality and more stable. 
This may indicates that performance of the PCA-fed LDA classification model is 
improved when the absorbance filter tool is applied compared to the use of standard 
deviation. However, as with the application of standard deviation filter, a huge number 
of spectra are eliminated from the dataset. Furthermore, significant improvements on 
the performance of the PCA-fed LDA classification model was achieved using three cell 
line group model compared to that of five cell line group model. 
 
Overall, cross-validation testing of LDA models developed with statistically significant 
principal components has demonstrated that 25 PC’s are sufficient to produce a good 
model. In addition, 0
th
 derivative and the absorbance filter tool on frozen spectral 
dataset are the standard parameters for constructing an optimised PCA-fed-LDA 
classification model as 90% of 3183 spectra were correctly classified in the frozen, 
filtered five cell line group model. In the frozen filtered three cell line group model 88% 
of 2972 spectra were correctly classified 
 
7.3 Normal and CLL blood classification model performance 
 
To avoid loss of huge amounts of spectra from original datasets as a result of standard 
deviation and absorbance spectral filter tool, targeted point spectra measurements were 
collected from 10 normal and 12 CLL blood samples. Several regions of whole blood, 
plasma and buffycoat preparations were probed for their IR signature to evaluate 
spectral variations. The point spectra measurement overcomes contributions from CaF2 
and acquires a more pure spectrum of better quality. Hence, this leads to improved 
performance of classification model. The limitation with point spectra measurements is 
that it can be time consuming and hence produce a smaller spectral dataset.  
 
Significant spectral differences were noted between the three blood components of 
normal and CLL blood including whole blood, buffycoat and plasma. Further spectral 
variations between the different blood components were emphasised using difference 
spectra. Peak intensity ratios were found to be in agreement with the difference spectra 
indicating higher protein distribution in buffy-coat and whole blood spectra compared to 
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that in plasma in both normal and CLL blood. Higher nucleic acid distribution is seen in 
buffy-coat spectra compared to that in whole blood and plasma. The spectra of plasma 
mainly comprised of lipids, carbohydrates, amino acids and lactate contributions.  
 
Variations are also observed in peak intensity ratios between normal and CLL whole 
blood spectra; normal and CLL buffy coat spectra and normal and CLL plasma spectra. 
In general higher protein/lipid distribution is seen in normal whole blood, plasma and 
buffycoat spectra compared to that of CLL whole blood, plasma and buffycoat spectra. 
Furthermore, higher nucleic acid/protein distribution is seen in CLL whole blood and 
buffycoat spectra compared to that of normal whole blood and buffycoat spectra. The 
increase in the nucleic acid/protein peak intensity ratio in CLL buffycoat coincides with 
study by Boydston-White 1999, Schultz 1996; Schultz 1997 and Bendetti 1984. The 
observed results suggest that concentration of nucleic acids increase in leukaemia cells 
during the replication of DNA. 
 
Multivariate analysis reveals that PCA-fed-LDA classification model constructed using 
spectra from buffycoat samples shows better performance compared to that using whole 
blood or plasma with higher sensitivity and specificity values. It has been demonstrated 
that higher number of spectra are classified correctly in the classification model 
constructed from buffycoat spectra. Using LOOCV, the whole blood model correctly 
classified 70% of 1736 spectra, measured on 22 samples (sensitivity 69.6% and 
specificity 66.7%). The plasma model correctly classified 80.6% of 331 spectra 
(sensitivity and specificity of 66.7%). The buffy coat model correctly classified 99.5% 
of 1438 spectra (sensitivity 99.2% and specificity 99.2%). 
 
The prediction of the five most frequently occurring cellular components of blood was 
attempted with PLS regression, which was applied to buffycoat spectra in the mid-
infrared fingerprint region from 1800–900 cm-1. The calibration (training) set for PLS 
regression was composed of cellular component of neutrophil, lymphocyte, monocyte, 
eosinophil and basophil from normal buffycoat samples at different concentrations. The 
cellular analyte concentration of the 12 CLL samples (validation dataset) was predicted 
using PLS analysis. FBC values obtained from both normal and CLL buffycoat samples 
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show very little variations in concentration values. Hence, PLS in this case is not 
accurate and has not been able to predict the true concentration values.  
 
7.4 Clinical relevance 
 
The lack of studies in the literature comparing spectral differences between multiple 
subtypes of leukaemia and lymphomas has been highlighted. This thesis has served to 
improve the results within the literature. This study has demonstrated the ability of FT-
IR spectroscopic classification models, to differentiate up to five cell line groups 
covering a range of haematological malignancies as well normal and CLL blood 
samples. Furthermore, combination of FT-IR spectroscopy with multivariate feature 
extraction and classification methods has the potential to become an ideal 
complementary tool to conventional assays for early detection of leukaemia and 
lymphoma. Additionally, as only small blood samples are obtained during routine 
check-up, this will be ideal for FT-IR spectroscopic measurements as only small sample 
volume is required.  
 
FT-IR spectral imaging demonstrated potential for differentiating different cell line 
types and blood samples. The pseudo-colour maps of the principal component scores 
calculated from the FT-IR spectral dataset have been shown to provide information on 
the distribution of biochemical constituents. Further work in this area encompassing 
biochemical studies would hopefully elicit more information and add to the 
understanding of complex biochemical constituents at cellular level. Infrared imaging 
provides a potential window into the disease processes, revealing compositional and 
structural information. It also provides the added benefit that instrumentation does not 
require reagents to promote a visible change in colour. It also ensures that all IR 
compositional data is stored in a single data set, permitting the rapid extraction of 
information of components of interest. These initial results further indicate that this 
approach provides the added benefit that instrumentation does not require staining 
reagents to promote a visual change in colour and ensures that all compositional data is 
stored in a single dataset. With further improvements and analytical work, an objective 
discrimination method can be developed.  
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The potential of FT-IR and chemometrics as a rapid and accurate diagnostic tool is 
clearly demonstrated by the results presented in this thesis. However, more work would 
be needed to see this through to clinical application and this study leads to many further 
research recommendations, which fall into three distinct areas: 
 Improvements in study design 
 Improvements in chemometric techniques 
 Exploitation of other optical diagnostic techniques 
 
8.1 Improvements in study design  
 
In regards to the cell line work, cell preparation and sampling methods need to be 
standardised. Further controlled experimental work need to be carried out to account for 
the extent of air-drying and freezing of cell lines samples and the affect this may have 
on the cell viability. Future experimental designs must incorporate obtaining and 
comparing spectra from samples air-dried and freezed ranging at 1hour to 24 hours. 
These observations can be further extended to days and weeks to provide a better 
understanding of the effects of air-drying and freezing on cell line samples over a period 
of time and provide a measure of degree of cellular decomposition.  
 
To futher limit other compounding factors that may effect the biochemical composition 
of the spectral fingerprint, future experimental designs must also consider using cell 
lines at a specific phase of the cell cycle (G1, G2 and S phase). Results from the cell 
line work presented in this thesis do not take into account the possible varations that 
may occur within cells in different phases of the cell cycles. Sample preparation 
methods including cell cultering and mitotic selection (or “mitotic shake-off”) have 
been previously used to isolate cell at different stages of the cell division cycle 
(Boydston-White 2006). By isolating cells at different stages of the cell cycle, changes 
in the FT-IR spectra of individual cells can be correlated with their biochemical age. 
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The cross validation testing of the FT-IR classification models indicated that sufficient 
population variance was not accounted for within the spectral datasets. This was 
particularly the case for the spectral dataset constructed from blood sample 
measurements. Therefore larger spectral models are required to account for the variation 
in spectra expected to be encountered in clinical practice. Ideally, the use of an 
unknown test set would provide a more robust independent analysis of sensitivity and 
specificity of the technique. 
 
Further evaluation of the clinical relevance of FT-IR spectroscopy is required. It will be 
interesting to see whether the FT-IR spectroscopy is able to classify other rare forms of 
leukaemia such as acute myeloid leukaemia (AML), acute lymphoblastic leukaemia 
(ALL) and chronic lymphocytic leukaemia (CML). There is scope to broaden the 
applications of the study design to include fine needle aspiration biopsy (FNAB) sample 
from lymph nodes and bone marrow to identify spectral change associated with stages 
of cell differentiation and maturation as well as cell lineages involved. This may predict 
early changes before the disease progresses therefore further rigorous testing of models 
constructed from testing of heterogeneous material such as FNAB sample is also 
required. Although this was planned in the original ethics application, due to time 
constraints, further work was not possible.  
Other avenues to exploit involve monitoring effectiveness of drugs during 
chemotherapy using FT-IR spectroscopy. Key objective would be to 1) assess the 
potential of FT-IR spectroscopy for the follow-up of leukaemia treatment 2) assess 
spectral and biochemical changes that occur in white blood cells of a CLL patient 
during chemotherapy and monitor and evaluate WBC populations before and after as 
well as during the various stages of chemotherapy. These investigations would be useful 
to indentify possible biomarkers which may indicate successful remission for the 
patient. 
 
This study has demonstrated the potential of FT-IR spectroscopy as a complementary 
analytical tool in haematology. Although, the ability to influence early detection is an 
appealing prospect, there is still much work to be undertaken before it can be clinically 
implemented. Large multicentre clinical trials are required to determine the sensitivity 
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and specificity, cost effectiveness and effect on clinical outcome of FT-IR spectroscopy 
for the detection of haematological malignancies. In addition, this will also overcome 
discrepancies associated with system standardisation and transferability. This will 
indeed require setting up multicentre sites on a very large scale and expanding 
collaboration with surgeons, haematologists and scientists.  
 
8.2 Improvements in chemometric techniques 
 
Improvements in the spectral analysis techniques are also required. Selection of 
significant spectral regions may enable faster measurement and processing and may 
improve prediction by removing unrelated data. Incorporating the entire spectral region 
(4000 – 700cm-1) must be considered to account for variations in lipid and fatty acid 
profile of normal and cancer cells. As previously mentioned much work is required to 
optimise the PLS model with improvements in the calibration dataset and testing the 
quality of predictions using an independent test set. Furthermore, it will be useful to 
investigate alternative and advanced analytical methods such as: 
 Cluster analysis as a complimentary imaging technique 
 Artificial neural network (ANN) as classification model 
 Biochemical fitting using non-negative least squares to estimate relative 
concentrations of biochemical components in normal and CLL cells as well as 
different subtypes of leukaemia cells. 
 
Much improvement is required in the optimisation of the PLS model. Various factors 
need to be considered to improve our understanding. These include: 
 Improve calibration dataset with more variation in concentration. This may be 
achievable by preparing artificial mixtures, which involves isolating different 
cellular analytes from the original buffycoat sample maybe with an aid of a flow 
cytometer coupled to a sorter or a traditional centrifugal method (where different 
cell types separate due to variation in density). Then spiking serum/plasma 
samples with known concentration of cellular analytes. Each serum/plasma 
sample shall have a known concentration of individual cellular analyte 
(neutrophil, lymphocyte, monocyte, eosinophil or basophil) ranging from cell 
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count of 10^20/L to 10^5/L. This may achieve a more reliable and accurate 
calibration dataset. 
 
 Testing the quality of predictions using an independent test set, this involves 
using a series of samples that have been left out of the original calculation. 
 
8.3 Exploitation of other optical diagnostic techniques 
Exploitation of Raman spectroscopy as a complementary technique is necessary for 
further biochemical analysis at single cell level. Raman spectrometry benefits from a 
higher spatial resolution (1-2 µm) compared to FT-IR spectrometry (10-20 µm). This 
will allow biochemical analysis of single cells at sub-cellular level providing qualitative 
and quantitative information on the molecular composition of various regions of a cell 
(e.g. cytoplasm, nucleus and cell membranes). Use of near-infrared radiation (NIR) 
Raman spectroscopy also overcomes the limitation of spectral interference of water and 
provides a higher spatial resolution which allows detection of biochemical constituents 
present within a single cell and at a sub-cellular level. Furthermore, due the differences 
in the selection rules, the analysis of Raman spectra can provide complementary 
biochemical information reflecting Raman inelastic scattering of non-polar bonds (e.g. 
C-C,C=C, and aromatic rings) that give a stronger Raman signals which are otherwise 
weak in the infrared spectra. 
 
ATR-FTIR spectroscopy is a technique enabling the measurement of aqueous solutions. 
The ATR accessory eliminates sample preparation required for FT-IR analysis by 
transmission techniques and thereby speeds the measurement. In this way, ATR FT-IR 
spectroscopic studies of liquid cell line suspensions and blood samples could be 
feasible. 
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Appendix A 
1. Lymphatic System 
 
The lymphatic system - the target of lymphomas - is a subsystem of the circulatory 
system. The components of the lymphatic system are divided into two groups: the 
primary organs and the secondary organs. The bone marrow and the thymus gland are 
primary organs. They regulate the production blood-forming (haematopoietic) elements 
and differentiation of lymphocytes that make up the immune system of the body. The 
secondary organs include the lymphatic (a network of very fine vessels that connect the 
lymph nodes scattered throughout the body), lymph nodes, aggregated lymphoid tissue 
and spleen. These secondary organs are involved in lymphatic functions including; 
assisting in circulating body fluids by transporting excess fluids away from interstitial 
spaces in body tissue and return it to the bloodstream to prevent the backflow of the 
lymph fluid and transporting infection-fighting cells called lymphocytes to combat 
bacteria and foreign entities and removes cell debris by phagocytosis forming part of the 
body’s immune system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The lymphatic system.  
Source: www.naturalypure.com/HerbalLymphaticSystemMedicine.htm 
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2. Bone Marrow 
 
Bone marrow (or "medulla ossea") is the soft tissue comprising the cavities of large 
bones and is the most active haematopoietic organ in the body. It is a network of 
connective tissue fibres, adipocytes, blood vessels, and blood-producing 
(haematopoietic) stem cells (figure 21). As needed, the HSCs differentiate to become a 
particular type of cell- a RBC (erythrocytes), platelet (thrombocytes) or WBC 
(lymphocytes), and only after maturation these cells are released from the myeloid 
tissue of the bone marrow into the blood stream.  The immature T-lymphocytes move to 
the thymus for final development, but the B- lymphocytes remains in the bone marrow 
during maturation. After maturation, both B- and T- lymphocytes circulate in the lymph 
and accumulate in secondary lymphoid organs, where they await recognition of 
antigens.  
 
 
Figure 2: Structure and characteristic appearance of bone marrow tissue.  
Source: www-sdc.med.nagasaki-u.ac.jp/n50/disaster/Leukemia-E.html  
 
B-lymphocytes play a large role in the humoral immune response. They react against 
antigens (invading bacteria or viruses and toxins) that produce an immune response in 
the body by making antibodies.  Antibodies are antigen specific, and the immune 
system is able to remember each antigen it fights. Once a B-cell makes antibodies 
 III 
against a certain antigen, e.g., bacteria, it keeps a memory of that antigen. If the antigen 
appears again, the B-cell can produce a large number of antibodies very rapidly. In this 
way, a second infection with that bacterium is often prevented.  
 
T cells play a central role in cell-mediated immunity. There are four different types of T 
cells with different immunological functions: 
 
 Cytotoxic T cells destroy virally infected cells and tumor cells, and are also 
implicated in transplant rejection. 
 Helper T cells divide rapidly and secrete cytokines that regulate or "help" the 
immune response. They also enhance the production of antibodies by B cells. 
 Inflammatory T cells that recrit macrophages and neutrophils to the site of 
infection or other tissue damage. 
 Natural Killer T cells posses the ability to recognise and luse virus infected cells 
and certain tumour cells as a natural function without requiring antibodies or 
other mediation. They are effective early in the course of viral infection, and 
may limit the spread of infection during this early stage. 
 
3. Lymph nodes 
 
Lymph nodes (small bean-shaped organ, 2.5 cm in diameter) are specialized collections 
of lymph tissue which are supported within by a meshwork of connective tissue called 
reticulin fibres. Lymph nodes occur along the entire length of the lymphatic system and 
tend to increase in size as they become closer to the thoracic duct. They appear to be 
strategically distributed in chains or clusters in the neck, armpits, pelvis, abdomen and 
groin.  Lymph nodes are enclosed by a capsule of connective tissue and comprised of 
several lymph nodules, which are populated by dense aggregates of lymphocytes (T-
cells and B-cells) and macrophages that collect and destroy bacteria and viruses as well 
as many cells in the precancerous stages of development. The nodules are separated by 
spaces called "lymph sinuses." The lymph node filters lymph which is brought to the 
cortex of the node by the afferent lymphatics, and there are several per node. The lymph 
is then filtered for antigens and particulate matter in the cortex, and an immune response 
 IV 
is generated, if necessary. The filtered lymph leaves the node through one or two 
efferent vessels near an indentation called the "hilum." Blood vessels also enter and exit 
the node at the hilum. 
 
 
  
 
Figure 3: Illustration of a lymph node.  
Source: www.droid.cuhk.edu.hk/web/specials/lymph_nodes/lymph_nodes.htm 
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Clinical staging of both HL and NHL is used for determining the extent of the disease 
and is done once the diagnosis is confirmed. Clinical stages depend on the number of 
lymph nodes affected, location and distribution of the affected lymph nodes and how far 
it has spread throughout the body (figure 8). This gives rise to four clinical stages 
according to the Ann Arbour Staging classification system: 
 Stage I: tumour hasn’t spread. Apparent involvement of a single lymph node 
region or a single organ, such as bone.  
 Stage II: More than one tumour, all found in lymph nodes on the same side of 
the diaphragm. Stage II can also mean that a tumour has spread to another organ, 
but that it is close to the original lymph node tumour.  
 Stage III: More than one tumour with the tumours found on different sides 
(above and below) of the diaphragm. There may be tumours in the spleen or 
more than one tumour in nearby organs.  
 Stage IV: Many tumours spread throughout an organ such as the liver or 
stomach, as well as in the lymph nodes. Stage IV can also refer to a single 
tumour in another organ, plus tumours in distant lymph nodes. 
 
 
Figure 1: Clinical staging of Hodgkin’s and non-Hodgkin lymphoma.  
Source: www.med-ed.virginia.edu/courses/path/innes/wcd/lymphoma.cfm 
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Table 1: Infrared Peak Assignment 
 
v: stretching vibrations, δ: bending (scissoring) vibrations, s: symmetric, as: 
asymmetric 
 
Molecular Motion Wavenumber  
(cm
-1
) 
References 
v(C=O): Amide I, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α-helices 
ß-sheet 
turns 
coils 
1652-1656 
1643 
1643 
1600-1720 
1589-1713 
1620-1690 
1640-1660 
1640 
1655 
1645 
1650 
1658 
1655 
1657 
1650 
1635 
1650 
1640 
1652 
1645 
1610-1690 
1645 
1650 
1655 
1655 
1620-1690 
1620-1690 
1645-1662  
1613-1637 
1662-1682 
1637-1645 
Schultz C.P et al., 1996 
Erukhimovitch. V et al., 2005 
Erukhimovitch. V et al., 2002 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
Lasch. P et al., 2002 
Benedetti et al., 1997 
Ahmad et al., 2000 
Nevilliappan et al.,  2002 
Boydston-White et al., 2005 
Boydston-White et al., 1999 
Chiriboga et al., 1998 
Chiriboga et al., 1998 
Sahu et al., 2005 
Diem et al., 2004 
Colley et al., 2004 
Diem et al., 2000 
Gasparri et al., 2003 
Lui et al., 1997  
Moss et al., 2005 
Jackson et al., 1995 
Krafft et al., 2005 
Beleites et al., 2005 
Liu Kan-Zhi et al., 2002 
Benedetti et al., 1998 
Andrus and Strickland 1998 
Mourant et al., 2003 
Byler and Susi 1988 
Byler and Susi 1988 
Byler and Susi 1988 
Byler and Susi 1988 
δ(N-H): Amide II, α-helix, 
proteins 
1540 
1544 
1544 
1480-1600 
1474-1589 
1530-1570 
1530-1545 
1545 
J.Sule-Suso et al., 2005 
Erukhimovitch. V et al., 2005 
Erukhimovitch. V et al., 2002 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
Lasch. P et al., 2002 
Benedetti et al., 1997 
Ahmad et al., 2000 
 VIII 
1545 
1540 
1530 
1541 
1545 
1530 
1550 
1538 
1542 
1550 
1543 
1530 
1546 
1549 
1530-1570 
Nevilliappan et al.,  2002 
Boydston-White et al., 2005 
Boydston-White et al., 1999 
Chiriboga et al., 1998 
Sahu et al., 2005 
Colley et al., 2004 
Diem et al., 2000 
Gasparri et al., 2003  
Lui et al., 1997 
Jackson et al., 1995 
Krafft et al., 2005 
Beleites et al., 2005 
Liu Kan-Zhi et al., 2002 
Benedetti et al., 1998 
Andrus and Strickland 1998 
Amide III (C-N stretching and 
N-H bending) 
1300 
1254 
1270 
1240-1340 
1200-1330 
1240-1310 
1245 
1307/1242 
1304 
1230 
1240-1340 
1240-1340 
J.Sule-Suso et al., 2005 
Beleites et al., 2005 
Erukhimovitch. V et al., 2005 
Lasch. P et al., 2002 
Benedetti et al., 1997 
Ahmad et al., 2000 
Boydston-White et al., 1999 
Chiriboga et al., 1998 
Krafft et al., 2005 
Benedetti et al., 1998 
Andrus and Strickland 1998 
Gasparri et al., 2003 
CH3 deformation 
CH3 asymmetric deformation 
1450 
1455 
1455 
1455 
J.Sule-Suso et al., 2005 
Schultz C.P et al., 1996 
Lasch. P et al., 2002 
Ahmad et al., 2000 
δCH2 lipid acyl bending 1468 
1467 
Schultz C.P et al., 1996 
Liu Kan-Zhi et al., 2002 
PO2 
-
 symmetric stretching  
 
 
 
 
 
 
 
 
 
 
 
 
 
PO2
-
 asymmetric stretching  
1080 
1080 
1087 
1082 
1095 
1080 
1000-1150 
1083 
1084-1088 
1087 
1000-1100 
1084 
1088 
 
1240 
J.Sule-Suso et al., 2005 
Nevilliappan et al.,  2002 
Schultz C.P et al., 1996 
Erukhimovitch. V et al., 2002 
Chiriboga et al., 1998 
Gasparri et al., 2003 
Ramesh et al., 2002 
Lasch. P et al., 2002 
Ahmad et al., 2000 
Lui et al., 1997 
Ramesh et al.,  2002 
Jackson et al., 1995 
Liu Kan-Zhi et al., 2002 
 
J.Sule-Suso et al., 2005 
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 1240 
1237 
1220-1250 
1240 
1243 (1200-1400) 
1170-1313 
1230 
1237 
1240 
1240 
1200-1245 
1226 
1242 
Schultz C.P et al., 1996 
Lasch. P et al., 2002 
Ahmad et al., 2000 
Nevilliappan et al., 2002 
Erukhimovitch. V et al., 2002 
Ramesh et al., 2002 
Chiriboga et al., 1998 
Colley et al., 2004 
Gasparri et al., 2003 
Lui et al., 1997 
Ramesh et al., 2002 
Jackson et al., 1995 
Liu Kan-Zhi et al., 2002 
DNA 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleic acids (DNA:RNA) 
966 
968 
970 
970 
965 
965 
966 
965 
966 
950 
965 
965 
 
1020 
1000-1200 
1060-1095 
1000-1150 
1080 
1080/1235 
1000/1080 
1000/1140 
1070/1100 
1080/1234 
1020/1121 
1080/1240 
Schultz C.P et al., 1996 
Lasch. P et al., 2002 
Benedetti et al., 1997 
Nevilliappan et al.,  2002 
Boydston-White et al., 1999 
Chiriboga et al., 1998 
Sahu et al., 2005 
Gasparri et al., 2003 
Lui et al., 1997 
Mourant et al., 2003 
Ramesh et al., 2002 
Ramesh et al., 2003 
 
Andrus and Strickland 1998 
Ramesh et al., 2002 
Boydston-White et al., 1999 
Chiriboga et al., 1998 
Sahu et al., 2005 
Diem et al., 2004 
Colley et al., 2004 
Gasparri et al., 2003 
Mourant et al., 2005 
Diem et al., 2002 
Ramesh et al., 2003 
Beleites et al., 2005 
RNA  v(C2=O) 
            
vδ ring of Uracyl 
           
 v(C-O) ribose 
 
1960-1705 
 
996 
 
1015 
1121 
1085 
Benedetti et al., 1997 
 
Benedetti et al., 1997 
 
Benedetti et al., 1997 
Andrus and Strickland 1998 
Boydston-White et al., 1999 
v(C=O )lipids, cholesterol 
esters, triglyceride 
2850 and 2920 
1732-1739 
1713-1739 
Schultz C.P et al., 1996 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
 X 
1737 
1700-1750 
2800-3000 
2850 
2800-2950 
1730 
1742 
1740 
Lasch. P et al., 2002 
Erukhimovitch. V et al., 2002 
Andrus and Strickland 01998 
Mourant et al., 2005 
Mourant et al., 2003 
Beleites et al., 2005 
Mourant et al., 2003 
Lasch et al., 2002  
v(C-C/C-O): saccharides, 
glucose, lactate, glycerol 
 
 
 
 
 
C = O (ester) stretch 
1397 
900-1300 
900-1300 
1061-1138 
1150 
1170 
900-1500 
1099 
Schultz C.P et al., 1996 
Erukhimovitch. V et al., 2005 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
Lasch. P et al., 2002 
Colley et al., 2004 
Diem et al., 2000 
Mourant et al., 2003 
v(COO
-
): amino acids 1360-1430 
1360-1430 
1370-1420 
1397 
1395 
1400 
Erukhimovitch. V et al., 2005 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
Lasch. P et al., 2002 
Chiriboga et al., 1998 
Jackson et al., 1995 
δas (CH3), δas (CH2),: fatty 
acids, phospholipids and 
triglyceride   
δs (CH2): 
 
 
 
 
 
 
δs (CH3), δs (CH2) 
1430-1480 
1430-1480 
1468 
1400-1455 
1448 
1452/1467 
1467 
1468 
1446 
 
1378 
1352 
1352 
Erukhimovitch. V et al., 2005 
Deleris and Petibois 2005 
Lasch. P et al., 2002 
Nevilliappan et al.,  2002 
Colley et al., 2004 
Lui et al., 1997 
Jackson et al., 1995 
Beleites et al., 2005 
Liu Kan-Zhi et al., 2002 
 
Liu Kan-Zhi et al., 2002 
Lasch et al., 2002  
Erukhimovitch et al., 2002 
δNH2 (amino acids) 1592 
1560-1630 
1455 
1400 
1517 (tyrosine) 
1582 (arginine) 
Erukhimovitch. V et al., 2005 
Deleris and Petibois 2003 
Chiriboga et al., 1998 
Mourant et al., 2003 
Jackson et al., 1995 
Jackson et al., 1995 
Carbohydrate  
 
Carbohydrate: C-OH 
stretching 
1056 
1050 
 
1155 
Erukhimovitch. V et al., 2005 
Lasch. P et al., 2002 
 
Nevilliappan et al.,  2002 
v(CH): unsaturated fatty acids, 
cholesterol esters 
 
3000-3020 
3000-3020 
 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
 
 XI 
vs (CH) saturated fatty acids 3081 
2934 
Colley et al., 2004 
Colley et al., 2004 
vas(CH3): (methyl) cholesterol 
esters, triglyceride 
2950-2990 
2950-2990 
 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
 
vas(CH2): long chain fatty 
acids, phospholipids  
2880-2950 
2880-2950 
2870-2960 
2945-2980 
2800-3000 
2926 
2850 
 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
Nevilliappan et al.,  2002 
Gasparri et al., 2003 
Ramesh et al., 2002 
Kan-Zhi Liu., 2002  
Lasch. P et al., 2002 
vs(CH3) cholesterol esters, 
triglyceride, glycerol 
2860-2880 
2860-2880 
2800-3000 
2800-3000 
Deleris and Petibois 2003 
Deleris and Petibois 2005 
Sahu et al., 2005 
Ramesh et al., 2002 
 vs(CH2): Fatty acids, 
phospholipids and triglyceride   
vas(CH2): 
vs(CH2): 
2819-2996 
2920 
2800-3000 
2800-3000 
2830-2870 
2800-3000 
2851/2924 
2852 
2852, 2874  
Deleris and Petibois 2003 
Lasch. P et al., 2002 
Ramesh et al., 2002 
Sahu et al., 2005 
Deleris and Petibois 2003 
Sahu et al., 2005 
Colley et al., 2004 
Kan-Zhi Liu., 2002  
Lasch et al., 2002 
 
-CO-O-C asymmetric stretch  
 
1173 
 
Lasch. P et al., 2002 
-CO-O-C symmetric stretch  1063 Lasch. P et al., 2002 
Albumin  1488-1600 Deleris and Petibois 2003 
Glucose 997-1062 Deleris and Petibois 2003 
Fibrinogen  1363-1428 Deleris and Petibois 2003 
Immunoglobulin- G2 1622-1652 Deleris and Petibois 2003 
Lactate  1115-1134 Deleris and Petibois 2003 
Glycerol  837-882 Deleris and Petibois 2003 
Triglyceride  1091-1122 
2800-3200 
Deleris and Petibois 2003 
Kan-Zhi Liu., 2002 
Cholesterol  1033-1074 
1700-1800 
2800-3000 
Deleris and Petibois 2003 
Kan-Zhi Liu., 2002 
Kan-Zhi Liu., 2002 
Cholesterol esters 1147-1186 Deleris and Petibois 2003 
Immunoglobulin- G1 1316-1419 Deleris and Petibois 2003 
α1- Antitrypsin 691-712 Deleris and Petibois 2003 
α2- Macroglobulin 983-1116 Deleris and Petibois 2003 
Transferin 1292-1338 Deleris and Petibois 2003 
Apolipoprotein- A1 1427-1484 Deleris and Petibois 2003 
 XII 
Urea  1632-1652 Deleris and Petibois 2003 
Apolipoprotein- B 2835-2862 Deleris and Petibois 2003 
Immunoglobulin- M 1360-1428 Deleris and Petibois 2003 
Apolipoprotein- C3 1660-1676 Deleris and Petibois 2003 
Immunoglobulin- A 1372-1418 Deleris and Petibois 2003 
Immunoglobulin- G4 1505-1538 Deleris and Petibois 2003 
Immunoglobulin- G3 1628-1652 Deleris and Petibois 2003 
Immunoglobulin- D 1464-1479 Deleris and Petibois 2003 
Haptoglobulin  1378-1428 Deleris and Petibois 2003 
α1- Acid glycoprotein  1279-1337 Deleris and Petibois 2003 
Fatty acyl moieties  2819-2996 Deleris and Petibois 2003 
Amino acids  1369-1430  Deleris and Petibois 2003 
Glycogen C-O stretching or C-
OH bending 
 
1025-1047 Nevilliappan et al.,  2002 
C-OH groups of serine, 
threonine and tyrosine (cell 
proteins) 
1170 Nevilliappan et al.,  2002 
 
Collagen  1031-1082 
1204,1240 and 
1283 
Andrus and Strickland 1998 
Jackson et al., 1995 
Glycogen  1025  
900-1185 
1150 
950-1200 
1300 
1280 
900-1200 
Andrus and Strickland 1998 
Sahu et al., 2005 
Diem et al., 2000 
Diem et al., 2002 
Mourant et al., 2003 
Chiriboga et al., 1998 
Chiriboga et al., 1998 
 
 XIII 
Appendix E 
Normal blood components spectra 
 
  
Figure 1: Represents the average IR spectra for whole blood (normal) in the range 
900-1800 cm
-1
 
  
 
 
 
Figure 2: Represents the average IR spectra for plasma (normal) in the range 900-
1800 cm
-1
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Figure 3: Represents the average IR spectra for buffycoat (normal) in the range 
900-1800 cm
-1
 
 
CLL Blood Component Spectra 
 
 
 
Figure 4: Represents the average IR spectra for buffycoat (CLL) in the range 900-
1800 cm
-1
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Figure 5: Represents the average IR spectra for plasma (CLL) in the range 900-
1800 cm
-1 
 
 
 
Figure 6: Represents the average IR spectra for whole blood (CLL) in the range 
900-1800 cm
-1
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Appendix F 
 
Principal 
Components 
F-Values % Variance 
 Dataset 
1 
Dataset 
2 
Dataset  
3 
Dataset 
1 
Dataset 
2 
Dataset  
3 
1 9.9298 11485.1 382.4847 55.2016 85.5357 59.6138 
2 1.8567 0.596 143.185 74.5043 95.2741 81.6748 
3 3.0947 4.546 177.9044 88.7037 98.6421 88.6043 
4 46.7434 0.9492 84.8351 93.3296 99.3189 93.0126 
5 1217.807 0.1339 6.8547 95.3255 99.5061 95.3197 
6 36.1405 0.0006 134.7953 96.5466 99.6603 96.4974 
7 9.2294 2.2741 22.8498 97.4737 99.79 97.4897 
8 187.5219 0.0352 29.9669 98.0436 99.8683 98.1046 
9 21.3296 0.1529 62.683 98.5315 99.91 98.5419 
10 5.2501 0.0178 41.3933 98.8596 99.9298 98.7856 
11 34.547 0.0406 12.6872 99.0678 99.9441 99.0038 
12 142.087 0.0057 69.7272 99.2148 99.957 99.2032 
13 63.6541 0.0028 0.0014 99.3255 99.965 99.329 
14 49.8919 0.0715 14.1777 99.4199 99.9714 99.429 
15 3.0017 0.0024 0.0604 99.4956 99.9764 99.5101 
16 14.9621 0.0004 0.8801 99.5598 99.98 99.5748 
17 16.3289 0.0056 1.2848 99.6099 99.9834 99.6233 
18 0.1409 0.0044 0.0594 99.6512 99.9855 99.6625 
19 0.0364 0.0002 18.6598 99.6865 99.987 99.6955 
20 0.1748 0.0474 0.1224 99.7211 99.9883 99.724 
21 0.0003 0.0074 4.5083 99.7507 99.9894 99.7503 
22 10.9174 0.0018 3.0323 99.7765 99.9905 99.7724 
23 3.5482 0.0154 0.954 99.799 99.9913 99.7907 
24 7.8314 0.0057 0.1705 99.8173 99.992 99.8056 
25 3.7248 0.0127 0.9301 99.8317 99.9926 99.8175 
 
Table 1: ANOVA F-value and percentage of variance corresponding to the first 25 
PCs for datasets 1, 2 and 3. The highest F- values highlighted in red represent the 
most significant PCs, which are then plotted against one another in a two-
domensional scatter plot to visualise the natural clustering of cell line populations. 
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Figure 1: PC scores scatter plot (PC5 vs. PC8) represents clustering of normal and 
CLL whole blood (dataset 1). Each symbol represents one spectrum. Normal whole 
blood= green stars and CLL whole blood = blue circles  
 
 
 
Figure 2: PC scores scatter plot (PC1 vs. PC3) represents clustering of normal and 
CLL whole blood.(dataset 2). Normal plasma= green stars and CLL plasma = blue 
circle 
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Figure 3: PC scores scatter plot (PC1 vs. PC3) represents clustering of normal and 
CLL whole blood.(dataset 2). Normal buffycoat= green stars and CLL buffycoat = 
blue circles  
 
 
 
 
 XIX 
Appendix G 
 
List of Publications and Posters  
 
 
Publications 
 
Babrah, J., McCarthy, K., Lush, R.J., Rye, A.D., Bessant, C. and Stone, N. (2009). 
Fourier transform infrared spectroscopic studies of T-cell lymphoma, B-cell lymphoid 
and myeloid leukaemia cell lines. Analyst, 134, 763–768. 
 
Babrah, J., McCarthy, K., Lush, R.J., Rye, A.D., Bessant, C. and Stone, N. (2007). FT-
infrared spectroscopic studies of lymphoma, lymphoid, and myeloid leukemia cell lines. 
Proc. SPIE, 6628, 66280R. 
 
Posters  
 
Vibrational spectroscopy for the diagnosis of leukaemia, SPEC 2006, Heidelberg, 
Germany 
 
Cancer diagnostics using infrared spectroscopy, Cranfield Health Conference 2006. 
 
Fourier Transform-Infrared Spectroscopic Studies of Lymphoma, Lymphoid and 
Myeloid Leukaemia Cell Lines, British Society of Haematology, 2007 
 
 
Prizes  
 
Poster prize for the poster titled “Cancer diagnostics using infrared spectroscopy”, 
Cranfield Health Conference 2006 
 
 
 
 
 
 
 
 
 
 1
FT-Infrared Spectroscopic Studies of Lymphoma, Lymphoid and 
Myeloid Leukaemia Cell Lines 
Jaspreet Babrah 1,4, Keith P. McCarthy 3, Richard Lush 2, Adam D. Rye 2, Conrad Bessant 4 
Nicholas Stone 1,4. 
1 Biophotonics Research Group, Gloucestershire Royal Hospital, Gloucester, UK 
Tel: 01452 395708, Email: j.babrah@medical-research-centre.com 
2 Department of Haematology, Gloucestershire Royal Hospital, Gloucester, UK 
3 Department of Histopathology, Gloucestershire Royal Hospital, Gloucester, UK 
4 Cranfield Health, Cranfield University, Silsoe, UK. 
 
ABSTRACT 
 
This paper presents a novel method to characterise spectral differences that distinguish leukaemia and 
lymphoma cell lines. This is based on objective spectral measurements of major cellular biochemical 
constituents and multivariate spectral processing. Fourier transform infrared (FT-IR) maps of the 
lymphoma, lymphoid and myeloid leukaemia cell samples were obtained using a Perkin-Elmer 
Spotlight 300 FT-IR imaging spectrometer. Multivariate statistical techniques incorporating principal 
component analysis (PCA) and linear discriminant analysis (LDA) were used to construct a 
mathematical model. This model was validated for reproducibility. Multivariate statistical analysis of 
FTIR spectra collected for each cell sample permit a combination of unsupervised and supervised 
methods of distinguishing cell line types. This resulted in the clustering of cell line populations, 
indicating distinct bio-molecular differences. Major spectral differences were observed in the 4000 to 
800 cm-1 spectral region. Bands in the averaged spectra for the cell line were assigned to the major 
biochemical constituents including; proteins, fatty acids, carbohydrates and nucleic acids. The 
combination of FT-IR spectroscopy and multivariate statistical analysis provides an important insight 
into the fundamental spectral differences between the cell lines, which differ according to the cellular 
biochemical composition. These spectral differences can serve as potential biomarkers for the 
differentiation of leukaemia and lymphoma cells. Consequently these differences could be used as the 
basis for developing a spectral method for the detection and identification of haematological 
malignancies.  
 
Keywords: lymphoid leukaemia cell lines, myeloid leukaemia cell lines, lymphoma cell line, haematological 
malignancies, Fourier transform infrared (FT-IR) spectroscopy, multivariate statistical analysis, principal 
component analysis (PCA), linear discriminant analysis (LDA).  
 
 
1. INTRODUCTION 
 
Fourier transform infrared (FT-IR) spectroscopy is a vibrational technique that monitors changes in biochemical 
composition of cells at a molecular level. Haematological malignancies manifest at single cell level by subtle 
biochemical changes, which are often not obvious in histopathological studies. The non-invasive FT-IR 
spectroscopic method has been proposed to overcome limitations of current “gold standards” providing a diagnostic 
tool for haematological malignancies without the need for staining. Automated, repetitive analyses can therefore be 
carried out at a low cost with the added advantage of utilizing small sample volumes. In addition, FT-IR 
spectroscopy can distinguish differences in the characteristics of diverse molecules by probing chemical bond 
vibrations. These molecular and sub-molecular profiles can be used to define and differentiate cell types. The appeal 
of these factors has forced the exploitation of FT-IR spectrometers that combine superior spectral sensitivity with 
powerful multivariate statistical analysis. This permits essentially all of the relevant biochemical information buried 
in the spectrum to be usefully extracted.  
 
 
 
 
 
 2
FT-IR spectroscopy uses the mid-infrared (IR) part of the electromagnetic radiation (4000-400 cm-1) to obtain an IR 
spectrum. It is based on the principle that when a sample is interrogated with an IR beam, the functional groups 
within the sample absorb the IR radiation. This induces vibrational motions (bending, stretching, etc) of covalently 
bonded moieties. The IR absorptions, when plotted against the wavelength of the light, produce a unique 
“biochemical fingerprint” of the molecular species present in the sample1. If this molecular fingerprint is modified by 
a disease process, then FT-IR spectroscopy can be used to detect and monitor the disease processes. Particular 
absorptions are assigned to various functional groups in an attempt to extract biochemical information. In complex 
biological materials such as cells, the major IR absorption bands arise from N-H, C=O, C-H and P=O bonds; found 
in proteins (present in cytoplasm), lipids (originate in cell membranes) and nucleic acids (found in nucleus)2. The 
sum or the specific arrangement of the bands in the IR spectra can provide qualitative and semi-quantitative 
information. This can be used to distinguish between normal and cancerous cells or tissues.  
 
To date FT-IR spectroscopy has proven to be a powerful analytical tool to probe the structure and confirmation of 
lipids, proteins and nucleic acids3 and also of complex biological materials such as tissues, body fluids and cell 
cultures4,5. The ability of FT-IR spectroscopy to detect changes in the chemical composition and morphology of cells 
led to its use in distinguishing differences among cell populations; for example, between normal and cancerous 
cells6,7 as well as characterisation of cancerous state using proliferative cell lines at various stages of the cell cycle8. 
Consequently, FT-IR spectroscopic study has become an active area of research in the field of haematology, 
particularly in detecting and monitoring characteristic changes in molecular compositions and structures that 
accompany the transformation from a normal to a cancerous state. There have been various studies of FT-IR 
spectroscopy into haematological malignancies, including studies of differentiation between normal leucocytes and 
leukaemia cells based on qualitative and quantitative differences at the DNA, protein and lipid levels9, 10; follow-up 
chemotherapy assessments to predict drug-sensitive or drug-resistant11-13, determination of apoptosis in leukaemia 
cells14, 15 and differentiation of clinically aggressive (high-grade) and clinically indolent (low-grade) lymphomas 
based on the nucleic acid absorbance ratio16. 
 
Here we describe a novel method based on a combination of mid-FTIR spectroscopy of dry films with advanced 
multivariate statistical analysis. There are several reasons to favour this approach; only microliters of cell culture are 
required for measurement, the cultured cells are much more homogeneous with high sensitivity to certain key 
analytes. This report presents preliminary results obtained from the analysis of lymphoma, myeloid and lymphoid 
leukaemia cell lines based on spectral variations due to biochemical differences. The spectral data were subjected to 
both unsupervised and supervised methods of multivariate statistics, in particular principal component analysis fed 
linear discriminate analysis (PCA-fed LDA) to elucidate the spectral variations between the lymphoma, myeloid and 
lymphoid leukaemia cell lines. The enduring aim of this study is to demonstrate that multivariate statistical methods 
can differentiate between cell types, which may aid in the development of a diagnostic algorithm to analyse blood 
and bone marrow aspirate specimens.   
 
 
2. MATERIALS AND METHODS 
 
2.1 CELL CULTURE  
Lymphoma (Karpas), lymphoid (REH and ACV) and myeloid (HL60 and Meg01) leukaemia cell lines were obtained 
from the Section of Haemato-Oncology, at the Institute of Cancer Research, Sutton, UK. REH and ACV are derived 
from human lymphoid leukaemia, HL60 and Meg01 are derived from human myeloid leukaemia and Karpas 299 is 
derived from Hodgkin’s lymphomas. The cells were grown as a suspension in 80-90% RPMI 1640 medium 
containing 10-20% fetal bovine serum (FBS). Cells were maintained at 37ºC in a humidified atmosphere with 5% 
CO2.  
 
2.2 SAMPLE PREPARATION 
Prior to spectroscopy, cells were washed and diluted (1:5) in cold, sterile saline (0.9% NaCl) solution. The samples 
were pelleted by centrifugation at 3000rpm for 3min to concentrate the cells. The pellet was re-suspended in 0.9% 
saline solution and the washing cycle was repeated twice more. Typically 50 µL of the final diluted cell sample was 
transferred onto two CaF2 slides by CytospinTM (1500 rpm for 5 min), a method formerly developed for cytology. 
The aim of this technique is to produce a monolayer of cells. The slides were then allowed to air dry at room 
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temperature for 30 min as thin circular disk films (diameter of 2-3 mm). The cell samples were examined by FT-IR 
spectroscopy and a transmission spectrum was acquired for the resulting films. This approach finesses the difficulties 
associated with strong water absorptions by simply eliminating water from the specimen. In addition to eliminating 
the spectral inference of water, this approach can provide better spectral resolution by the virtue of eliminating the 
water/solute interactions. 
 
2.3 SPECTRAL MEASUREMENT 
The infrared spectral data presented in this study were collected using a Perkin-Elmer Spectrum One/Spotlight FT-IR 
Imaging 300 System based at Gloucestershire Royal Hospital. This instrument is incorporated with a computerised 
microscope XYZ stage, visual image capture software and a highly sensitive, liquid nitrogen-cooled 16 x 16 element 
HgCdTe (MCT) focal plane array detector with a step scanning interferometer. Visual images of lymphoid, myeloid 
and lymphoma cell lines were collected via a CCD camera under white light LED illumination in transmission mode. 
The desired regions of the visual image map were selected and measured using a resolution of 8 cm-1 with a step size 
of 6.25 µm and 128 scans per pixel (spp) to increase the signal-to-noise ratio. Absorption spectra were acquired in 
the wavenumber range of 4000 to 720 cm-1.  Measurements of each cell type were repeated three times with 
subsequent sets (1-3) prepared at different times. Background scans were obtained from a region of no sample and 
ratioed against the sample spectrum each time. 
 
2.4 DATA ANALYSIS/PRE-PROCESSING 
Prior to multivariate statistical analysis, the absorption spectra were converted using PS convert (Perkin Elmer) to a 
more compact data format. MATLAB (version 6.1, © The MathWorks Inc.1994-2006) was used to pre-process the 
data. This aims to enhance the spectral features that incorporate information regarding biochemical composition and 
effectively to suppress or eliminate unnecessary artefacts. The dataset was cropped in spectral dimension (typically 
between 1800 – 800 cm-1). The truncated spectra were then smoothed using a 9-point Savitsky-Golay algorithm and 
normalized to minimise intensity variations between the spectral data set. All the spectra were then mean centred 
which calculates the average spectrum of the data set and subtracts that average from each spectrum. Peak positions 
were determined by using Spectrum/spotlight software (version 5.0.01). For each cell type, the mean spectrum was 
taken as an average of three different regions at various sites of the sample. Two different multivariate statistical 
analyses were employed in this study using MATLAB. This allows virtually all of the data present within the IR 
spectrum to be utilised. As the variation in spectral morphology seen between the different cell lines involves subtle 
differences across the range of wavenumbers, multivariate statistical analysis allows better separation of the cell line 
types.  
 
Firstly, an unsupervised PCA was applied to the spectral dataset in order to compress data, without losing relevant 
information. It is a well-established method ideally suited to distinguish and visualise small, reoccurring spectral 
variations in large data sets. It was used to describe the major trends of variation in the data and to establish whether 
or not spectra of cells group into classes due to cell type. Therefore, it can be used as a first step for classification of 
the 5 cell line groups. In this study, it was employed to generate pseudocolour maps of the significant principal 
component scores for each cell sample. ANOVA was performed to determine which PCs best differentiate between 
the cell line groups. The differences in the spectra across each cell sample were used for the clustering of cell line 
populations. Spectra from different cell line types were assigned different colours. The colour coded scatter plots 
enabled the natural separation of the data to be visualized.  
 
The second methodology was a supervised LDA, where the number of groups (cell line class identity) is dictated 
rather than discovered during the analysis. The scores for a specified number of principal components are used as the 
input data for LDA. For the purpose of this study, LDA was used to, without altering the data contained within the 
spectra emphasize the clustering of different cell line types following PCA. LDA for the different cell line types 
involves finding a linear discriminate function (LDF) that maximises the separation in discriminate space between 
different cell line types, whilst minimising the separation within each group. The combination of these two statistical 
methods referred to as PCA fed LDA was used to create algorithms for the different cell line types. The constructed 
algorithm was tested for its ability to correctly predict the cell line type. The results are presented as the proportion of 
spectra correctly predicted or classified into a group.  
 
 
 4
3. RESULTS AND DISCUSSION 
 
In the present study, FT-IR spectroscopy of pure lymphoma (Karpas), lymphoid (REH and ACV) and myeloid (HL60 
and Meg01) cell lines was carried out. We demonstrated reproducibility of the spectroscopic and multivariate 
statistical methods to distinguish between cell line types. Figure 1 shows white light image and pseudocolour maps, 
of total intensity at each point, in transmission mode of REH cell line. The pseudocolour maps shows absorbencies of 
varying intensities, where blue indicates low and red indicates high absorbance values. These were produced for all 
five cell lines by using a motorized XYZ stage to collect spectra, in an XY co-ordination, from a selected area. This 
way each pixel region on the map represents the spectrum for that point. The variation of spectral differences across 
a sample was established by calculating principal components. Each PC is composed of PC loads, which are the 
spectral components and PC scores, which relates to the abundance of that spectral component in the sample. Figure 
2 show the PC scores and loads of the first 10 principal components for REH. As the number of principal 
components increase more subtle variations can be seen. The score map from the second principal component was 
used to identify the major differences between spectra across the map. Peak assignment of the loads demonstrates 
further variation in the distribution of lipids, proteins and nucleic acids. Averaged spectra from the three regions of 
interest were plotted for comparison and identification of spectral differences as shown in figure 3. The spectrum in 
figure 4 is the mean representative spectrum for the REH cell line highlighting the prominent absorptions. 
Pseudocolour maps as well as their representative mean spectra were obtained for each cell type, but have not been 
presented in this paper due to the sheer number of data sets. Figure 5 represents the mean spectra from three sets of 
measurements obtained for each cell line (REH, ACV, HL60, Meg01 and Karpas) as representative spectra for further 
spectral analysis.  Figure 5 also shows the peak intensity variations between the mean IR spectra of the five cell lines 
groups.  
 
The IR spectra of cell lines are complex, with hundreds of data points due to the sheer number of contributing bio-
molecules and therefore contain many overlapping bands. In addition, the spectral homogeneity of spectra from cells 
belonging to similar lineage makes the visual inspection of individual spectra nearly impossible, and requires the use 
of methods of multivariate analyses for a meaningful interpretation. The subsequent results from these evaluation 
techniques are discussed in sections 3.2 and 3.3.  
 
A      B 
 
 
 
 
 
 
 
Figure 1: a) White light image of REH cell line and b) pseudocolour map of REH cell line in transmission mode. Black box 
highlights the region of interest.  
 
A PC Loads     B PC scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: First 10 PC loads and corresponding pseudocolour score maps for the REH cell line. 
Steps in X direction 
Steps in Y 
direction 
Wavenumber (cm-1) 
Intensity 
(a.u.) 
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A      B 
 
Figure 3: a) PC 2 score map with three selected regions of interest marked, b) mean IR spectra from three selected areas, region 1 
(red line), region 2 (blue line) and region 3 (green line). 
 
 
 
Figure 4: Representative mean spectra for REH cell line indicating major bio-molecular constituents. 
 
Figure 5:  Mean normalised spectra of lymphoid (REH and ACV), myeloid (HL60 and Meg01) and lymphoma (Karpas) cell lines 
from 3 sets of measurements. Set 1 is indicated by solid line (        ), set 2 is indicated by dotted line (       ) and set 3 is indicated 
by dash-dot line (      ). 
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3.1: PEAK INTENSITY ANALYSIS 
The IR absorption spectra acquired in the region 800-1800 cm-1 using the methods described in section 2.3 were 
consistent with those described in various publications8-10. The IR spectra of cell lines show differences in the 
intensities of the peaks caused by differences in the bio-chemical constituents. This indicates considerable variation 
between the different cell line groups with subtle variation within the samples (figure 4 and 5). The most intensity 
variations are seen in the region of intensity 800-1300 cm-1 indicating major variations in the lipid and nucleic acid 
content of the cell lines. Figure 5 shows higher nucleic acid content in myeloid cell lines (e.g. Meg01) and lower 
amide I and amide II protein levels in lymphoma cell line (karpas). In comparison, lymphoma cell line has higher 
proteins levels and lower nucleic acid content.  
 
Despite the minor spectral differences, the IR spectra of all cell lines are dominated by bands assigned to the 
absorption modes of proteins: the most intense is the amide I band, centred near 1656 cm-1, which corresponds to the 
C=O stretching coupled to the N-H bending and the C-H stretching modes of peptidic bonds. It has been reported 
previously that the shape of the amide I band is influenced by the overall secondary structure of cellular proteins. In 
particular, the peaks assigned to α-helices, β-sheets, turns and coils have absorption maxima between 1645-1662 cm-
1, 1613-1637 cm-1, 1662-1682 cm-1 and 1637-1645 cm-1 respectively. The amide II band at 1547 cm-1 arises from the 
vibrational modes that involve the C-N-H bending and C-N stretching of peptidic bonds. The amide III at 1242 cm-1 
is contributed by proteins arising form C-N stretching and N-H bending. The peaks at 1400-1460 cm-1 are attributed 
to amino acids. The complex band pattern between 900-1300 cm-1 region represents the superimposed contributions 
of nucleic acids (DNA, RNA), carbohydrates and phosphates. In particular, the band centred at 1089 cm-1 is assigned 
to C-O bending modes of saccharides (glucose and fatty acids) and the peak at 969 cm-1 form the C-C stretching 
mode of (deoxy) ribose that is present in the DNA and RNA. 
  
 
3.2: PRINCIPAL COMPONENT ANALYSIS 
Multivariate analysis by PCA was initially used alone to classify the cell types for visual comparison. PCA allows 
the degree to which the algorithm groups spectra from the same cell line type, and separates the spectra from 
different cell line types to be represented visually using scatter plots. Scores of principal components (PC2 vs. PC4) 
were used for the plots with the position of each of the spectra marked on the plot. The separation of lymphoma and 
lymphoid and myeloid leukaemia cell lines produced is shown as two-dimensional plot in figure 6. 
 
As a result of strong similarities in their spectral signatures, the lymphoid leukaemia cell types (REH and ACV) 
formed one cluster with overlapping spectra and the myeloid leukaemia cell types (HL60 and Meg01) produced the 
second cluster again with overlapping spectra. The third cluster belongs to the lymphoma (Karpas) cell line. PC 
scatter plots reveal good homogeneity of the spectra belonging to a particular lineage. This indicates prominent 
spectral variation between the different cell lines with very little intra-variability within the samples. 
       
  
 
Figure 6: a) scores scatter plot (PC2 vs. PC4) represents clustering of lymphoid, myeloid and lymphoma cells lines. Each symbol 
represents one spectrum. Each symbol represents one spectrum. Lymphoid leukaemia cell lines (ACV= red upward triangle and 
REH= magenta squares), myeloid leukaemia cell lines (HL60= blue squares and Meg01= green stars) and lymphoma cell line 
(Karpas= cyan downward triangle).  
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3.3: LINEAR DISCRIMINANT ANALYSIS 
The five cell line group classification model generated using PC fed LDA demonstrated good separation of the 
spectra in linear discriminant space. LDA was performed to maximise the distance between the groups, whilst 
minimising the distance between members within each group. This is illustrated as the two-dimensional plot of the 
scores of the LD1 against the scores of LD4 in figure 7. The training performance of the model was 95%. It also 
generated good sensitivity ranging from 94-99% and a specificity of 98-100% across the 5 cell line group 
classification model.  
 
Figure 7: Scatter plot of the 5 cell line groups as generated by PCA fed LDA. Each symbol represents one spectrum. Each symbol 
represents one spectrum. Lymphoid leukaemia cell lines (ACV= red upward triangle and REH= magenta squares), myeloid 
leukaemia cell lines (HL60= blue squares and Meg01= green stars) and lymphoma cell line (Karpas= cyan downward triangle).  
 
FT-IR Analysis 
 ACV Hl60 Karpas Meg01 REH Total 
ACV 1365 0 0 3 62 1430 
Hl60 59 1322 1 12 14 1408 
Karpas 0 0 1293 6 10 1309 
Meg01 0 0 56 2000 41 2097 
REH 118 0 0 1 1876 1995 
 
 
 
 
Class  
Total 1542 1322 1350 2022 2003 8239 
Table 1: FT-IR five cell line group prediction model. 
 
Class ACV Hl60 Karpas Meg01 REH 
FT-IR Sensitivity (%) 96 94 99 96 94 
FT-IR Specificity (%) 98 100 99 99.7 98 
Table 2: Sensitivities and specificities achieved by the five group classification model as predicted by PCA fed LDA.  
 
4. CONCLUSION 
 
This study shows that small spectral differences exist between the infrared spectra of lymphoma, lymphoid and 
myeloid leukaemia cells. Irrespective of subtle spectral differences between cell types, it is possible to classify cells 
of different lineages via its spectral signature and unsupervised and supervised methods of multivariate statistics in 
particular PCA fed LDA. Spectral differences between the cell lines differ according to the cellular biochemistry, 
which can serve as potential biomarkers lymphoma, lymphoid and myeloid leukaemia. These initial results further 
indicate that this approach could be useful for early diagnosis of haematological malignancies. It also provides the 
added benefit that instrumentation does not require reagents to promote a visible change in colour. It also ensures 
that all IR compositional data is stored in a single data set, permitting the rapid extraction of information of 
components of interest. Further work will be carried out using additional cell lines to assess and compare sensitivity, 
specificity and reproducibility of FT-IR spectroscopy as a complementary diagnostic tool in the field of clinical 
haematology. With some improvement in the technique and the analytical approach, a very objective discrimination 
method can be developed. This could be promising for investigations based on fine needle aspirations and blood 
specimens. 
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This paper presents Fourier transform infrared (FT-IR) spectroscopy to characterise spectral
differences that distinguish cells derived from human T-cell lymphoma, B-cell lymphoid, and myeloid
leukaemia cell lines. This methodology is based on spectral measurements of major cellular biochemical
constituents and multivariate spectral processing. Major spectral differences were observed in the 1800–
900 cm1 ‘fingerprint’ spectral region. Bands in the averaged spectra for each cell line were assigned to
major biochemical constituents including: proteins, lipids, carbohydrates and nucleic acids.
Multivariate statistical analysis of the spectra was carried out to develop a classification model to
discriminate the five cell types. The results show that FT-IR spectroscopy displays high sensitivity and
specificity when discriminating between T-cell lymphoma, B-cell lymphoid, and myeloid leukaemia
cells based on intrinsic biomolecular signatures. FT-IR spectroscopy in combination with multivariate
statistical analysis provides an important insight into T-cell lymphoma, B-cell lymphoid, and myeloid
leukaemia cell line identification. In conclusion, this paper demonstrates a potential for this technique
to be used in developing a clinical tool for the detection and identification of haematological
malignancies.
1. Introduction
Leukaemia and lymphoma are haematological malignancies that
result from the clonal expansion and accumulation of lymphoid
or myeloid progenitors in the bone marrow.1 Normally, 25% of
the white blood count is made up of lymphocytes including both
T- and B-cells, which play a major role in humoral and cellular
immunity respectively.2 At the time of diagnosis, the normal
marrow cell population has usually been replaced by the
leukaemia clone accompanied by haematogenous dissemination
to a variety of extramedullary sites. Current immunological,
cytopathological and molecular biology procedures identify
variations in cellular morphology or granularity, staining
patterns or use antibodies to detect abnormal leucocytes and cell-
specific marker proteins.3–5 Although these methods are well
established, they are invasive, requiring extensive sample prep-
aration and staining techniques as well as highly trained
personnel.
The ultimate aim of this research is to provide practical,
effective methods that will compete successfully on all levels with
the present gold standards in diagnosis, analysis, and imaging of
haematological malignancies. This will potentially provide new
or complementary information to clinicians that is otherwise not
available. Fourier transform infrared (FT-IR) spectroscopy,
a non-invasive method, has been proposed to overcome some of
the limitations of current ‘gold standard’ methods and therefore
potentially provides a diagnostic tool for haematological
malignancies without the need for staining. Automated, repeti-
tive analyses can therefore be carried out at a low cost with the
added advantage of utilizing a small volume of sample. FT-IR
spectroscopy is a vibrational spectroscopic technique that
monitors subtle changes in the biochemical composition of cells
at a molecular level which are often not obvious in cytopatho-
logical or molecular studies. It uses the mid-infrared (mid-IR)
part of the electromagnetic radiation frequencies (4000–400
cm1) to obtain an IR spectrum, which reflects a unique set of
molecular vibrations. These infrared-active vibrations can then
be correlated directly to the biochemical species and the resultant
IR spectrum can then be described as a ‘fingerprint’ of the
molecular species. If this molecular fingerprint is modified by
a disease process then IR spectroscopy can be used to detect and
monitor disease processes. FT-IR spectroscopy holds great
promise as an analytical tool to probe chemical bond vibrations
as well as compositional and structural changes at the molecular
and sub-molecular levels with minimal sample preparation.
To date, FT-IR spectroscopy has proven to be a powerful
analytical tool to probe the structure and confirmation of lipids,
proteins and nucleic acids6 and also of complex biological
materials such as body fluids and cell cultures.7,8 The ability of
FT-IR spectroscopy to detect changes in the chemical composi-
tion and morphology of cells led to its use in distinguishing
differences among cell populations; for example, between normal
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and cancerous cells9–11 as well as biochemical and morphological
characterisation of myeloid leukaemia (ML-1), cervical cancer
(HeLa) and murine embryonic stem (ES) cells at various differ-
ential phases of their life cycle and stages of cell proliferation.12–15
A recent study pioneered by the Krafft group demonstrated that
FT-IR microscopic imaging can identify the differentiation state
of individual human mesenchymal stem cells.16 A classification
model based on multivariate statistical analysis was used to
distinguish cell types by their IR spectroscopic fingerprint.
Extensive FT-IR spectroscopic studies have also been performed
on identification of various colonies of micro-organisms17 as well
as differentiation of bacterial species; for example, Candida
albicans,18 Listeria species19 and Escherichia coli strains.20 FT-IR
spectroscopy has further been employed to investigate multiple
aspects of leukocyte physiology, for example, to characterise
differentiation and apoptotic processes,21,22 to predict drug
sensitivity and resistance in leukaemic patients undergoing
chemotherapy and to monitor the response of leucocytes to
chemotherapy.23–26
This paper investigates whether FT-IR spectroscopy can be
applied as an alternative analytical technique in the classification
of haematological malignancies using cell lines derived from
leukaemia and lymphomas. This method combines superior
spectroscopic sensitivity with powerful multivariate statistical
analysis to extract the relevant biochemical information buried in
the spectrum. These statistical techniques aid in the identification
of characteristic features such as peak intensity changes and
shifts, within the IR spectrum, and the construction of a classi-
fication model for distinguishing leukaemia and lymphoma cell
lines. This may aid in the development of a diagnostic algorithm
to ultimately analyse blood and bone marrow aspirate specimens
in future spectroscopic studies.
2. Materials and methods
2.1 Cell culture
The following cells were obtained from the Section of Haemato-
Oncology, at the Institute of Cancer Research, Sutton: Karpas
299 (Human T-cell lymphoma cell line) cells, REH (Human acute
lymphoid cell line) cells, RCH-ACV (Human acute lymphoid cell
line) cells, HL60 (Human acute myeloid leukaemia cell line) cells
and Meg01 (Human chronic myeloid cell line) cells. A total of 5
sets of the same cell types were supplied as separate batches. The
cells were grown as a suspension in 80–90% RPMI 1640 medium
containing 10–20% fetal bovine serum (FBS). Cells were main-
tained at 37 C in a humidified atmosphere with 5% CO2.
2.2 Sample preparation
Prior to spectroscopic measurements the cells were washed and
diluted (1 : 5) in cold, sterile saline (0.9% NaCl) solution. The
samples were pelleted by centrifugation at 3000 rpm for 3 min to
concentrate the cells. The pellet was re-suspended in 0.9%
phosphate buffer saline solution and the washing cycle was
repeated twice more. Typically 200 mL of the final diluted cell
samples was transferred onto CaF2 slides by Shandon Cytospin

Cytocentrifuge (1500 rpm for 5 min), a method formerly devel-
oped for cytology as described below. The slides were then
allowed to air-dry at room temperature under airflow for 30 min
as thin circular disk films (diameter of 5 mm) and frozen at 80
C. This approach overcomes the difficulties associated with
strong water absorptions by simply eliminating water from the
specimen. The slides were then examined by FT-IR spectroscopy
and a number of transmission spectra were acquired for the
resulting films.
2.3 Spectral measurements
The infrared spectral data presented in this study were collected
using a Perkin-Elmer Spectrum One/Spotlight FT-IR Imaging
300 System based at Biophotonic Research Group, Gloucester-
shire Royal Hospital. This instrument is incorporated with
a computerised microscope x-y-z stage, visual image capture
software and a highly sensitive, liquid nitrogen-cooled 1  16
element HgCdTe (MCT) array detector with a step scanning
interferometer. Visual images of lymphoid, myeloid and
lymphoma cell lines were collected via a CCD camera under
white light LED illumination in transmission mode. From the
visual image, area of high cellular content was selected for
spectral imaging. The average size of the area probed was
approximately 200–400 mm for each cell line sample. Spectral
images were measured by scanning the computer controlled
microscope stage in an x-y direction in increments corresponding
to the 6.25 mm step size, using a spectral resolution of 8 cm1 and
128 scans per pixel (spp) to increase the signal-to-noise ratio.
Transmittance spectra were acquired in the wavenumber range
of 4000–720 cm1. Background scans were obtained from
a region of clean calcium fluoride (i.e. area with no sample) to
allow contributions to the spectrum from the instrument to be
removed when ratioed against the tissue spectra during data
processing. Measurements of each cell type were repeated five
times with subsequent batch sets (1–5) prepared at different times
to test for reproducibility.
2.4 Data analysis
The raw FSM (binary) file was imported into Matlabª using
a combination of in-house functions and a Perkin-Elmerª data
plugin script which converted and truncated (1800–900 cm1) the
raw binary data into an ASCII format which can then be pro-
cessed by Matlabª. This loading process also converted the data
from transmittance into absorbance values. All subsequent
multivariate data analysis was performed in Matlabª to perform
data reduction and discriminant analysis as well as to carry out
leave-one-out cross-validation using in-house designed scripts.
An in-house absorbance spectral filter tool was applied to the
loaded hyperspectral data cube to filter out weak or low absor-
bance. All spectra outside the absorbance range of 0.2 (upper
absorbance limit) and 0.15 (lower absorbance limits) were
removed. This absorbance range was chosen to optimise the
stability of the classification model. The absorbance filter tool in
combination with other pre-processing techniques such as nor-
malisation was employed to enhance the spectral features that
incorporate information regarding biochemical composition and
effectively suppresses or eliminates unnecessary artefacts, noise,
calcium fluoride, water and CO2 signals as well as variations in
sample thickness. This absorbance spectral filter tool was applied
to all raw FSM for all 5 cell samples from 5 subsequent batches.
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The absorbance-filtered spectra for all 5 cell samples from each
of the 5 batches were combined to create a new filtered dataset
with most weak absorbance and saturated spectra removed. The
dataset was then mean-centred prior multivariate classification
to ensure that each spectrum could be statistically compared to
the mean of the dataset. This was achieved by calculating the
mean of the dataset and subtracting that mean from each
spectrum.
The mean-centred data were inputted into a Principal
Component Analysis (PCA)-fed Linear Discriminant Analysis
(LDA) classification algorithm.27,28 PCA was performed on all
spectra to extract and visualise persistent features of spectra from
individual cell types and to compare different cell types against
each other. LDA was performed to assess the performance of the
model in distinguishing the different cell line types. This method
uses the scores from PCA as inputs to develop a pathology
classification model. The first 25 principal component scores
(describing the greatest variance in the dataset) were used as the
input data for LDA. The constructed classification method was
tested for its ability to correctly predict the cell line type. In this
study we used leave-one-out cross-validation (LOOCV) to test
the accuracy of the predictions of the PCA-fed LDA classifica-
tion model. Classification accuracy was assessed whereby the
class of spectra within a batch is predicted by holding out all of
the spectra measured from a particular batch (the test set) and
building an LDA model with the remaining data (the training
set). This method is repeated so that each batch in the dataset is
left out in turn and used once as the test data. Sensitivities and
specificities were calculated as a measure of model accuracy and
performance to evaluate the efficacy of classification systems. In
our analysis, sensitivity is defined as the ratio of the number of
true positives to the sum of true positives and false negatives and
the specificity is defined as the ratio of the number of true
negatives to the sum of true negatives and false positives – see eqn
(1) and (2).
Sensitivity ¼ No: of true positives
No: of true positivesþNo: of false negatives
 100%
(1)
Specificity ¼ No: of true negatives
No: of true negativesþNo: of false positives
 100%
(2)
3. Results
In the present study, FT-IR spectroscopic measurements of pure
lymphoma (Karpas 299), lymphoid (REH and ACV) and myeloid
(HL60 and Meg01) cell lines were carried out. We demonstrated
the reproducibility of the spectroscopic and multivariate statis-
tical methods to distinguish between cell line types. Fig. 1a and
1b show a white light image and the corresponding average
absorbance image for the Meg01 cell line. The average absor-
bance image shows absorbencies of varying intensities, where
blue indicates low and red indicates high absorbance values.
These were produced for all five cell lines by using a motorized x-
y-z stage to collect spectra, in an x-y co-ordination, from
a selected area. This way each pixel region on the map represents
the spectrum for that point. Fig. 1c represents the average
absorbance image after the absorbance spectral filter tool was
applied to filter out weak and saturated spectra. The spectral
Fig. 1 (A) White light image of Meg01 cell sample. The red box (200 300 mm) highlights the region of interest. (B) Corresponding average absorbance
image of Meg01: the blue areas indicate low and red areas indicate high absorbance values. (C) Filtered average absorbance image: the white areas
represent weak or saturated spectra that have been filtered out.
This journal is ª The Royal Society of Chemistry 2009 Analyst, 2009, 134, 763–768 | 765
dataset shown in Fig. 2a and 2b represents the original unfiltered
dataset and the remaining good quality filtered spectra. Average
absorbance images as well as their representative mean spectra
were obtained for each cell type, but have not been presented in
this paper due to the sheer number of datasets.
3.1 Peak intensity analysis
In order to identify significant spectral signatures of the various
cell types, a standard univariate method of assigning key peak
positions was employed. This monitors vibrations due to pre-
assigned specific functional groups and explores changes in these
functional groups as potential biomarkers. The representative
mean spectra from five sets of measurements for each cell line
(REH, ACV, HL60, Meg01 and Karpas 299) are depicted in
Fig. 3. The mean spectra of the five cell types do have a degree of
similarity. However, there are also many spectral features
differentiating the different cell types due to slight variations in
peak positions and intensities. The intensities of the IR spectra
provide quantitative information while the absorption positions
(wavenumber (cm1)) reveal qualitative characteristics about the
nature of the chemical bonds and their structure.
Peak shapes and positions are repeatable although the peak
intensities tend to vary due to differences in the biochemical
constituents. Most significant changes in peak intensities occur in
the fingerprint region between 900 and 1500 cm1 corresponding
to the nucleic acids, amino acids, amide III, lipids and carbo-
hydrates. There are also variations in peaks corresponding to
amino acids (1401 cm1), lipids (1452 cm1) as well as the amide I
(1655 cm1) and amide II (1549 cm1) peaks. Despite the minor
spectral differences, all five cell types were found to display
prominent characteristic spectral features. The most distinctive
peaks in the IR absorption spectra are assigned to the absorption
modes of proteins: the most intense is the amide I band, centred
near 1655 cm1, which corresponds to the C]O stretching
coupled to the N–H bending and the C–H stretching modes of
peptide bonds.19,20 It has been reported previously that the shape
of the amide I band is influenced by the overall secondary
structure of cellular proteins.21 In particular, the peaks assigned
to a-helices, b-sheets, b-turns and random coils have absorption
maxima in the ranges 1645–1662 cm1, 1613–1637 cm1, 1662–
1682 cm1 and 1637–1645 cm1 respectively. The amide II band
at 1549 cm1 arises from the vibrational modes that involve the
C–N–H bending and C–N stretching of peptidic bonds.22 The
Fig. 2 (A) Unfiltered normalised spectral dataset and (B) remaining good quality normalised filtered spectra.
Fig. 3 Representative average IR spectra from five sets of measurements obtained for each cell line (REH, RCH-ACV, HL60, Meg01 and Karpas 299)
in the range 900–1800 cm1.
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amide III at 1242 cm1 is contributed by proteins arising from C–
N stretching and N–H bending.22,23 The peaks at 1400–1460 cm1
are attributed to CH2 and CH3 deformation vibrations primarily
due to lipid contribution. Nucleic acid signals contribute to the
infrared spectra at 1091 cm1 (sym. PO2
), 1065 cm1 (PO2
 and
ribose groups) and 972 cm1 (phosphodiester group present in
the DNA and RNA).20 Lipids have long hydrocarbon chains and
therefore their have peaks at 1352 cm1 (CH3 vibration) and 1740
cm1 (C]O bending) although the peak at 1787 cm1 emerges
somewhat as a shoulder (Fig. 3). Phosphate bands of phospho-
lipids are also found between 1080 and 1230 cm1. The position
and amplitude of these absorption bands (Fig. 3) are governed by
the nature and concentration of the constituents, including the
molecular conformation of the constituents and interactions
among them. Overall, we show that the relative intensities of
DNA and amide III modes increase in malignant cells, indicating
increased cellular nuclear content. Although these findings are
consistent with those described in various publications,13,16,17
these cannot solely be used as a diagnostic algorithm.
Visual inspections reveal that the IR absorption spectra of cell
lines are complex, with numerous data points due to the sheer
number of contributing bio-molecules and therefore contain
many overlapping bands. In addition, the spectral homogeneity
of spectra from cells belonging to similar lineage makes the
visual interpretation of individual spectra nearly impossible.
It is therefore essential that these vibrational spectroscopic
measurements are combined with univariate methods (peak
assignment) as well as multivariate statistical analyses for
a meaningful interpretation.
3.2 Multivariate analysis
The ability of FT-IR spectroscopy to distinguish between the cell
types was assessed using multivariate analysis based on spectral
differences within the dataset. PCA was used in this study as
a technique that reduces the number of parameters needed to
represent the variance in the spectral dataset. The principal
components were then used to generate a linear discriminant
model. PCA is a chemometric technique that can resolve
a complete spectral dataset into a few key spectral components
and can thus identify and isolate important trends within the
dataset.27 LDA applies a linear discriminant function that
maximises the variance in the data between groups and mini-
mises the variance between members of the same group.28 All 5
cell types were discriminated as shown in Fig. 4. The classifi-
cation model was tested using leave-one-out cross-validation
(LOOCV). Classification results in Table 1 show that most of
the spectra within the 5 cell line group model have been classi-
fied correctly with only a small number of spectra misclassified.
The reason for this misclassification may be associated with
small inconsistencies within the spectra belonging to leukaemia
and lymphoma cell line populations. Misclassifications are also
due to the relatedness of the cell type. Based on the cross-vali-
dation results, sensitivity and specificity values were calculated
(Table 1). The model obtained sensitivity ranging between 74
and 100% and specificity ranging between 94 and 100%. Similar
methods have been used previously in investigation of synovial
fluids from joints affected by rheumatoid arthritis and osteo-
arthritis29 and classification of gastric inflammation and malig-
nancy on endoscopic biopsies.30 Ideally, the use of an unknown
test set would provide a more robust independent analysis of
sensitivity and specificity of the technique and this is planned for
future work.
4. Conclusions
This study shows that, on first examination, the IR spectra are
visually similar but detailed spectral analysis reveals noticeable
variations that could give an insight into the biochemical
differences that exist between the IR spectra of T-cell lymphoma,
B-cell lymphoid and myeloid leukaemia cell lines. Irrespective of
subtle spectral differences between cell types, it is possible to
classify cells of different lineages via its spectral signature.
Although the subtle spectral differences between leukaemia and
lymphoma cell lines show potential for discrimination, the
obtained spectra are complex and their exact molecular origins
are only partially understood. We believe that further biochem-
ical studies need to be applied to assess the contribution of
complex biochemical constituents at the cellular level.
The present study is the first to demonstrate that methods of
multivariate statistics, in particular PCA-fed LDA, have the
Fig. 4 Scatter plot (LD2 vs. LD3) of the 5 cell line groups as generated
by PCA-fed LDA. Each symbol represents one spectrum. Lymphoid
leukaemia cell lines (ACV ¼ crosses and REH ¼ stars), myeloid
leukaemia cell lines (HL60 ¼ circles and Meg01 ¼ squares) and
lymphoma cell line (Karpas 299 ¼ upward triangles).
Table 1 Summary of cross-validation results and sensitivity and speci-
ficity values
FT-IR prediction
Diagnosis (cell type)
ACV HL60 Karpas 299 Meg01 REH
ACV 545 0 23 0 36
HL60 0 658 1 0 7
Karpas 299 0 74 543 0 8
Meg01 0 0 0 646 0
REH 3 83 81 0 475
Number correct 545 658 543 646 475
Sensitivity (%) 90.2 98.8 86.9 100 73.9
Specificity (%) 99.9 93.8 95.9 100 97.9
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ability to group mid-FT-IR spectra by leukaemia and lymphoma
cell type. Cross-validation reveals that a combination of FT-IR
spectroscopy with multivariate feature extraction and classifica-
tion methods has the potential to become an ideal complemen-
tary tool to conventional assays for early detection of leukaemia
and lymphoma. These initial results further indicate that this
approach provides the added benefit that instrumentation does
not require contrast reagents to promote a visual change in
colour and ensures that all compositional data are stored in
a single dataset. With some improvements in the technique and
the analytical approach, an objective discrimination method can
be developed which combines pattern recognition and classifi-
cation models. This could be promising for future investigations
based on fine needle aspirations and blood specimens for diag-
nosing haematological malignancies.
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